



**First Annual Report
from the Evaluation of
the Oncology Care
Model: Baseline Period
Appendices**

Contract # HHSM-500-2014-00026I T0003

Final

Report Release Date: February 2018

Prepared for:

Susannah Cafardi

Centers for Medicare and
Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244

Submitted by:

Abt Associates

4550 Montgomery Avenue
Suite 800 North
Bethesda, MD 20814

In Partnership with:

The Lewin Group
Harvard Medical School
GDIT
Dartmouth College

Table of Contents

1. Methodology for Baseline Comparison Group Selection 1

 1.1 Comparison Group Selected Using PSM 1

 1.2 Refinements to the Comparison Group 2

 1.3 Assessing Balance in the Baseline Comparison Group 3

2. Episode Characteristics, Detailed Results 6

3. Practice Characteristics Detailed Results 28

4. Market Characteristics Detailed Results 30

5. Subgroup Analyses Detailed Results 32

Exhibits

Exhibit A1-1: Variables included in the Propensity Score Model 2

Exhibit A1-2: Standardized Differences of PSM Variables between the OCM and Comparison Group 4

Exhibit A2-1: Share of Episode Volume by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 7

Exhibit A2-2: Share of Episode Volume by Beneficiary Characteristics in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 8

Exhibit A2-3: Distribution of Standardized Part A and B, and Part D Costs per Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 9

Exhibit A2-4: Distribution of Part B and Part D Chemotherapy Costs per Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 10

Exhibit A2-5: Inpatient Stays per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 11

Exhibit A2-6: Inpatient Days per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 12

Exhibit A2-7: 30-Day Hospital Readmissions per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 13

Exhibit A2-8: Intensive Care Unit Admissions per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 14

Exhibit A2-9: Part A Inpatient Costs per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 15

Exhibit A2-10: Part A Costs for 30-Day Hospital Readmissions per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 16

Exhibit A2-11: Proportion of Episodes Using Home Health Services by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 17

Exhibit A2-12: Proportion of Episodes with at Least One Imaging Visit by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 18

Exhibit A2-13: Standard Imaging Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)..... 19

Exhibit A2-14: Advanced Imaging Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)..... 20

Exhibit A2-15: Episode Utilization of Outpatient Therapy Services in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 21

Exhibit A2-16: Unique Part D Prescriptions Each Month per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 22

Exhibit A2-17: Monthly Part D Prescription Cost per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 23

Exhibit A2-18: Claims-Based End-of-Life Measures for Decedent Patients in the Oncology Care Model Evaluation 24

Exhibit A2-19: End-of-Life Measures for Decedent Cancer Patients as Assigned by the Most Recent Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 26

Exhibit A2-20: End-of-Life Measures for Decedent Hospice-Using Cancer Patients as Assigned by the Most Recent Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 27

Exhibit A3-1: Practice Provider NPI Characteristics in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 28

Exhibit A3-2: Practice Provider NPI Characteristics in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)..... 29

Exhibit A4-1: Market Supply Characteristics of Practices in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 30

Exhibit A4-2: Healthcare Utilization and Plan Enrollment in Markets in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	31
Exhibit A5-1: Cancer-Related E&M Services per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	33
Exhibit A5-2: Part B and D Chemo Services per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	34
Exhibit A5-3: ED Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	35
Exhibit A5-4: SNF Stays per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	36
Exhibit A5-5: SNF Days per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	37
Exhibit A5-6: Proportion of Episodes Utilizing Radiation Therapy by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	38
Exhibit A5-7: Radiation Therapy Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015).....	39
Exhibit A5-8: Total Cost of Care per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)	40
Exhibit A5-9: Cancer-Related E&M Costs per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015).....	41
Exhibit A5-10: Part B and D Chemotherapy Cost per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	42
Exhibit A5-11: Beneficiary Cost Sharing per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015).....	43
Exhibit A5-12: All-Cause Mortality by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	44
Exhibit A5-13: Characteristics of Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	45
Exhibit A5-13: Characteristics of Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued	46
Exhibit A5-14: Characteristics of Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	47

Exhibit A5-14: Characteristics of Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued 48

Exhibit A5-15: Utilization within Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 49

Exhibit A5-16: Utilization within Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 50

Exhibit A5-17: Total Cost of Care and Cost Sharing of Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 51

Exhibit A5-18: Total Cost of Care and Cost Sharing of Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 52

Exhibit A5-19: Share of Episodes by Cancer Bundle, Dual vs. Non-Dual Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 53

Exhibit A5-20: Share of Episodes by Cancer Bundle, White vs. Non-White Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 54

Exhibit A5-21: Share of Episodes by Cancer Bundle, High Risk vs. Low Risk Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 55

Exhibit A5-22: Episode Services, Dual vs. Non-Dual Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 56

Exhibit A5-23: Episode Services, White vs. Non-White Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 57

Exhibit A5-24: Episode Cancer E&M Services by Cancer Bundle, High vs. Low Risk Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 58

Exhibit A5-25: Episode Services, High vs. Low Risk Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 -Jun. 2015) 59

Exhibit A5-26: Share of Episodes by Cancer Bundle, High HCC vs. Low HCC Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 60

Exhibit A5-27: Episode Services, High vs. Low HCC Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 61

Exhibit A5-28: Episode Total Cost of Care and Cost Sharing, High vs. Low HCC Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 62

Exhibit A5-29: Share of Episodes by Cancer Bundle, High vs. Low Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 63

Exhibit A5-30: Episode Share by Cancer Bundle, High and Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 64

Exhibit A5-31: Episode Share by Cancer Bundle and Affiliation Type in Performance Period -2 (Episodes initiating Jan. – Jun. 2015)..... 65

Exhibit A5-32: Episode Characteristics, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015) 66

Exhibit A5-32: Episode Characteristics, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015), Continued 67

Exhibit A5-33: Episode Characteristics, Low vs. High Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 68

Exhibit A5-33: Episode Characteristics, Low vs. High Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued 69

Exhibit A5-34: Episode Characteristics, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 70

Exhibit A5-34: Episode Characteristics, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued 71

Exhibit A5-35: Episode Characteristics, High vs. Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 72

Exhibit A5-35: Episode Characteristics, High vs. Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued 73

Exhibit A5-36: Episode Characteristics by Affiliation Type in Performance Period -2 (Episodes initiating Jan. – Jun. 2015)..... 74

Exhibit A5-37: Episode Services, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 75

Exhibit A5-38: Episode Services, Low vs. High Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)..... 76

Exhibit A5-39: Episode Services, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015) 77

Exhibit A5-40: Episode Services, High vs. Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)	78
Exhibit A5-41: Episode Services by Affiliation Type in Performance Period -2 (Episodes initiating Jan. – Jun. 2015)	79
Exhibit A5-42: Episode Total Cost of Care and Cost Sharing, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	80
Exhibit A5-43: Episode Total Cost of Care and Cost Sharing, Low vs. High Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	81
Exhibit A5-44: Episode Total Cost of Care and Cost Sharing, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015).....	82
Exhibit A5-45: Episode Total Cost of Care and Cost Sharing, High vs. Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	83
Exhibit A5-46: Episode Total Cost of Care and Cost Sharing by Affiliation Type in Performance Period -2 (Episodes initiating Jan. - Jun. 2015).....	84
Exhibit A5-47: Episode Characteristics, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015).....	85
Exhibit A5-47: Episode Characteristics, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015), Continued.....	86
Exhibit A5-48: Episode Characteristics, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	87
Exhibit A5-48: Episode Characteristics, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued	88
Exhibit A5-49: Episode Characteristics, Large vs. Small Population Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	89
Exhibit A5-49: Episode Characteristics, Large vs. Small Population Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued	90
Exhibit A5-50: Episode Services, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)	91
Exhibit A5-51: Episode Services, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)	92
Exhibit A5-52: Episode Services, Large vs. Small Population Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015).....	93

Exhibit A5-53: Episode Total Cost of Care and Cost Sharing, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 94

Exhibit A5-54: Episode Total Cost of Care and Cost Sharing, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 95

Exhibit A5-55: Episode Total Cost of Care and Cost Sharing, Large vs. Small Population Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)..... 96

1. Methodology for Baseline Comparison Group Selection

As part of the OCM evaluation, participating OCM practices are compared to a selected group of comparison TINs on cost, utilization, and quality outcomes. We identified a large sample of 319 comparison TINs through propensity score matching (PSM). PSM matched comparison TINs to OCM practices based on a predicted probability of treatment (i.e., participation in OCM) given a set of observable factors. Through this matching technique, we identified a comparison sample that was similar to OCM practices across a number of market, practice and episode characteristics.

While the comparison group selection began with PSM, once selected, we made several refinements to the group of TINs. These refinements included replacing and removing TINs based on three main factors: 1) face validity concerns; 2) TINs that shared NPIs and health system affiliation with OCM practices; and 3) TINs that did not bill cancer-related E&Ms for chemotherapy patients in the first half of 2016. The comparison group refinements were made as we learned more about practice and TIN structure (e.g., NPI specialties and likelihood of overseeing an episode of care), constructed information on practice affiliation, and reviewed more recent billing data indicating that some TINs may have closed or been acquired. Additional detail on the selection of the comparison group and the adjustments applied are described below.

1.1 Comparison Group Selected Using PSM

To select the comparison group, we started with the population of 1,958 non-OCM TINs identified after applying the exclusion criteria detailed in Section 2.5.1. We ran the PSM model using untransformed variable forms, treating non-OCM TINs as single entities, and not censoring the value of episode count. In doing so, there were five OCM practices without matches within the specified caliper; further investigation revealed that the TINs associated with these five OCM practices did not match any non-OCM TINs because they had very high episode volume, which substantially increased the estimated propensity scores.

We tested methods to match these five OCM practices by censoring the episode count variable and breaking each practice apart geographically. The censored model imposed a cap on the episode count at the 99th percentile of the distribution (2,041 episodes), which censored episode volume for 10 OCM practices and 13 non-OCM TINs. By keeping all other attributes of TINs intact, the importance of episode volume was reduced in determining the match. The censored approach had more intuitive appeal than breaking up the large OCM practices because of the difficulty in determining reasonable ways to divide these large organizations based on the claims data or their OCM applications. Ultimately, we censored episode count to ensure all OCM practices were matched with at least one non-OCM TIN.

Exhibit A1-1: Variables included in the Propensity Score Model

Affiliation with Academic Medical School	Percent Endocrine only Therapy for Prostate Cancer
Participation in Other CMMI Initiatives	Percent Endocrine only Therapy for Breast Cancer
Total NPI Count	Percent of Cancer Patients treated by TIN with at least one chemo episode
Percent NPIs with Oncology Specialty	Mortality Rate (6-month)
Percent Lung Cancer Bundle	Multiple sites (Number of Sites >1)
Percent Colorectal Cancer Bundle	Multiple markets (Number of Markets >1)
Percent Lymphoma Cancer Bundle	Median Household Income
Percent Leukemia Cancer Bundle	Primary Care Providers per 10,000
Percent Melanoma Bundle	Medicare Advantage Penetration
Percent Bladder Cancer Bundle	Percent of Benes in Other CMMI Initiatives
Percent Radiation Oncologists	Home Market Share
Percent Medicaid Dual Eligible	Home Dependence
Percent Female	Population
Percent Black	High Cost Provider in Market
Percent Hispanic	Episode Count
Mean 2014 HCC Score	

1.2 Refinements to the Comparison Group

The PSM model selected 352 unique TINs into the comparison group. We closely examined these TINs and made manual modifications to the comparison group as we learned more about the OCM practices and comparison TINs, particularly with regards to face validity, practice affiliations, and billing history.

Face Validity of Specialty Practices and TINs: While PSM ensures statistical validity of matches, it does not necessarily ensure face validity because the match is made based upon probability of participation, rather than matching each unique variable included in the PSM. In several cases, we found substantial differences between the OCM practice and selected matches for key variables such as cancer mix (e.g., specialization in urology, gynecologic oncology, or breast cancer) and provider specialty (e.g., the PSM selected a urology practice as a match for a gynecologic oncology practice). We replaced the original TINs that were lacking face validity with new TINs which had both statistical and face validity.

Practice and TIN Affiliations: We examined the suitability of comparison TINs involving organizations that were potentially affiliated with OCM practices, as we were concerned about spillover effects and introducing bias to the comparison sample if these affiliations were present. We identified practices and TINs that were both affiliated with the same health system, and assessed NPI overlap between the organizations. If we found substantial overlap in the NPIs billing to the OCM practice and comparison TIN, we removed the TIN from the comparison group. Prior to doing so, we ensured that the comparison TIN was not matched to another, more valid, OCM practice. We also assessed TINs that were part of organizations that do not primarily serve the Medicare FFS population and removed those as well.

Claims Data Availability: Upon review of more recent claims data, we discovered that several TINs in the comparison group were no longer billing cancer-related E&Ms for chemotherapy patients in the first half of 2016 (the comparison group was selected using data from 2014). It is likely that these TINs will

also have no attributed episodes during the OCM intervention period (starting July 2016), and we removed them from the comparison group.

After assessing the comparison group originally selected by PSM and making manual modifications to address concerns with face validity, affiliation, and billing history, the comparison group consisted of 319 TINs.

1.3 Assessing Balance in the Baseline Comparison Group

To assess balance between the 190 OCM practices and the comparison group, we computed standardized differences for each variable in the PSM model. The standardized difference compares the differences in means in relation to the pooled standard deviation. The average standardized difference was computed to assess overall balance. Exhibit A1-2 shows the distributions and standardized difference for the OCM practices and comparison group for each variable. Stuart (2010) recommends a threshold of 0.25 as an indication of potential balance issues, but we used an even lower threshold of 0.20. The average standardized difference was 0.101, indicating good balance overall. There were five variables with a standardized difference greater than 0.20: episode count, proportion of high cost TINs, NPI count, proportion of melanoma episodes, and proportion of multi-site practices. These differences were noted and will be controlled for in future impact analyses.

Exhibit A1-2: Standardized Differences of PSM Variables between the OCM and Comparison Group

Characteristics	OCM						Selected Comparison TINs						Standardized Differences
	N	Mean	Minimum	Median	Maximum	Variance	N	Mean	Minimum	Median	Maximum	Variance	
Episode Count	190	533.20	1.00	311.00	10,810.50	1.14E+06	319	265.63	4.50	172.50	1,906.50	89830.85	0.342*
% NPIs with Oncology Specialty	190	0.61	0.00	0.64	1.00	0.08	319	0.60	0.02	0.58	1.00	0.10	0.032
Affiliation with Academic Medical Center	190	0.16	0.00	0.00	1.00	0.13	319	0.11	0.00	0.00	1.00	0.10	0.152
Participation in Other CMMI Initiatives	190	0.13	0.00	0.00	1.00	0.11	319	0.10	0.00	0.00	1.00	0.09	0.093
Median Household Income	190	55,628	32,666	53,546	105,217	1.76E+08	319	54,132	31,487	51,650	110,507	1.85E+08	0.111
Medicare Advantage Penetration	190	30.89	4.34	29.64	62.03	154.16	319	30.45	1.65	29.70	63.44	185.32	0.034
High Cost Provider in Market	190	0.20	0.00	0.00	1.00	0.16	319	0.30	0.00	0.00	1.00	0.21	-0.235*
Multiple Markets	190	0.18	0.00	0.00	1.00	0.15	319	0.16	0.00	0.00	1.00	0.13	0.073
Mean 2014 HCC Score	190	1.87	1.01	1.86	2.70	0.06	319	1.86	1.06	1.86	3.21	0.08	0.024
% Medicaid Dual Eligible	190	0.14	0.00	0.12	0.69	0.01	319	0.15	0.00	0.13	0.85	0.01	-0.069
% Black	190	0.10	0.00	0.07	0.48	0.01	319	0.10	0.00	0.06	0.97	0.02	-0.049
% Hispanic	190	0.06	0.00	0.02	0.83	0.01	319	0.05	0.00	0.02	1.00	0.01	0.026
Total NPI Count	190	40.96	1.00	20.00	443.00	3,635.46	319	26.75	1.00	10.50	248.00	1,507.05	0.280*
% Female	190	0.61	0.00	0.62	1.00	0.01	319	0.60	0.03	0.61	1.00	0.02	0.050
% Lung Cancer Bundle	190	0.10	0.00	0.10	0.24	0.00	319	0.10	0.00	0.09	0.31	0.00	-0.006
% Colorectal Cancer Bundle	190	0.07	0.00	0.07	0.24	0.00	319	0.07	0.00	0.06	0.28	0.00	-0.057
% Lymphoma Cancer Bundle	190	0.07	0.00	0.07	0.19	0.00	319	0.06	0.00	0.06	0.57	0.00	0.102
% Leukemia Cancer Bundle	190	0.04	0.00	0.04	0.11	0.00	319	0.04	0.00	0.04	0.14	0.00	0.107

APPENDIX 1

Characteristics	OCM						Selected Comparison TINs						Standardized Differences
	N	Mean	Minimum	Median	Maximum	Variance	N	Mean	Minimum	Median	Maximum	Variance	
% Melanoma Bundle	190	0.01	0.00	0.00	0.05	0.00	319	0.00	0.00	0.00	0.03	0.00	0.263*
% Bladder Cancer Bundle	190	0.02	0.00	0.02	0.21	0.00	319	0.02	0.00	0.01	0.23	0.00	-0.040
% Radiation Oncologists	190	0.11	0.00	0.00	1.00	0.03	319	0.12	0.00	0.00	1.00	0.04	-0.008
% Endocrine only Therapy for Prostate Cancer	190	0.10	0.00	0.07	0.75	0.01	319	0.11	0.00	0.07	0.84	0.02	-0.105
% Endocrine only Therapy for Breast Cancer	190	0.26	0.00	0.26	0.82	0.01	319	0.26	0.00	0.25	0.70	0.01	0.053
% of Cancer Patients treated by TIN with at least one chemo episode	190	0.85	0.15	0.89	0.98	0.02	319	0.85	0.17	0.88	1.00	0.01	0.053
Multiple Sites	190	0.56	0.00	1.00	1.00	0.25	319	0.41	0.00	0.00	1.00	0.24	0.304*
% of Benes in Other CMMI Initiatives	190	0.15	0.00	0.14	0.46	0.01	319	0.14	0.00	0.13	0.65	0.01	0.081
Mortality Rate	190	0.11	0.00	0.11	0.22	0.00	319	0.11	0.00	0.11	0.26	0.00	0.058
Primary Care Provider per 10,000	190	8.80	2.73	8.44	17.50	6.66	319	8.74	2.61	8.29	44.71	11.36	0.020
% Market Share	190	0.39	0.00	0.22	1.00	0.14	319	0.35	0.00	0.22	1.00	0.12	0.116
Home Flow	190	0.72	0.10	0.77	1.00	0.05	319	0.74	0.05	0.82	1.00	0.05	-0.099
Population	190	1,300,000	21947	549414	10,100,000	4.22E+12	319	1,120,000	10,202	392,702	10,100,000	4.16E+12	0.086
Overall													0.101

Source: Practice-level aggregate file with summarized episode, market, and practice characteristics, 2014. **Note:** Asterisk (*) indicates a standardized difference > 0.2.

2. Episode Characteristics, Detailed Results

Exhibit A2-1: Share of Episode Volume by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Number of Episodes	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	298,752	10.8%	7.1%	31.3%	15.9%	7.3%	1.5%	3.7%	0.5%	2.7%	19.0%
	OCM	101,192	11.6%	7.5%	32.1%	12.3%	8.2%	1.7%	4.0%	0.5%	2.2%	20.0%
	Comparison	80,345	10.8%	7.0%	30.4%	16.4%	7.2%	1.5%	3.9%	0.6%	2.8%	19.5%
	NONC	117,215	10.2%	6.9%	31.3%	18.7%	6.8%	1.4%	3.4%	0.4%	3.2%	17.7%
-7	National	259,926	10.2%	6.9%	32.1%	16.1%	7.0%	1.5%	3.8%	0.5%	2.7%	19.3%
	OCM	88,489	10.9%	7.3%	32.9%	12.6%	7.8%	1.6%	4.0%	0.6%	2.1%	20.2%
	Comparison	70,523	10.2%	6.7%	31.2%	16.6%	6.8%	1.5%	3.9%	0.6%	2.7%	20.0%
	NONC	100,914	9.6%	6.7%	32.1%	18.9%	6.3%	1.4%	3.5%	0.3%	3.1%	17.9%
-6	National	287,531	9.9%	6.5%	33.6%	15.4%	6.7%	1.4%	3.9%	0.5%	2.7%	19.4%
	OCM	97,611	10.6%	6.8%	34.4%	11.9%	7.4%	1.7%	4.1%	0.6%	2.2%	20.3%
	Comparison	79,677	10.0%	6.4%	32.7%	15.6%	6.5%	1.5%	4.0%	0.6%	2.6%	20.0%
	NONC	110,243	9.2%	6.3%	33.6%	18.4%	6.1%	1.2%	3.6%	0.4%	3.1%	18.0%
-5	National	278,171	9.7%	6.4%	34.0%	15.2%	6.5%	1.5%	3.9%	0.5%	2.7%	19.7%
	OCM	95,027	10.4%	6.7%	34.7%	11.8%	7.3%	1.6%	4.2%	0.6%	2.1%	20.5%
	Comparison	77,374	9.8%	6.4%	33.0%	15.2%	6.5%	1.5%	4.1%	0.6%	2.7%	20.3%
	NONC	105,770	9.0%	6.1%	34.0%	18.1%	5.9%	1.3%	3.6%	0.4%	3.1%	18.5%
-4	National	303,016	9.4%	6.3%	34.1%	15.6%	6.3%	1.4%	4.0%	0.5%	2.8%	19.6%
	OCM	102,988	10.0%	6.6%	34.8%	12.0%	7.2%	1.5%	4.3%	0.6%	2.2%	20.7%
	Comparison	85,643	9.5%	6.2%	33.0%	15.9%	6.2%	1.5%	4.1%	0.6%	2.9%	20.3%
	NONC	114,385	8.8%	6.0%	34.2%	18.5%	5.7%	1.2%	3.7%	0.4%	3.2%	18.2%
-3	National	294,303	9.2%	6.2%	34.5%	15.4%	6.2%	1.4%	4.1%	0.6%	2.6%	19.8%
	OCM	99,600	9.8%	6.4%	35.4%	12.0%	7.0%	1.5%	4.3%	0.6%	2.1%	20.9%
	Comparison	83,828	9.3%	6.2%	33.3%	15.7%	6.1%	1.6%	4.2%	0.7%	2.6%	20.4%
	NONC	110,875	8.6%	6.0%	34.6%	18.3%	5.7%	1.3%	3.8%	0.4%	2.9%	18.4%
-2	National	312,437	9.0%	6.1%	34.3%	15.6%	6.2%	1.4%	4.1%	0.7%	2.6%	19.9%
	OCM	106,978	9.6%	6.4%	35.1%	12.1%	7.2%	1.6%	4.3%	0.8%	2.2%	20.8%
	Comparison	89,961	9.3%	6.0%	32.9%	16.1%	6.0%	1.5%	4.2%	0.8%	2.6%	20.7%
	NONC	115,498	8.4%	5.9%	34.6%	18.5%	5.5%	1.2%	3.9%	0.5%	3.0%	18.5%

Source: Episode characteristics file, 2012-2015.

Exhibit A2-2: Share of Episode Volume by Beneficiary Characteristics in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/ TIN Type	Percent of Episodes Among Females	Percent of Episodes among Dual Eligibles	Percentage of Episodes by Age Bracket						Percentage of Episodes by Race			
				< 65	65-69	70-74	75-79	80-84	85+	Non-Hispanic White	Non-Hispanic Black	Hispanic	Other
-8	National	57.0%	15.6%	11.0%	23.7%	22.4%	18.7%	14.0%	10.2%	83.0%	9.2%	4.9%	2.9%
	OCM	59.3%	13.5%	10.9%	24.9%	22.9%	18.5%	13.5%	9.3%	83.0%	9.1%	5.3%	2.7%
	Comparison	56.2%	15.9%	11.9%	23.9%	22.2%	18.5%	13.6%	9.9%	82.7%	10.1%	4.2%	2.9%
	NONC	55.7%	17.4%	10.6%	22.5%	22.1%	18.9%	14.6%	11.2%	83.2%	8.6%	5.1%	3.1%
-7	National	57.4%	16.0%	11.3%	23.5%	22.4%	18.8%	13.7%	10.4%	82.8%	9.2%	5.0%	3.0%
	OCM	59.6%	13.6%	11.0%	24.5%	22.9%	18.6%	13.5%	9.5%	83.1%	9.0%	5.1%	2.8%
	Comparison	56.5%	16.2%	12.3%	23.9%	22.3%	18.4%	13.0%	10.0%	82.3%	10.3%	4.4%	3.0%
	NONC	55.9%	18.0%	10.8%	22.4%	22.1%	19.1%	14.3%	11.3%	82.8%	8.7%	5.2%	3.3%
-6	National	58.4%	15.0%	11.0%	23.6%	22.9%	18.8%	13.6%	10.2%	82.5%	9.5%	4.8%	3.2%
	OCM	60.5%	12.8%	10.8%	24.5%	23.2%	18.7%	13.4%	9.4%	82.7%	9.5%	4.9%	2.9%
	Comparison	57.7%	15.2%	12.0%	24.0%	22.7%	18.4%	12.9%	9.9%	82.1%	10.5%	4.2%	3.2%
	NONC	57.0%	16.9%	10.6%	22.6%	22.6%	19.0%	14.1%	11.1%	82.6%	8.9%	5.1%	3.4%
-5	National	58.7%	15.1%	11.1%	23.6%	22.9%	18.9%	13.3%	10.3%	82.4%	9.4%	4.9%	3.4%
	OCM	60.6%	12.8%	10.6%	24.5%	23.3%	19.0%	13.1%	9.5%	82.5%	9.4%	5.0%	3.1%
	Comparison	58.1%	15.2%	12.0%	24.3%	22.6%	18.5%	12.8%	9.8%	81.9%	10.4%	4.3%	3.5%
	NONC	57.3%	17.0%	10.7%	22.4%	22.7%	19.0%	13.8%	11.3%	82.6%	8.8%	5.1%	3.5%
-4	National	58.5%	14.4%	10.8%	23.9%	23.0%	19.0%	13.1%	10.2%	82.6%	9.3%	4.7%	3.4%
	OCM	60.5%	12.1%	10.2%	24.9%	23.6%	19.1%	12.8%	9.3%	82.8%	9.1%	5.0%	3.2%
	Comparison	57.6%	14.4%	11.6%	24.4%	22.7%	18.7%	12.7%	9.9%	82.0%	10.4%	4.1%	3.5%
	NONC	57.2%	16.4%	10.7%	22.7%	22.7%	19.1%	13.6%	11.2%	82.8%	8.7%	4.9%	3.6%
-3	National	58.7%	14.4%	10.7%	24.2%	23.1%	19.0%	12.9%	10.2%	82.6%	9.2%	4.8%	3.5%
	OCM	60.9%	11.9%	10.1%	24.9%	23.7%	19.1%	12.7%	9.4%	82.7%	9.1%	4.9%	3.3%
	Comparison	57.7%	14.4%	11.6%	24.7%	22.9%	18.4%	12.5%	9.8%	82.3%	10.0%	4.1%	3.5%
	NONC	57.4%	16.5%	10.7%	23.0%	22.6%	19.2%	13.4%	11.1%	82.7%	8.6%	5.1%	3.6%
-2	National	58.4%	13.9%	10.6%	24.5%	23.2%	18.9%	12.8%	9.9%	82.5%	9.2%	4.7%	3.6%
	OCM	60.5%	11.5%	10.0%	25.4%	23.8%	19.0%	12.6%	9.3%	82.7%	9.1%	4.8%	3.4%
	Comparison	57.5%	14.0%	11.4%	24.9%	23.2%	18.5%	12.6%	9.4%	82.2%	9.8%	4.3%	3.7%
	NONC	57.1%	16.2%	10.6%	23.3%	22.8%	19.1%	13.3%	10.9%	82.4%	8.7%	5.1%	3.8%

Source: Episode characteristics file, 2012-2015

Exhibit A2-3: Distribution of Standardized Part A and B, and Part D Costs per Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	N	Mean	Standard Deviation	Minimum	1st Quartile	Median	3rd Quartile	Maximum
-8	OCM	101,192	\$25,817	\$24,249	\$0	\$6,209	\$20,150	\$38,055	\$499,769
	Comparison	80,345	\$23,979*	\$23,773	\$0	\$4,892	\$17,912	\$35,337	\$375,731
-7	OCM	88,489	\$26,018	\$24,588	\$1	\$6,168	\$20,284	\$38,509	\$516,477
	Comparison	70,523	\$24,389*	\$24,794	\$0	\$4,832	\$18,188	\$36,121	\$1,312,285
-6	OCM	97,611	\$26,278	\$25,450	\$0	\$5,596	\$20,399	\$39,265	\$1,117,612
	Comparison	79,677	\$24,939*	\$29,294	\$0	\$4,612	\$18,721	\$37,181	\$4,416,721
-5	OCM	95,027	\$26,295	\$25,384	\$0	\$5,426	\$20,306	\$39,378	\$498,657
	Comparison	77,374	\$24,883*	\$26,954	\$0	\$4,564	\$18,610	\$37,082	\$2,812,493
-4	OCM	102,988	\$26,780	\$25,709	\$0	\$5,287	\$20,514	\$40,637	\$531,357
	Comparison	85,643	\$25,521*	\$25,931	\$0	\$4,468	\$18,678	\$38,649	\$570,965
-3	OCM	99,600	\$26,960	\$26,281	\$0	\$5,206	\$20,761	\$40,546	\$480,289
	Comparison	83,828	\$25,816*	\$26,067	\$0	\$4,626	\$19,325	\$38,840	\$544,588
-2	OCM	106,978	\$28,366	\$27,522	\$0	\$5,373	\$21,624	\$43,312	\$686,160
	Comparison	89,961	\$27,303*	\$27,605	\$0	\$4,736	\$20,149	\$41,674	\$638,283

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-4: Distribution of Part B and Part D Chemotherapy Costs per Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	N	Mean	Standard Deviation	Minimum	1st Quartile	Median	3rd Quartile	Maximum
-8	OCM	101,192	\$8,800	\$13,777	\$0	\$50	\$1,455	\$13,163	\$332,933
	Comparison	80,345	\$8,107*	\$13,467	\$0	\$35	\$1,110	\$11,438	\$210,199
-7	OCM	88,489	\$9,189	\$14,217	\$0	\$57	\$1,370	\$14,031	\$235,272
	Comparison	70,523	\$8,517*	\$14,039	\$0	\$42	\$1,060	\$12,415	\$216,846
-6	OCM	97,611	\$9,370	\$14,875	\$0	\$23	\$1,088	\$14,322	\$260,486
	Comparison	79,677	\$8,870*	\$14,648	\$0	\$12	\$972	\$12,985	\$271,136
-5	OCM	95,027	\$9,683	\$15,172	\$0	\$24	\$1,105	\$15,034	\$235,831
	Comparison	77,374	\$9,059*	\$14,932	\$0	\$15	\$961	\$13,410	\$207,841
-4	OCM	102,988	\$10,282	\$16,138	\$0	\$9	\$1,134	\$15,748	\$247,313
	Comparison	85,643	\$9,755*	\$16,059	\$0	\$0	\$1,016	\$14,351	\$205,865
-3	OCM	99,600	\$10,318	\$16,304	-\$36,478	\$10	\$1,253	\$15,805	\$405,181
	Comparison	83,828	\$9,895*	\$16,310	\$0	\$1	\$1,085	\$14,547	\$224,484
-2	OCM	106,978	\$11,453	\$17,999	\$0	\$6	\$1,338	\$17,447	\$631,878
	Comparison	89,961	\$11,087*	\$18,055	\$0	\$0	\$1,087	\$16,441	\$295,978

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-5: Inpatient Stays per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of Inpatient Stays									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	0.72	0.56	0.21	0.28*	0.50	0.73	0.51	0.57	0.52*	0.64
	OCM	0.72	0.55	0.21	0.31	0.49	0.76	0.53	0.58	0.63	0.65
	Comparison	0.67*	0.54	0.21	0.27*	0.51	0.67*	0.51	0.63	0.55*	0.62*
	NONC	0.75*	0.57	0.21	0.26*	0.50	0.74	0.50	0.49	0.44*	0.66
-7	National	0.71	0.57	0.21	0.28*	0.48	0.72	0.52	0.58	0.53*	0.62
	OCM	0.71	0.56	0.22	0.31	0.48	0.72	0.51	0.59	0.63	0.63
	Comparison	0.66*	0.53	0.21*	0.26*	0.48	0.74	0.51	0.59	0.54*	0.60*
	NONC	0.74	0.59*	0.21*	0.27*	0.48	0.71	0.53	0.54	0.47*	0.64
-6	National	0.69	0.56	0.19	0.26*	0.48	0.70	0.50	0.56	0.52*	0.61
	OCM	0.70	0.55	0.20	0.29	0.48	0.74	0.51	0.60	0.66	0.62
	Comparison	0.65*	0.54	0.19*	0.25*	0.49	0.69	0.50	0.55	0.50*	0.59*
	NONC	0.71	0.58	0.19	0.24*	0.47	0.66	0.50	0.53	0.43*	0.62
-5	National	0.68	0.54	0.19*	0.27*	0.49	0.69	0.47	0.57	0.51*	0.59
	OCM	0.69	0.54	0.19	0.30	0.50	0.70	0.48	0.61	0.63	0.60
	Comparison	0.63*	0.51	0.19	0.26*	0.50	0.67	0.45	0.58	0.50*	0.57*
	NONC	0.70	0.57	0.18*	0.25*	0.48	0.69	0.47	0.50*	0.44*	0.60
-4	National	0.66	0.55	0.18	0.25*	0.46	0.69	0.48	0.64	0.50*	0.59*
	OCM	0.67	0.55	0.19	0.29	0.45	0.70	0.49	0.64	0.62	0.61
	Comparison	0.62*	0.55	0.19	0.24*	0.47	0.68	0.44*	0.67	0.48*	0.57*
	NONC	0.68	0.55	0.18	0.24*	0.47	0.69	0.49	0.60	0.45*	0.59*
-3	National	0.67	0.55	0.19	0.26*	0.48	0.66	0.48	0.60	0.51*	0.59*
	OCM	0.68	0.56	0.19	0.30	0.49	0.66	0.47	0.62	0.65	0.61
	Comparison	0.64*	0.53*	0.19	0.26*	0.48	0.66	0.47	0.60	0.51*	0.57*
	NONC	0.68	0.57	0.18	0.24*	0.48	0.67	0.49	0.56	0.41*	0.59*
-2	National	0.66	0.53	0.18	0.25*	0.48	0.67	0.45	0.54	0.49*	0.58*
	OCM	0.68	0.53	0.18	0.28	0.49	0.69	0.46	0.56	0.61	0.60
	Comparison	0.61*	0.51	0.17	0.24*	0.48	0.66	0.45	0.52	0.48*	0.55*
	NONC	0.68	0.55	0.18	0.24*	0.47	0.65	0.44	0.54	0.41*	0.58

Source: Episode characteristics file, 2012-2015. Note: * Denotes a significant difference from OCM practices.

Exhibit A2-6: Inpatient Days per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of Inpatient Days (among episodes with 1+ inpatient stay)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	8.68	8.91	6.52	6.90*	9.90	9.96	11.58	7.41	8.95	9.47
	OCM	8.74	8.73	6.55	7.24	9.86	9.89	11.48	7.53	9.59	9.33
	Comparison	8.14*	8.97	6.43	6.80*	10.16	9.02	11.55	7.53	8.56*	9.62
	NONC	8.99	9.02	6.56	6.73*	9.75	10.73	11.73	7.10	8.71*	9.51
-7	National	8.76	9.16	6.70	7.18	9.95	9.83	11.24	7.99	9.16	9.48
	OCM	8.60	8.81	6.87	7.37	10.04	9.88	11.61	8.84	9.65	9.41
	Comparison	8.51	9.11	6.72	6.94*	10.08	10.40	11.36	7.77	8.91	9.58
	NONC	9.10*	9.52*	6.53*	7.21	9.75	9.35	10.79	7.05*	8.95	9.47
-6	National	8.50	8.69	6.44	6.97	9.81	9.58	11.28	7.87	8.87	9.34
	OCM	8.56	8.62	6.58	7.33	9.83	9.89	11.90	7.89	9.42	9.39
	Comparison	8.44	8.42	6.24*	6.77*	9.77	9.14	11.07	8.32	9.19	9.33
	NONC	8.48	8.94	6.45	6.87*	9.82	9.59	10.79*	7.38	8.14*	9.30
-5	National	8.65	8.84	6.52	7.00	10.22	9.66	11.31	8.17	8.70	9.43
	OCM	8.74	8.77	6.64	7.31	10.63	9.85	10.97	8.61	8.91	9.51
	Comparison	8.32*	8.72	6.39	6.99	10.11	9.53	11.00	8.17	8.78	9.37
	NONC	8.79	9.00	6.49	6.79*	9.84*	9.55	11.94	7.51	8.46	9.40
-4	National	8.47	8.66	6.41	6.88	9.91	9.57	10.73	8.22	8.81	9.26
	OCM	8.58	8.76	6.42	6.98	9.93	9.42	10.70	8.56	9.30	9.35
	Comparison	8.03*	8.40	6.42	6.74	9.88	9.55	11.21	7.86	8.55	9.43
	NONC	8.69	8.77	6.39	6.90	9.91	9.76	10.39	8.18	8.58	9.04*
-3	National	8.59	8.68	6.63	7.07	9.96	9.56	10.84	8.23	8.82	9.18
	OCM	8.62	8.93	6.66	7.35	10.44	9.69	11.16	8.32	9.27	9.27
	Comparison	8.43	8.05*	6.55	6.91*	9.98	9.39	10.87	8.18	8.70	9.13
	NONC	8.69	8.93	6.66	6.98	9.44*	9.57	10.50	8.18	8.49	9.12
-2	National	8.52	8.52	6.31	6.62*	10.22	9.47	10.75	8.30	8.45*	9.15
	OCM	8.53	8.43	6.35	7.02	10.54	9.65	11.03	8.33	9.27	9.31
	Comparison	8.15*	8.49	6.17	6.38*	10.26	9.62	10.59	8.47	8.44*	8.92*
	NONC	8.80	8.63	6.38	6.51*	9.81*	9.09	10.56	8.06	7.71*	9.18

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-7: 30-Day Hospital Readmissions per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of 30-Day Hospital Readmissions (among episodes with 1+ inpatient stay)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	0.47	0.37	0.24	0.29	0.56	0.50	0.57	0.38	0.41	0.47*
	OCM	0.47	0.35	0.25	0.31	0.59	0.52	0.57	0.35	0.42	0.45
	Comparison	0.42*	0.38	0.24	0.29	0.57	0.44	0.58	0.50	0.40	0.48*
	NONC	0.49	0.38	0.24	0.27*	0.52*	0.52	0.58	0.28	0.40	0.49*
-7	National	0.46	0.38	0.25	0.30	0.55	0.49	0.56	0.41	0.44	0.47
	OCM	0.45	0.37	0.26	0.33	0.55	0.50	0.56	0.45	0.44	0.45
	Comparison	0.44	0.36	0.25	0.28*	0.56	0.48	0.55	0.45	0.45	0.46
	NONC	0.47	0.39	0.24*	0.29*	0.54	0.49	0.58	0.31	0.43	0.49*
-6	National	0.46	0.35	0.25	0.29	0.59	0.49	0.58	0.43	0.41	0.47
	OCM	0.46	0.34	0.26	0.32	0.60	0.50	0.57	0.39	0.45	0.46
	Comparison	0.44	0.33	0.24	0.27*	0.61	0.50	0.56	0.50	0.40	0.46
	NONC	0.46	0.39*	0.25	0.29	0.56	0.45	0.59	0.43	0.38*	0.49
-5	National	0.46	0.35	0.24	0.29*	0.61	0.47	0.55	0.35	0.38	0.44
	OCM	0.47	0.35	0.25	0.34	0.65	0.50	0.56	0.38	0.40	0.43
	Comparison	0.43*	0.34	0.24	0.27*	0.64	0.46	0.53	0.33	0.40	0.44
	NONC	0.47	0.37	0.23	0.27*	0.53*	0.44	0.56	0.32	0.34	0.45
-4	National	0.45	0.36	0.24	0.29	0.60	0.48	0.54	0.47	0.42	0.45
	OCM	0.45	0.36	0.25	0.30	0.61	0.46	0.55	0.51	0.44	0.46
	Comparison	0.41*	0.36	0.25	0.28	0.64	0.48	0.51	0.50	0.38	0.46
	NONC	0.46	0.37	0.23	0.29	0.55	0.51	0.54	0.38	0.42	0.44
-3	National	0.45	0.37	0.25	0.29	0.59	0.46	0.52	0.42	0.40	0.44
	OCM	0.45	0.37	0.24	0.31	0.63	0.51	0.53	0.46	0.44	0.44
	Comparison	0.44	0.34	0.26	0.30	0.59	0.46	0.50	0.40	0.39	0.43
	NONC	0.46	0.38	0.25	0.27*	0.54*	0.40*	0.52	0.40	0.37*	0.44
-2	National	0.46	0.35	0.24	0.29*	0.65	0.49	0.50	0.43	0.38	0.45
	OCM	0.45	0.34	0.25	0.32	0.68	0.54	0.52	0.44	0.44	0.47
	Comparison	0.44	0.34	0.23	0.27*	0.67	0.45	0.49	0.43	0.39	0.43*
	NONC	0.48	0.37	0.24	0.27*	0.60*	0.47	0.51	0.41	0.33*	0.46

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-8: Intensive Care Unit Admissions per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of Intensive Care Unit Admissions (among episodes with 1+ inpatient stay)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	0.24	0.20	0.15	0.19	0.21	0.29	0.23	0.22	0.25	0.23
	OCM	0.25	0.21	0.16	0.19	0.22	0.30	0.22	0.30	0.26	0.23
	Comparison	0.22*	0.19*	0.15	0.19	0.20	0.24*	0.23	0.16*	0.25	0.24
	NONC	0.25	0.19*	0.15	0.18	0.21	0.30	0.25	0.20	0.23	0.22
-7	National	0.24*	0.22	0.15	0.19	0.22	0.29	0.24	0.18	0.23	0.23
	OCM	0.26	0.22	0.16	0.20	0.24	0.26	0.26	0.20	0.24	0.24
	Comparison	0.21*	0.19	0.15	0.18	0.18*	0.32	0.22	0.18	0.22	0.23
	NONC	0.24*	0.24	0.15	0.18	0.22	0.30	0.24	0.17	0.23	0.22*
-6	National	0.25	0.20	0.15	0.19	0.22	0.29	0.24	0.24	0.25	0.24
	OCM	0.26	0.19	0.16	0.20	0.22	0.29	0.25	0.29	0.25	0.25
	Comparison	0.24*	0.18	0.15	0.18	0.20	0.31	0.22	0.22	0.26	0.24
	NONC	0.25	0.21	0.15*	0.19	0.24	0.28	0.26	0.19	0.24	0.22*
-5	National	0.24	0.23	0.16	0.19	0.24	0.28	0.23	0.26	0.23	0.24
	OCM	0.26	0.23	0.17	0.19	0.25	0.28	0.25	0.27	0.25	0.25
	Comparison	0.22*	0.22	0.16	0.19	0.23	0.30	0.21	0.32	0.22	0.23
	NONC	0.24	0.22	0.15*	0.19	0.23	0.25	0.23	0.17*	0.22	0.23
-4	National	0.25	0.21	0.16	0.20	0.23	0.28	0.23	0.23	0.27	0.23*
	OCM	0.26	0.22	0.16	0.21	0.22	0.27	0.23	0.25	0.30	0.25
	Comparison	0.22*	0.20	0.16	0.18*	0.22	0.32	0.24	0.22	0.26	0.22*
	NONC	0.25	0.21	0.16	0.20	0.24	0.25	0.22	0.23	0.24*	0.22*
-3	National	0.25*	0.20	0.16	0.20	0.24	0.29	0.25	0.30	0.25	0.23*
	OCM	0.27	0.22	0.16	0.20	0.26	0.29	0.27	0.32	0.26	0.25
	Comparison	0.23*	0.17*	0.16	0.18	0.21*	0.29	0.25	0.30	0.26	0.21*
	NONC	0.24*	0.21	0.16	0.20	0.23	0.29	0.23	0.26	0.24	0.22*
-2	National	0.25	0.20	0.16	0.18	0.22	0.28	0.23	0.25	0.22	0.23
	OCM	0.26	0.22	0.16	0.19	0.23	0.27	0.23	0.23	0.23	0.24
	Comparison	0.22*	0.19	0.15	0.18	0.23	0.31	0.23	0.28	0.22	0.22*
	NONC	0.27	0.20	0.16	0.18	0.21	0.27	0.23	0.22	0.22	0.22*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-9: Part A Inpatient Costs per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/ TIN Type	Average Part A Inpatient Costs (among episodes with 1+ inpatient stay)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	\$12,726	\$12,927	\$9,860	\$10,533	\$15,116	\$14,751	\$18,567	\$11,948	\$14,077	\$14,128
	OCM	\$12,981	\$12,764	\$9,749	\$10,897	\$15,192	\$15,057	\$18,679	\$12,833	\$14,800	\$14,031
	Comparison	\$11,972*	\$13,194	\$9,883	\$10,378	\$15,550	\$13,820	\$19,054	\$11,562	\$13,679	\$14,341
	NONC	\$12,993	\$12,901	\$9,946	\$10,390	\$14,724	\$15,104	\$18,064	\$11,168	\$13,775	\$14,070
-7	National	\$12,949	\$13,399	\$10,060	\$11,183	\$15,260	\$14,504	\$17,756	\$11,638	\$14,119	\$14,319
	OCM	\$12,760	\$13,097	\$10,381	\$11,616	\$15,480	\$14,169	\$18,073	\$12,038	\$14,564	\$14,364
	Comparison	\$12,668	\$13,349	\$10,122	\$10,844*	\$15,271	\$15,883	\$18,251	\$11,631	\$13,841	\$14,657
	NONC	\$13,325*	\$13,710	\$9,722*	\$11,103	\$15,015	\$13,814	\$17,077	\$11,076	\$13,959	\$14,022
-6	National	\$13,109	\$13,113	\$10,255	\$11,065	\$15,635	\$14,706	\$18,854	\$12,382	\$14,214	\$14,574
	OCM	\$13,298	\$12,758	\$10,363	\$11,482	\$15,565	\$14,879	\$19,538	\$12,641	\$14,397	\$14,706
	Comparison	\$13,071	\$12,950	\$10,031	\$10,857	\$15,968	\$15,066	\$18,670	\$13,115	\$15,078	\$14,599
	NONC	\$12,948	\$13,558*	\$10,311	\$10,919	\$15,455	\$14,128	\$18,288	\$11,260	\$13,438	\$14,421
-5	National	\$12,977	\$13,409	\$10,293	\$11,172	\$16,171	\$14,746	\$18,877	\$12,981	\$14,124	\$14,634
	OCM	\$13,085	\$13,230	\$10,402	\$11,144	\$16,511	\$15,448	\$18,089	\$13,609	\$14,148	\$14,866
	Comparison	\$12,668	\$13,429	\$10,246	\$11,461	\$16,501	\$15,190	\$18,387	\$12,985	\$14,347	\$14,682
	NONC	\$13,095	\$13,565	\$10,223	\$11,010	\$15,536	\$13,625*	\$20,156*	\$11,997	\$13,951	\$14,363
-4	National	\$12,946	\$13,083	\$10,312	\$11,117	\$15,816	\$14,648	\$18,211	\$13,227	\$14,583	\$14,464
	OCM	\$12,997	\$13,130	\$10,283	\$11,151	\$15,561	\$14,031	\$18,257	\$13,732	\$15,418	\$14,671
	Comparison	\$12,634	\$12,989	\$10,469	\$11,038	\$16,336	\$14,762	\$19,069	\$13,367	\$14,324	\$14,615
	NONC	\$13,133	\$13,111	\$10,224	\$11,144	\$15,684	\$15,275	\$17,525	\$12,316	\$14,070*	\$14,119*
-3	National	\$12,986	\$13,304	\$10,631	\$11,401	\$15,874	\$14,839	\$18,146	\$12,836	\$14,598	\$14,547
	OCM	\$13,182	\$13,521	\$10,688	\$11,644	\$16,559	\$15,315	\$18,760	\$12,643	\$15,084	\$14,759
	Comparison	\$12,845	\$12,699*	\$10,580	\$11,236	\$15,829	\$15,499	\$18,302	\$12,813	\$14,440	\$14,704
	NONC	\$12,895	\$13,555	\$10,616	\$11,344	\$15,171*	\$13,736	\$17,396	\$13,125	\$14,274	\$14,200*
-2	National	\$13,217	\$13,404	\$10,464	\$11,419	\$16,822	\$15,332	\$19,189	\$13,498	\$14,616	\$14,857
	OCM	\$13,137	\$13,296	\$10,448	\$12,138	\$16,822	\$14,545	\$19,846	\$13,442	\$15,186	\$15,168
	Comparison	\$12,753	\$13,639	\$10,530	\$11,113*	\$17,663	\$16,710	\$18,963	\$14,597	\$14,866	\$14,635*
	NONC	\$13,672*	\$13,337	\$10,431	\$11,129*	\$16,122	\$14,927	\$18,674	\$12,268	\$13,907*	\$14,710

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-10: Part A Costs for 30-Day Hospital Readmissions per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Average Part A Costs for 30-Day Readmissions (among episodes with 1+ readmission)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	\$12,228	\$12,687	\$10,736	\$11,457	\$15,996	\$14,690	\$20,619	\$11,463	\$12,630	\$13,747
	OCM	\$12,229	\$12,604	\$11,078	\$11,872	\$16,358	\$15,897	\$19,800	\$13,925	\$13,170	\$13,557
	Comparison	\$11,646	\$12,936	\$9,758*	\$11,547	\$15,971	\$14,287	\$20,870	\$10,637	\$11,775	\$13,897
	NONC	\$12,587	\$12,596	\$11,096	\$11,091	\$15,626	\$13,683	\$21,340	\$9,230	\$12,856	\$13,818
-7	National	\$12,391	\$12,916	\$11,267	\$11,600	\$16,272	\$14,510	\$17,422	\$10,502	\$13,571	\$13,692
	OCM	\$11,900	\$12,368	\$11,437	\$11,489	\$15,897	\$15,182	\$17,238	\$10,191	\$14,230	\$13,798
	Comparison	\$11,917	\$12,753	\$11,069	\$11,900	\$16,838	\$14,862	\$16,707	\$9,644	\$12,767	\$13,982
	NONC	\$13,196*	\$13,529	\$11,233	\$11,504	\$16,277	\$13,577	\$18,125	\$12,689	\$13,603	\$13,384
-6	National	\$12,563	\$12,554	\$11,324	\$12,147	\$16,278	\$15,047	\$20,202	\$12,514	\$12,493	\$14,034
	OCM	\$12,861	\$11,943	\$11,651	\$13,118	\$15,887	\$15,526	\$20,995	\$13,957	\$12,326	\$14,128
	Comparison	\$12,703	\$12,203	\$10,764	\$11,293*	\$17,443	\$16,148	\$20,169	\$14,557	\$13,474	\$13,612
	NONC	\$12,175	\$13,265*	\$11,390	\$11,986	\$15,784	\$13,310	\$19,418	\$8,797*	\$11,927	\$14,267
-5	National	\$12,216	\$13,070	\$11,585	\$11,508	\$17,773	\$15,355	\$20,110	\$13,351	\$12,482	\$14,325
	OCM	\$12,474	\$12,559	\$11,554	\$11,068	\$17,903	\$16,749	\$19,831	\$13,298	\$11,684	\$14,543
	Comparison	\$12,033	\$12,839	\$11,803	\$12,234	\$18,832	\$15,436	\$18,701	\$11,353	\$13,005	\$14,130
	NONC	\$12,087	\$13,720	\$11,449	\$11,412	\$16,713	\$13,655	\$21,522	\$16,638	\$12,906	\$14,259
-4	National	\$12,439	\$12,314	\$11,152	\$11,954	\$17,232	\$14,492	\$18,969	\$13,668	\$12,332	\$13,952
	OCM	\$12,324	\$12,071	\$11,355	\$11,796	\$17,584	\$13,204	\$19,384	\$15,041	\$12,673	\$14,219
	Comparison	\$12,169	\$12,178	\$11,504	\$11,906	\$17,386	\$16,003	\$19,564	\$13,247	\$12,081	\$13,810
	NONC	\$12,743	\$12,668	\$10,666	\$12,101	\$16,706	\$14,653	\$18,096	\$12,057	\$12,178	\$13,784
-3	National	\$13,534	\$13,898	\$13,033	\$12,981	\$19,374	\$17,857	\$21,585	\$13,905	\$14,907	\$15,483
	OCM	\$13,797	\$13,993	\$12,897	\$13,707	\$19,363	\$19,596	\$21,836	\$13,411	\$14,140	\$15,546
	Comparison	\$12,945	\$13,199	\$12,466	\$12,456	\$20,742	\$17,977	\$20,529	\$15,303	\$15,331	\$15,687
	NONC	\$13,722	\$14,283	\$13,588	\$12,800	\$18,328	\$15,582	\$22,176	\$12,943	\$15,394	\$15,252
-2	National	\$15,508*	\$16,006	\$14,938*	\$15,549	\$24,525	\$20,153	\$26,023	\$18,454	\$16,929	\$18,663
	OCM	\$14,578	\$15,477	\$13,889	\$17,310	\$24,713	\$22,228	\$26,074	\$18,451	\$17,985	\$18,504
	Comparison	\$15,398	\$16,220	\$15,717*	\$14,933	\$25,352	\$20,255	\$25,742	\$20,230	\$16,668	\$18,784
	NONC	\$16,527*	\$16,346	\$15,450*	\$14,601	\$23,556	\$17,569*	\$26,196	\$16,401	\$16,023	\$18,738

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-11: Proportion of Episodes Using Home Health Services by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Proportion of Episodes Utilizing Home Health Services											
		N	Overall	Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	298,752	18.1%	26.6%	26.5%	11.4%	12.3%	16.8%	37.2%	15.4%	19.7%	20.3%	25.2%
	OCM	101,192	19.4%	27.7%	26.4%	12.0%	14.2%	17.6%	41.1%	17.3%	21.1%	26.0%	25.5%
	Comparison	80,345	17.7%	25.3%	27.1%	11.1%	12.2%	16.7%	36.3%	13.6%	18.3%	21.2%	24.5%
	NONC	117,215	17.2%	26.6%	26.1%	11.1%	11.2%	16.1%	33.7%	15.0%	19.5%	16.3%	25.4%
-7	National	259,926	18.0%	27.2%	26.9%	11.4%	12.5%	16.3%	36.7%	15.8%	22.2%	20.3%	24.6%
	OCM	88,489	19.0%	28.3%	26.5%	12.0%	14.1%	16.9%	39.3%	15.9%	22.2%	24.7%	24.9%
	Comparison	70,523	17.8%	25.9%	27.1%	11.0%	12.0%	15.9%	35.2%	16.6%	23.2%	20.8%	24.7%
	NONC	100,914	17.2%	27.1%	27.2%	11.1%	11.8%	16.0%	35.2%	15.1%	21.0%	17.3%	24.3%
-6	National	287,531	17.6%	26.6%	27.1%	10.9%	12.4%	16.2%	38.0%	15.9%	20.4%	21.5%	24.1%
	OCM	97,611	18.7%	27.6%	26.2%	11.8%	13.8%	16.5%	38.5%	16.9%	20.6%	26.7%	24.6%
	Comparison	79,677	17.3%	25.2%	28.0%	10.4%	12.1%	15.7%	38.5%	16.2%	18.2%	21.7%	24.0%
	NONC	110,243	16.7%	26.6%	27.3%	10.4%	11.7%	16.4%	36.7%	14.6%	22.4%	18.2%	23.7%
-5	National	278,171	17.6%	26.7%	27.1%	10.6%	12.8%	17.0%	37.6%	15.1%	23.8%	20.8%	24.2%
	OCM	95,027	18.6%	28.0%	26.6%	11.3%	14.1%	17.3%	38.6%	16.1%	26.0%	23.6%	24.7%
	Comparison	77,374	17.3%	25.0%	27.5%	10.3%	12.5%	16.7%	37.5%	14.9%	23.1%	22.0%	24.0%
	NONC	105,770	16.8%	26.8%	27.2%	10.2%	12.3%	16.8%	36.6%	14.3%	21.6%	18.2%	23.9%
-4	National	303,016	17.2%	27.3%	26.7%	10.3%	12.1%	16.3%	36.5%	15.7%	22.5%	19.9%	24.0%
	OCM	102,988	18.5%	28.5%	27.1%	10.9%	13.3%	17.0%	38.1%	17.3%	23.1%	25.0%	25.0%
	Comparison	85,643	16.9%	26.2%	27.0%	9.8%	12.1%	16.1%	36.0%	14.0%	21.9%	20.1%	23.6%
	NONC	114,385	16.2%	26.8%	26.0%	10.1%	11.4%	15.7%	35.2%	15.3%	22.3%	16.6%	23.3%
-3	National	294,303	17.2%	26.7%	26.7%	10.4%	12.5%	17.0%	36.4%	15.4%	21.6%	20.3%	23.8%
	OCM	99,600	18.5%	27.8%	27.3%	11.2%	14.2%	17.6%	37.4%	16.1%	21.8%	25.5%	24.8%
	Comparison	83,828	17.0%	25.7%	26.9%	10.0%	12.3%	16.5%	36.3%	14.9%	22.1%	20.4%	23.4%
	NONC	110,875	16.2%	26.4%	25.9%	10.0%	11.5%	16.6%	35.5%	15.1%	20.8%	17.0%	23.1%
-2	National	312,437	17.1%	26.7%	26.5%	10.3%	12.3%	16.5%	36.7%	15.1%	20.5%	20.1%	23.8%
	OCM	106,978	18.1%	28.3%	26.5%	10.6%	13.8%	17.1%	39.7%	16.1%	22.8%	25.2%	24.2%
	Comparison	89,961	16.9%	25.1%	27.2%	10.0%	12.3%	15.4%	35.7%	14.9%	19.7%	19.8%	23.6%
	NONC	115,498	16.2%	26.3%	25.8%	10.2%	11.4%	16.7%	34.2%	14.1%	18.4%	16.9%	23.6%

Source: Episode characteristics file, 2012-2015.

Exhibit A2-12: Proportion of Episodes with at Least One Imaging Visit by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Proportion of Episodes with at Least One Imaging Visit									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	98.4%	92.7%	85.2%	70.6%	89.4%	96.6%	74.8%	95.3%	82.0%	90.5%
	OCM	98.4%	93.0%	85.9%	74.1%	89.7%	97.3%	76.0%	95.6%	88.2%	90.6%
	Comparison	98.4%	93.0%	84.6%	71.5%	89.3%	95.9%	74.8%	96.5%	82.8%	91.1%
	NONC	98.4%	92.3%	85.0%	68.0%	89.0%	96.3%	73.7%	93.4%	77.9%	89.9%
-7	National	98.4%	93.2%	84.8%	71.0%	88.5%	96.5%	73.7%	94.6%	81.1%	89.9%
	OCM	98.6%	93.4%	85.5%	74.3%	89.0%	96.4%	74.2%	95.2%	86.8%	90.0%
	Comparison	98.5%	93.8%	84.9%	71.2%	89.0%	97.3%	74.3%	95.1%	80.2%	90.7%
	NONC	98.1%	92.6%	84.1%	68.9%	87.5%	96.1%	72.6%	93.2%	78.2%	89.1%
-6	National	98.3%	93.0%	84.6%	70.8%	88.1%	96.8%	74.2%	94.4%	80.6%	89.6%
	OCM	98.3%	93.3%	85.3%	73.6%	88.2%	97.8%	76.0%	96.2%	86.7%	89.7%
	Comparison	98.3%	93.6%	84.6%	71.5%	88.6%	96.2%	73.9%	95.7%	81.2%	90.0%
	NONC	98.3%	92.3%	84.1%	68.7%	87.5%	96.1%	72.6%	90.9%	76.4%	89.3%
-5	National	98.4%	92.6%	83.9%	70.8%	88.3%	96.7%	73.0%	94.4%	80.8%	89.7%
	OCM	98.6%	92.5%	84.4%	74.2%	89.0%	96.6%	74.7%	95.9%	86.0%	90.0%
	Comparison	98.4%	93.4%	83.8%	71.5%	88.0%	96.8%	72.5%	95.5%	82.4%	90.3%
	NONC	98.2%	92.0%	83.6%	68.5%	87.8%	96.7%	71.6%	91.2%	76.7%	89.0%
-4	National	98.3%	93.0%	83.9%	70.9%	88.0%	96.8%	73.5%	94.5%	81.2%	89.5%
	OCM	98.3%	93.7%	84.2%	74.1%	89.0%	97.2%	74.4%	95.2%	87.6%	89.4%
	Comparison	98.5%	93.3%	84.0%	71.4%	87.9%	96.7%	73.3%	95.1%	81.8%	90.0%
	NONC	98.1%	92.1%	83.6%	68.7%	87.0%	96.4%	72.7%	92.9%	77.0%	89.2%
-3	National	98.3%	93.4%	83.6%	71.8%	88.5%	97.2%	73.9%	95.9%	82.0%	89.8%
	OCM	98.4%	94.0%	84.0%	75.1%	88.9%	97.2%	73.8%	96.1%	88.3%	89.6%
	Comparison	98.5%	93.6%	83.6%	72.4%	88.5%	97.3%	74.9%	96.5%	84.1%	90.5%
	NONC	98.1%	92.7%	83.3%	69.6%	88.2%	97.1%	73.2%	94.9%	76.6%	89.5%
-2	National	98.5%	93.3%	84.1%	72.0%	88.0%	96.9%	73.6%	96.0%	80.5%	89.6%
	OCM	98.5%	93.8%	84.7%	74.5%	88.7%	96.8%	74.5%	96.4%	86.3%	89.4%
	Comparison	98.5%	93.7%	84.0%	72.3%	87.7%	97.1%	73.3%	96.4%	80.4%	89.9%
	NONC	98.3%	92.5%	83.7%	70.3%	87.4%	96.7%	72.8%	94.9%	76.7%	89.4%

Source: Episode characteristics file, 2012-2015.

Exhibit A2-13: Standard Imaging Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of Standard Imaging Visits (among episodes with 1+ imaging visit)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	3.78	2.52	2.8	2.31*	2.81	3.52	3.6	2.48	3.15*	3.41
	OCM	3.75	2.46	2.78	2.44	2.75	3.47	3.56	2.42	3.41	3.41
	Comparison	3.65	2.48	2.79	2.28*	2.86	3.44	3.63	2.64	3.2	3.38
	NONC	3.90*	2.62*	2.83	2.26*	2.85	3.63	3.6	2.37	2.94*	3.44
-7	National	3.71	2.54	2.78	2.33	2.82	3.35	3.68	2.67	3.18*	3.42
	OCM	3.61	2.49	2.76	2.35	2.79	3.28	3.6	2.71	3.44	3.44
	Comparison	3.59	2.44	2.79	2.3	2.83	3.47	3.85	2.67	3.14*	3.39
	NONC	3.92*	2.65*	2.79	2.33	2.85	3.33	3.63	2.61	3.03*	3.43
-6	National	3.62	2.46	2.76	2.22	2.72	3.39	3.55	2.41	3.05	3.35
	OCM	3.62	2.37	2.73	2.29	2.64	3.25	3.58	2.47	3.24	3.38
	Comparison	3.56	2.44	2.75	2.21	2.74	3.55	3.56	2.48	3.16	3.34
	NONC	3.67	2.57*	2.78*	2.19*	2.79*	3.42	3.51	2.26	2.83*	3.32
-5	National	3.58	2.44	2.7	2.23	2.82	3.25	3.5	2.57	3.02	3.37
	OCM	3.54	2.43	2.7	2.27	2.78	3.16	3.45	2.67	3.26	3.4
	Comparison	3.51	2.31	2.68	2.27	2.83	3.26	3.55	2.53	2.99	3.33
	NONC	3.69*	2.54	2.73	2.17*	2.86	3.34	3.53	2.48	2.88*	3.38
-4	National	3.49	2.32	2.71*	2.14	2.68	3.2	3.47	2.6	2.99*	3.24
	OCM	3.47	2.31	2.66	2.18	2.64	3.12	3.34	2.78	3.29	3.29
	Comparison	3.41	2.34	2.7	2.09	2.72	3.22	3.52	2.43	2.96*	3.23
	NONC	3.58	2.31	2.75*	2.15	2.7	3.27	3.57*	2.53	2.81*	3.21
-3	National	3.46	2.33	2.72	2.16*	2.73	3.15	3.52	2.5	2.92	3.25
	OCM	3.49	2.31	2.69	2.24	2.73	3.01	3.52	2.64	3.07	3.29
	Comparison	3.45	2.21	2.73	2.11*	2.69	3.38*	3.6	2.59*	2.98	3.2
	NONC	3.45	2.43	2.75*	2.15*	2.78	3.09	3.46	2.2	2.76*	3.24
-2	National	3.45	2.25	2.72*	2.10*	2.74	3.13	3.42	2.34	2.83	3.18
	OCM	3.4	2.24	2.67	2.19	2.74	2.96	3.4	2.41	3	3.22
	Comparison	3.34	2.23	2.7	2.05*	2.68	3.30*	3.5	2.19	2.79	3.09*
	NONC	3.58*	2.29	2.77*	2.07*	2.77	3.17	3.38	2.43	2.73*	3.21

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A2-14: Advanced Imaging Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of Advanced Imaging Visits (among episodes with 1+ imaging visit)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	6.77*	4.12*	2.14*	4.35	3.94*	9.26*	2.13*	5.48	4.08*	4.22*
	OCM	7.44	4.44	2.34	4.25	4.25	10.52	2.28	5.67	5.12	4.46
	Comparison	6.47*	3.98*	2.13*	3.90*	3.91*	8.27*	2.09*	5.88	3.97*	4.27*
	NONC	6.32*	3.93*	1.96*	4.70*	3.62*	8.67*	2.00*	4.76*	3.47*	3.95*
-7	National	6.62*	4.25*	2.10*	4.22	3.73*	9.74*	2.15*	5.26	4.09*	4.22*
	OCM	7.12	4.54	2.33	4.06	3.89	10.64	2.37	5.68	4.86	4.41
	Comparison	6.40*	3.99*	2.06*	3.74*	3.65*	9.55*	2.12*	5.55	4.15*	4.21*
	NONC	6.29*	4.16*	1.92*	4.63*	3.62*	8.96*	1.95*	4.27*	3.55*	4.05*
-6	National	6.94*	4.37*	2.04*	4.5	3.78*	10.70*	2.11	5.22	4.29*	4.27*
	OCM	7.47	4.66	2.24	4.3	4.01	11.73	2.2	5.45	5.34	4.52
	Comparison	6.87*	4.20*	2.02*	4.24	3.76*	10.15*	2.11	5.44	4.19*	4.28*
	NONC	6.46*	4.22*	1.87*	4.79*	3.54*	9.91*	2.02*	4.67*	3.62*	4.01*
-5	National	7.00*	4.34*	2.02*	4.48	3.78*	11.15	2.07*	5.15	4.44*	4.27*
	OCM	7.42	4.73	2.2	4.42	4.03	11.9	2.21	5.27	5.23	4.47
	Comparison	6.98*	4.20*	2.03*	4.15*	3.75*	10.58*	2.03*	5.69	4.53*	4.26*
	NONC	6.57*	4.07*	1.85*	4.73*	3.52*	10.79*	1.94*	4.32*	3.84*	4.08*
-4	National	7.27*	4.41*	2.02*	4.89	3.81*	11.38	2.14	5.68	4.52*	4.42*
	OCM	7.81	4.81	2.15	4.83	4.06	12.07	2.24	5.64	5.8	4.67
	Comparison	6.98*	4.30*	2.03*	4.41*	3.72*	10.75*	2.14	6.09	4.25*	4.40*
	NONC	6.94*	4.10*	1.90*	5.24*	3.61*	11.17	2.03*	5.22	3.81*	4.16*
-3	National	7.40*	4.38*	2.01*	4.8	3.74*	11.84	2.04	5.59	4.54*	4.45*
	OCM	7.76	4.7	2.15	4.63	3.96	12.68	2.1	5.84	5.71	4.64
	Comparison	7.22*	4.16*	2.04*	4.42	3.67*	11.46*	2.08	5.72	4.29*	4.39*
	NONC	7.17*	4.23*	1.87*	5.16*	3.53*	11.30*	1.94*	5.11*	3.87*	4.30*
-2	National	7.26*	4.41*	2.01*	4.88	3.77*	11.12*	2.07	5.6	4.45*	4.33*
	OCM	7.8	4.75	2.13	4.83	4	11.94	2.12	5.76	5.42	4.52
	Comparison	7.09*	4.30*	2.02*	4.58*	3.71*	10.63*	2.04	5.81	4.14*	4.25*
	NONC	6.83*	4.16*	1.87*	5.13*	3.53*	10.60*	2.04	5.09*	3.94*	4.20*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices

Exhibit A2-15: Episode Utilization of Outpatient Therapy Services in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/	Proportion of Episodes Utilizing Outpatient Therapy		Average Number of Outpatient Therapy Visits (among episodes with 1+ outpatient therapy visit)		
	TIN Type	N	%	N	Mean	Std Dev
-8	National	298,752	0.90%	2,736	10.82	11.71
	OCM	101,192	1.10%	1,136	10.62	11.04
	Comparison	80,345	0.80%	647	11.2	11.48
	NONC	117,215	0.80%	953	10.8	12.61
-7	National	259,926	0.80%	2,192	10.24	10.5
	OCM	88,489	1.00%	870	9.92	9.53
	Comparison	70,523	0.80%	539	10.01	10.85
	NONC	100,914	0.80%	783	10.75	11.24
-6	National	287,531	0.90%	2,527	10.07	9.56
	OCM	97,611	1.00%	999	10.03	9.03
	Comparison	79,677	0.80%	665	10.34	10.63
	NONC	110,243	0.80%	863	9.91	9.3
-5	National	278,171	0.80%	2,318	10.6	10.7
	OCM	95,027	1.00%	913	9.96	9.52
	Comparison	77,374	0.80%	625	10.83	11.31
	NONC	105,770	0.70%	780	11.17*	11.46
-4	National	303,016	0.90%	2,737	10.61	10.78
	OCM	102,988	1.10%	1,086	10.3	10.09
	Comparison	85,643	0.90%	739	10.8	10.95
	NONC	114,385	0.80%	912	10.83	11.41
-3	National	294,303	0.90%	2,562	9.91	9.48
	OCM	99,600	1.00%	997	10.29	9.48
	Comparison	83,828	0.90%	748	9.47	9.5
	NONC	110,875	0.70%	817	9.85	9.44
-2	National	312,437	0.90%	2,938	10.7	11.38
	OCM	106,978	1.10%	1,222	10.47	10.54
	Comparison	89,961	0.90%	810	11.17	12.82
	NONC	115,498	0.80%	906	10.58	11.07

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices

Exhibit A2-16: Unique Part D Prescriptions Each Month per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Average Number of Unique Part D Prescriptions (conditional on Part D enrollment)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	3.96*	3.21	4.31*	3.91	3.70	3.42	4.31	3.84	3.61	3.94*
	OCM	3.83	3.13	4.20	3.88	3.68	3.33	4.21	3.73	3.54	3.85
	Comparison	3.96*	3.18	4.31*	3.90	3.66	3.56	4.36	3.80	3.62	3.99*
	NONC	4.08*	3.29*	4.41*	3.93	3.74	3.42	4.36*	4.00	3.64	3.97*
-7	National	3.84*	3.10	4.34*	3.75	3.55	3.40	4.30	3.74	3.51	3.84*
	OCM	3.69	3.06	4.22	3.73	3.53	3.23	4.20	3.66	3.42	3.76
	Comparison	3.87*	3.13	4.34*	3.68	3.52	3.52*	4.39*	3.77	3.57	3.88*
	NONC	3.94*	3.12	4.44*	3.82*	3.61	3.48*	4.33	3.82	3.52	3.90*
-6	National	4.18*	3.43*	4.48*	4.12	3.87	3.67*	4.58	4.02	3.83	4.17*
	OCM	4.08	3.35	4.38	4.15	3.79	3.49	4.46	4.03	3.73	4.12
	Comparison	4.20*	3.48*	4.49*	4.05*	3.87	3.72*	4.70*	3.89	3.83	4.19*
	NONC	4.27*	3.47*	4.56*	4.15	3.95*	3.85*	4.59	4.13	3.89	4.22*
-5	National	4.12*	3.40	4.46*	4.09	3.84	3.55	4.54	3.98	3.79*	4.17
	OCM	4.02	3.33	4.37	4.08	3.80	3.50	4.44	4.01	3.60	4.16
	Comparison	4.09	3.45*	4.46*	4.01	3.84	3.57	4.66*	3.92	3.75	4.17
	NONC	4.25*	3.43*	4.54*	4.14	3.88	3.58	4.54	4.00	3.93*	4.18
-4	National	4.15	3.46	4.48*	4.15	3.91	3.66	4.63*	4.09	3.88	4.19
	OCM	4.09	3.40	4.38	4.17	3.88	3.60	4.50	4.14	3.79	4.15
	Comparison	4.17	3.46	4.50*	4.06*	3.91	3.64	4.73*	3.96	3.92	4.20
	NONC	4.20*	3.50*	4.55*	4.19	3.95	3.75	4.67*	4.18	3.92	4.23*
-3	National	4.12*	3.43	4.46*	4.10	3.91	3.53	4.63*	4.07	3.81	4.18
	OCM	4.02	3.36	4.36	4.11	3.83	3.46	4.50	4.13	3.74	4.17
	Comparison	4.14*	3.41	4.44*	4.05	3.92	3.52	4.66*	3.99	3.79	4.16
	NONC	4.20*	3.50*	4.56*	4.14	4.00*	3.61	4.73*	4.09	3.87	4.20
-2	National	4.17*	3.44*	4.47*	4.15	3.95	3.69	4.71*	4.06	3.82	4.25*
	OCM	4.09	3.36	4.38	4.17	3.89	3.63	4.58	4.01	3.72	4.20
	Comparison	4.24*	3.48*	4.45*	4.08*	3.93	3.77	4.83*	4.12	3.80	4.27*
	NONC	4.21*	3.48*	4.58*	4.18	4.03*	3.69	4.74*	4.07	3.90*	4.29*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. Part D enrollment is defined as at least one month of Part D enrollment during the episode; the Part D prescription count is the number of 30-day equivalents.

Exhibit A2-17: Monthly Part D Prescription Cost per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Average Monthly Part D Prescription Cost per Beneficiary (conditional on Part D enrollment)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	\$481*	\$158*	\$110*	\$242*	\$194	\$172*	\$1,714	\$1,048	\$123	\$1,088
	OCM	\$429	\$128	\$99	\$296	\$202	\$122	\$1,677	\$1,225	\$145	\$1,074
	Comparison	\$518*	\$144	\$106	\$244*	\$163*	\$171	\$1,743	\$931	\$109	\$1,113
	NONC	\$503*	\$194*	\$121*	\$211*	\$208	\$223*	\$1,727	\$968	\$118	\$1,082
-7	National	\$533*	\$231*	\$147*	\$398*	\$182	\$184*	\$1,783	\$867	\$117	\$1,105
	OCM	\$478	\$192	\$138	\$470	\$166	\$124	\$1,744	\$928	\$150	\$1,098
	Comparison	\$583*	\$231*	\$143	\$439	\$184	\$224*	\$1,784	\$761	\$109	\$1,139
	NONC	\$547*	\$267*	\$157*	\$330*	\$198	\$215*	\$1,819	\$908	\$103*	\$1,087
-6	National	\$608*	\$319*	\$159*	\$639*	\$250	\$195*	\$2,129	\$1,055	\$145	\$1,366
	OCM	\$560	\$285	\$149	\$784	\$244	\$146	\$2,088	\$1,048	\$153	\$1,369
	Comparison	\$669*	\$308	\$157	\$686*	\$246	\$234*	\$2,100	\$1,049	\$114	\$1,431*
	NONC	\$606*	\$358*	\$169*	\$528*	\$259	\$221*	\$2,191	\$1,071	\$158	\$1,310*
-5	National	\$599*	\$304*	\$163	\$677*	\$297	\$183	\$2,120	\$1,398	\$136	\$1,338
	OCM	\$548	\$267	\$156	\$853	\$300	\$177	\$2,037	\$1,305	\$153	\$1,342
	Comparison	\$645*	\$302	\$161	\$685*	\$319	\$198	\$2,118	\$1,343	\$123	\$1,385
	NONC	\$611*	\$339*	\$170*	\$569*	\$277	\$176	\$2,208*	\$1,586	\$134	\$1,297
-4	National	\$669*	\$330	\$173*	\$829*	\$481	\$222	\$2,677*	\$1,763	\$187*	\$1,505
	OCM	\$626	\$299	\$163	\$1,014	\$467	\$181	\$2,537	\$1,603	\$273	\$1,485
	Comparison	\$715*	\$326	\$169	\$879*	\$517	\$222	\$2,842*	\$1,872	\$157*	\$1,567*
	NONC	\$673	\$363*	\$184*	\$689*	\$466	\$265*	\$2,685*	\$1,866	\$155*	\$1,473
-3	National	\$665*	\$328	\$184*	\$842*	\$611	\$232	\$2,802	\$1,801	\$198	\$1,473
	OCM	\$614	\$298	\$173	\$1,011	\$629	\$200	\$2,700	\$1,669	\$247	\$1,457
	Comparison	\$722*	\$338	\$179	\$884*	\$602	\$226	\$2,903*	\$1,975	\$177	\$1,511
	NONC	\$668*	\$347*	\$197*	\$715*	\$599	\$270	\$2,821	\$1,783	\$182	\$1,455
-2	National	\$755	\$368	\$260*	\$1,029*	\$820	\$243*	\$3,364	\$1,677	\$168	\$1,763
	OCM	\$716	\$334	\$246	\$1,226	\$761	\$182	\$3,339	\$1,543	\$218	\$1,736
	Comparison	\$813*	\$366	\$271*	\$1,065*	\$949*	\$283*	\$3,437	\$1,651	\$141*	\$1,809*
	NONC	\$746	\$404*	\$265*	\$885*	\$778	\$274*	\$3,329	\$1,907	\$154*	\$1,749

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. Part D enrollment is defined as at least one month of Part D enrollment during the episode

We constructed ten claims-based end-of-life (EOL) measures focusing on patient-level outcomes related to EOL care. We describe below the detailed purpose and construction of these ten claims-based EOL measures:

Exhibit A2-18: Claims-Based End-of-Life Measures for Decedent Patients in the Oncology Care Model Evaluation

Measure	Purpose	Denominator	Measure Construction
Chemotherapy during the last 14 days of life	The objective of end-of-life care is to ensure patients' comfort and dignity while dying. A means to this goal is the cessation of futile, aggressive treatments that detract from life quality. The choice to continue aggressive treatment should solely rest with patients and their families, but any divergence in chemotherapy at end of life between OCM practices and comparison TINs would suggest changing treatment patterns. (NQF # 0210)	Cancer patients with observed dates of death	Flag patients with chemotherapy use within 14 days of death.
Inpatient Hospitalizations in the last 30 days of life	A concern is that terminally ill individuals might receive aggressive, invasive procedures that reduce the quality of their short remaining time, which they might prefer to spend in as much comfort as possible, at home with family and friends. Therefore, we view a reduction in inpatient hospitalizations immediately prior to death as improved end-of-life care.	Cancer patients with observed dates of death	Identify whether any inpatient discharge date occurs 30 days or fewer before the date of death.
Intensive Care Unit (ICU) use in the last 30 days of life	We examine hospital stays with ICU use as a subset of all hospital stays. (NQF # 0213)	Cancer patients with observed dates of death	Identify whether any inpatient discharge date occurs 30 days or fewer before the date of death; if so, further identify if ICU use occurred during hospital stay by the presence of ICU-related revenue center codes on the inpatient hospital claim.
Emergency Department (ED) visits in the last 30 days of life	We examine usage of the ED (including observational stays) in the last 30 days of life (NQF # 0211, modified)	Cancer patients with observed dates of death	Identify ED use by the presence of ED-related revenue center codes on the inpatient hospital claim, and ED Part B claims that occur 30 days or fewer before the date of death.
Deaths that occur in hospitals	The hospice philosophy places a strong emphasis on supporting patients at home for as long as possible, recognizing that most dying people prefer to be in a comfortable, familiar setting rather than in a hospital, at the end of life. We view a decrease in the rate of cancer patients dying in hospitals as an improvement in end-of-life care quality.	Cancer patients with observed dates of death	Match patients' date of death (taken from the beneficiary summary file) to hospital claims and note any patient that died during a hospital stay (or with a hospital discharge destination code of "death").
Deaths that occur in hospitals with ICU care during the terminal admission	In addition to emphasis of home care, as mentioned above an ideal for quality end-of-life care is to avoid unnecessary aggressive or invasive care at the end of life that detracts from life quality rather than enhances; for this reason, we particularly examine instances of hospital deaths where ICU use also occurred.	Cancer patients with observed dates of death	Match patients' date of death (taken from the beneficiary summary file) to hospital claims and note any patient that died during a hospital stay (or with a hospital discharge destination code of "death"). Of these occurrences, we determine if ICU use occurred by the presence of ICU-related revenue center codes on the inpatient hospital claim.

Measure	Purpose	Denominator	Measure Construction
Never admitted to hospice	We would never expect 100% hospice election rates, given patient preferences, but we view a decrease in the rate of cancer patients never using hospice as an improvement in end-of-life care, an improvement in caregiving quality, and a desirable objective of the OCM, perhaps suggesting improved coordination between oncology practices and hospice providers that raises hospice as an option for patients who might not otherwise have considered electing. (NQF # 0215)	Cancer patients with observed dates of death	Flag patients that do not have any associated hospice claims in the six months prior to death.
The number of days between hospice entry and death	A goal for terminally ill patients is to receive hospice care as soon as curative treatment is no longer beneficial. Unfortunately, we cannot know from claims when a patient receives their terminal prognosis or for how long they were expected to live at the time they were informed.	Hospice users discharged to death among cancer patients	Calculate as a continuous measure the number of hospice service days between hospice admission and death: (Date of death)-(Date of hospice entry)+1.
Being on hospice less than 3 days before death	For some patients who reach hospice only in the last two days of life, there may be insufficient time to bring symptoms (e.g., pain, anxiety) under control. A decrease in this measure would be viewed as an improved process quality outcome. (NQF # 0216)	Hospice users discharged to death among cancer patients	Calculate continuous measure of hospice service days between hospice admission and death: (Date of death)-(Date of hospice entry)+1; flag patients with values less than 3.
Disenrollment from hospice (for a hospitalization) then rapid return to hospice	Patterns of live hospice discharge, followed by hospitalizations and readmission to hospice, are recognized as problematic, as they suggest both fragmented medical care and a manner by which hospices avoid the financial responsibility of expensive hospitalizations. Cycling patients into and out of hospice could also be a strategy to reduce costs of care during OCM episodes, or could indicate patient dissatisfaction with inappropriately early referral to hospice.	Hospice users discharged to death among cancer patients	Flag patients that experienced a "problematic live discharge" as a hospital admission that follows within two days of a hospice live discharge in addition to and also a hospice readmission that follows within two days of that same hospitalization's discharge.

Note: ICU use was identified as those claims with a revenue center code of 0200, 0201, 0202, 0203, 0204, 0207, 0208, or 0209. ED use was identified as those claims with revenue center code of 0450, 0451, 0452, 0456, or 0459. NQF # 0211 is actually specified as *more than one* ED visit in the last 30 days of life, but we here examine any usage of ED visits to better harmonize our EOL measures internally (because specifically we also examine *any* inpatient admissions and *any* ICU visits in the last 30 days of life).

Exhibit A2-19: End-of-Life Measures for Decedent Cancer Patients as Assigned by the Most Recent Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	N	Chemotherapy during the Last 14 Days of Life	Hospital Use in the Last 30 Days of Life	Intensive Care Unit (ICU) Use in the Last 30 Days of Life	Emergency Department (ED) Use in the Last 30 Days of Life	Deaths that Occur in Hospitals	Deaths that Occur in Hospitals with ICU Care during the Terminal Admission	Never Admitted to Hospice
			Mean	Mean	Mean	Mean	Mean	Mean	Mean
-8	National	50,221	12.8%	55.4%	23.4%	55.7%	25.3%	12.5%	36.4%
	OCM	11,965	13.4%	54.8%	24.5%	54.5%	24.1%	13.0%	32.6%
	Comparison	8,797	12.2%	55.4%	21.3%	54.5%	25.0%	11.5%	35.1%
	NONC	29,459	12.7%	55.7%	23.6%	56.5%	25.8%	12.7%	38.3%
-7	National	43,807	13.2%	56.2%	24.0%	56.9%	25.7%	12.5%	37.4%
	OCM	10,776	13.4%	55.1%	25.3%	55.5%	24.6%	12.8%	33.9%
	Comparison	7,881	12.2%	56.1%	21.8%	56.1%	25.6%	11.5%	35.7%
	NONC	25,150	13.4%	56.6%	24.2%	57.8%	26.3%	12.6%	39.5%
-6	National	42,355	12.9%	54.7%	23.7%	56.2%	24.3%	12.0%	35.4%
	OCM	10,831	13.4%	54.7%	25.1%	56.1%	23.1%	12.0%	32.2%
	Comparison	8,298	12.5%	54.4%	21.7%	55.4%	23.0%	10.7%	33.2%
	NONC	23,226	12.9%	54.7%	23.7%	56.5%	25.3%	12.5%	37.6%
-5	National	40,857	13.3%	55.2%	24.8%	57.2%	24.8%	12.4%	36.4%
	OCM	10,918	14.0%	55.0%	26.3%	57.1%	23.5%	12.5%	33.4%
	Comparison	8,274	12.7%	54.8%	23.1%	56.1%	24.6%	11.7%	34.6%
	NONC	21,665	13.2%	55.4%	24.6%	57.6%	25.6%	12.5%	38.5%
-4	National	41,575	13.0%	54.6%	24.2%	57.2%	24.0%	11.6%	35.3%
	OCM	11,282	13.5%	55.2%	26.5%	57.2%	23.3%	12.0%	32.1%
	Comparison	8,759	13.0%	54.4%	22.2%	56.7%	24.1%	10.9%	34.7%
	NONC	21,534	12.7%	54.4%	23.8%	57.5%	24.4%	11.7%	37.2%
-3	National	40,547	12.9%	55.1%	25.0%	57.5%	24.6%	11.8%	36.7%
	OCM	11,046	13.3%	56.1%	27.6%	58.1%	24.4%	12.7%	34.1%
	Comparison	8,868	12.7%	55.1%	22.6%	56.5%	24.2%	10.7%	35.7%
	NONC	20,633	12.7%	54.6%	24.6%	57.6%	24.8%	11.8%	38.4%
-2	National	39,890	13.1%	54.9%	25.2%	57.8%	24.1%	11.5%	35.1%
	OCM	11,046	13.6%	55.9%	26.9%	58.0%	23.3%	11.8%	32.3%
	Comparison	8,760	12.6%	53.9%	23.0%	56.5%	23.8%	10.6%	33.9%
	NONC	20,084	13.0%	54.8%	25.2%	58.3%	24.8%	11.7%	37.2%

Source: Decedents file, 2012 – 2015.

Exhibit A2-20: End-of-Life Measures for Decedent Hospice-Using Cancer Patients as Assigned by the Most Recent Episode in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	N	Number of Days between Hospice Entry and Death		Being on Hospice Less than 3 Days before Death	Disenrollment from Hospice for a hospitalization) then Rapid Return to Hospice
			Mean	Std Dev	Mean	Mean
-8	National	30,565	20.2	24.8	11.0%	0.8%
	OCM	7,737	20.4	25.1	11.1%	0.9%
	Comparison	5,449	20.3	24.0	9.8%	1.0%
	NONC	17,379	20.0	24.9	11.4%	0.7%
-7	National	26,588	19.4	24.0	11.5%	0.7%
	OCM	6,933	19.3	23.5	11.7%	0.8%
	Comparison	4,904	19.7	23.5	10.4%	0.5%
	NONC	14,751	19.4	24.4	11.7%	0.8%
-6	National	26,661	20.1	24.6	11.3%	0.7%
	OCM	7,164	19.6	23.9	11.7%	0.6%
	Comparison	5,371	19.8	23.8	10.9%	0.6%
	NONC	14,126	20.6	25.2	11.2%	0.7%
-5	National	25,381	19.7	24.2	11.8%	0.8%
	OCM	7,132	19.1	23.4	12.1%	0.9%
	Comparison	5,282	19.4	23.4	12.0%	0.8%
	NONC	12,967	20.2	25.0	11.6%	0.8%
-4	National	26,216	19.6	23.9	11.6%	0.7%
	OCM	7,494	19.0	23.4	11.9%	0.7%
	Comparison	5,550	19.6	23.2	11.0%	0.8%
	NONC	13,172	20.0	24.4	11.7%	0.6%
-3	National	25,083	19.2	23.1	12.0%	0.7%
	OCM	7,115	18.2	22.2	12.8%	0.7%
	Comparison	5,560	19.4	23.4	11.7%	0.6%
	NONC	12,408	19.6	23.5	11.6%	0.7%
-2	National	25,293	19.5	23.4	11.7%	0.7%
	OCM	7,343	18.8	22.8	12.2%	0.8%
	Comparison	5,639	19.5	23.3	11.3%	0.7%
	NONC	12,311	19.9	23.9	11.5%	0.7%

Source: Decedents file, 2012 – 2015.

3. Practice Characteristics Detailed Results

**Exhibit A3-1: Practice Provider NPI Characteristics in the Expanded Baseline Period
(Episodes initiating Jan. 2012 – Jun. 2015)**

Performance Period	Practice/ TIN Type	N	Number of NPIs		Number of Oncologist NPIs		% Oncology NPIs ^a	% with Only Oncology Specialty ^b
			Mean	Std Dev	Mean	Std Dev	Mean	Mean
-8	National	1,986	12.89*	26.65	5.43*	12.18	67.0%*	51.8%*
	OCM	184	36.11	55.42	17.85	30.55	62.1%	27.7%
	Comparison	304	23.96*	34.46	9.05*	13.00	59.8%	41.1%*
-7	National	2,026	12.51*	25.45	5.51*	12.21	67.6%	51.6%*
	OCM	187	35.26	52.44	18.37	30.51	63.6%	28.9%
	Comparison	313	23.19*	33.51	9.18*	13.07	61.0%	42.5%*
-6	National	2,071	13.23*	27.07	5.64*	12.52	67.3%*	52.1%*
	OCM	188	38.08	57.13	18.99	31.64	61.6%	29.8%
	Comparison	316	24.64*	35.18	9.63*	13.42	60.9%	43.0%*
-5	National	2,098	13.23*	27.31	5.70*	12.59	68.1%*	52.8%*
	OCM	189	38.90	57.85	19.25	31.70	61.8%	31.2%
	Comparison	318	24.93*	35.69	9.83*	13.73	61.2%	41.8%*
-4	National	2,135	13.81*	28.59	5.85*	13.02	67.6%*	52.4%*
	OCM	189	40.86	60.10	20.08	32.98	61.1%	30.7%*
	Comparison	319	26.51*	38.51	10.22*	14.47	60.6%	41.1%*
-3	National	2,141	13.97*	29.11	5.93*	13.20	68.0%*	52.5%*
	OCM	190	41.24	60.68	20.09	33.14	61.8%	31.1%
	Comparison	319	26.98*	39.28	10.39*	14.98	60.3%	40.8%*
-2	National	2,126	14.79*	30.92	6.13*	13.83	67.4%*	52.0%*
	OCM	190	43.65	63.29	20.87	34.34	60.8%	30.5%
	Comparison	319	28.82*	42.95	10.80*	16.09	59.2%	39.8%*

Source: Practice characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. ^a The percentage Oncology NPIs is calculated based on the sum of oncology specialty NPIs divided by the total number of NPIs. ^b The percentage with Only Oncology Specialty is calculated based on the share of practices comprised solely of Oncology NPIs and NPs/PAs.

Exhibit A3-2: Practice Provider NPI Characteristics in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/TIN Type	N	NP/PA NPIs		Urologist NPIs		Hematology/ Medical Oncology NPIs		Surgical Oncology NPIs		Radiation Oncology NPIs		Gynecologic Oncology NPIs	
			Mean	%	Mean	%	Mean	%	Mean	%	Mean	%	Mean	%
-8	National	1,986	1.32*	5.8%*	1.18*	5.5%	3.80*	68.4%*	0.20*	2.8%	1.14*	23.9%*	0.29*	4.9%
	OCM	184	4.10	9.8%	2.46	4.3%	13.69	81.5%	0.57	2.2%	2.64	11.7%	0.96	4.7%
	Comparison	304	2.81	8.8%	2.14	6.0%	6.99*	82.9%	0.39	2.0%	1.19*	10.8%	0.48*	4.2%
-7	National	2,026	1.34*	6.2%*	1.21*	5.8%	3.91*	68.9%*	0.20*	2.8%	1.11*	23.6%*	0.30*	4.7%
	OCM	187	3.95	9.4%	2.50	4.7%	14.22	82.3%	0.57	2.2%	2.57	10.9%	1.01	4.6%
	Comparison	313	2.93	9.1%	2.13	5.7%	7.18*	83.4%	0.37	1.9%	1.15*	10.6%	0.48*	4.2%
-6	National	2,071	1.46*	6.4%*	1.24*	5.5%	3.96*	67.8%*	0.22*	3.1%	1.15*	24.1%*	0.31*	4.9%
	OCM	188	4.44	10.4%	2.63	4.5%	14.60	81.4%	0.62	2.5%	2.70	11.4%	1.07	4.7%
	Comparison	316	3.09*	9.2%	2.20	5.6%	7.48*	82.6%	0.41	2.0%	1.21*	10.7%	0.53*	4.7%
-5	National	2,098	1.53*	6.6%*	1.25*	5.6%	4.02*	68.1%*	0.22*	3.2%	1.14*	23.8%*	0.31*	4.9%
	OCM	189	4.92	11.1%	2.69	4.5%	14.86	82.2%	0.65	2.5%	2.70	10.9%	1.04	4.3%
	Comparison	318	3.29*	9.7%	2.20	5.9%	7.60*	81.5%	0.42	2.2%	1.26*	11.3%	0.55*	5.0%
-4	National	2,135	1.66*	7.1%*	1.29*	5.4%	4.10*	67.8%*	0.23*	3.2%	1.19*	23.9%*	0.33*	5.1%
	OCM	189	5.21	11.2%	2.80	4.4%	15.40	81.6%	0.67	2.4%	2.90	11.4%	1.11	4.6%
	Comparison	319	3.52*	10.1%	2.34	5.9%	7.89*	81.4%	0.44	2.1%	1.31*	11.3%	0.58*	5.1%
-3	National	2,141	1.72*	7.1%*	1.30*	5.5%	4.15*	67.4%*	0.24*	3.4%	1.21*	24.3%*	0.33*	5.0%
	OCM	190	5.44	11.6%	2.77	4.3%	15.44	81.7%	0.69	2.4%	2.87	11.5%	1.09	4.4%
	Comparison	319	3.71*	10.4%	2.31	5.6%	7.97*	81.0%	0.42	2.0%	1.41*	11.8%	0.59*	5.2%
-2	National	2,126	1.90*	7.5%*	1.36*	5.6%	4.28*	67.4%*	0.26*	3.3%	1.25*	24.2%*	0.34*	5.0%
	OCM	190	5.99	12.1%	2.86	4.4%	15.98	81.5%	0.77	2.6%	3.04	11.7%	1.08	4.2%
	Comparison	319	4.03*	10.6%	2.40	5.9%	8.18*	80.8%	0.45*	2.0%	1.54*	12.1%	0.63*	5.1%

Source: Practice characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

4. Market Characteristics Detailed Results

Exhibit A4-1: Market Supply Characteristics of Practices in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/ TIN Type	N	PCPs per 10,000 Population		Specialists per 10,000 Population		Hospital Beds per 10,000 Population	
			Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	National	1,986	8.32	2.91	11.27	8.34	37.14	22.32
	OCM	184	8.64	2.51	12.29	7.37	38.52	21.37
	Comparison	304	8.48	3.33	11.43	9.73	40.52	29.78
-7	National	2,025	8.31	2.89	11.25	8.31	37.08	21.96
	OCM	187	8.63	2.52	12.23	7.33	38.43	21.73
	Comparison	313	8.45	3.25	11.41	9.50	40.30	28.99
-6	National	2,070	8.45	2.95	11.19	8.18	35.62	20.80
	OCM	188	8.75	2.60	12.09	7.36	36.73	19.67
	Comparison	316	8.64	3.31	11.29	9.28	38.97	28.61
-5	National	2,098	8.46	2.96	11.15	8.15	35.54	20.95
	OCM	189	8.79	2.59	12.12	7.31	36.56	19.71
	Comparison	318	8.70	3.41	11.40	9.48	39.41	29.57
-4	National	2,134	8.46	2.94	12.21	8.97	35.52	21.22
	OCM	189	8.84	2.57	13.38	7.96	36.60	19.68
	Comparison	319	8.72	3.35	12.56	10.62	39.22	29.03
-3	National	2,141	8.47	2.95	12.24	9.02	35.50	21.03
	OCM	190	8.80	2.57	13.31	7.93	36.65	19.58
	Comparison	319	8.76	3.40	12.61	10.74	39.30	29.49
-2	National	2,126	8.43	2.94	12.17	8.96	35.39	21.31
	OCM	190	8.79	2.58	13.33	7.96	36.68	19.51
	Comparison	319	8.72	3.42	12.54	10.71	39.15	29.59

Source: Market characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A4-2: Healthcare Utilization and Plan Enrollment in Markets in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	N	ED Visits per 10,000 Population		Medicare Beneficiaries per 10,000 Population		Proportion of Medicare Beneficiaries Enrolled in Medicare Advantage	
			Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	National	1,986	4921.24	2346.61	1643.96	380.95	25.7%*	13.44
	OCM	184	5084.41	2386.37	1622.70	320.81	27.7%	12.83
	Comparison	304	5157.99	2645.92	1650.70	395.71	26.5%	13.55
-7	National	2,025	4916.18	2318.36	1641.61	379.36	25.7%	13.45
	OCM	187	5034.41	2426.30	1626.73	326.51	27.5%	12.79
	Comparison	313	5177.81	2627.33	1645.50	398.83	26.9%	13.67
-6	National	2,070	5102.83	2711.28	1680.68	384.84	27.2%	13.57
	OCM	188	5127.39	2503.78	1667.04	326.03	28.8%	12.99
	Comparison	316	5445.29	4585.31	1683.53	400.75	28.5%	13.58
-5	National	2,098	5092.64	2745.07	1682.67	386.44	27.1%	13.50
	OCM	189	5036.03	2357.97	1658.18	322.58	29.1%	12.93
	Comparison	318	5463.26	4776.85	1687.05	398.68	28.4%	13.60
-4	National	2,134	5084.18	2732.25	1718.98	397.77	29.2%	13.59
	OCM	189	5035.46	2356.86	1697.92	336.96	30.9%	12.48
	Comparison	319	5418.55	4652.45	1724.74	405.80	30.5%	13.62
-3	National	2,141	5087.02	2745.72	1721.11	398.69	29.2%	13.55
	OCM	190	5033.86	2348.25	1700.58	335.32	30.9%	12.39
	Comparison	319	5424.52	4750.79	1724.01	406.06	30.4%	13.61
-2	National	2,126	5068.13	2768.00	1753.06	403.31	30.3%	13.79
	OCM	190	5029.15	2356.86	1733.99	344.82	32.1%	12.55
	Comparison	319	5402.83	4768.63	1757.57	410.41	31.7%	13.77

Source: Market characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

5. Subgroup Analyses Detailed Results

Exhibit A5-1: Cancer-Related E&M Services per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Average Number of Cancer-Related E&M Services									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	7.87*	8.56*	3.57*	3.36*	5.92	8.75*	5.93*	6.35	5.57*	7.60*
	OCM	8.05	9.10	3.77	4.03	5.90	9.43	6.21	6.51	6.69	7.88
	Comparison	7.57*	8.04*	3.46*	3.33*	5.71*	8.29*	5.62*	6.18	5.33*	7.26*
	NONC	7.91*	8.41*	3.47*	3.00*	6.09*	8.38*	5.87*	6.34	5.05*	7.58*
-7	National	7.66*	8.48*	3.48*	3.38*	5.63	8.54*	5.55*	6.20	5.25*	7.39*
	OCM	7.92	9.21	3.69	4.01	5.62	9.07	5.82	6.54	6.36	7.73
	Comparison	7.34*	7.84*	3.36*	3.34*	5.45*	8.25*	5.20*	6.09	5.00*	7.06*
	NONC	7.62*	8.22*	3.38*	3.03*	5.78	8.22*	5.56	5.85*	4.75*	7.30*
-6	National	7.76*	8.44*	3.38*	3.35*	5.79	8.70*	5.68*	6.21	5.46*	7.42*
	OCM	8.05	9.12	3.56	3.94	5.83	9.40	5.95	6.55	6.67	7.73
	Comparison	7.46*	7.93*	3.30*	3.33*	5.63*	8.34*	5.45*	6.06	5.26*	7.17*
	NONC	7.69*	8.16*	3.29*	3.02*	5.87	8.18*	5.60*	5.95*	4.82*	7.32*
-5	National	7.57*	8.20*	3.33*	3.30*	5.76	8.50*	5.42*	5.92*	5.36*	7.26*
	OCM	7.83	8.85	3.52	3.97	5.86	9.04	5.75	6.41	6.59	7.59
	Comparison	7.28*	7.69*	3.26*	3.27*	5.48*	8.36*	5.13*	5.58*	5.23*	6.90*
	NONC	7.53*	7.94*	3.21*	2.93*	5.86	8.03*	5.31*	5.64*	4.69*	7.22*
-4	National	7.58*	8.36*	3.34*	3.28*	5.79*	8.66*	5.45*	6.10	5.26*	7.30*
	OCM	7.86	9.06	3.52	3.86	5.93	9.09	5.77	6.12	6.67	7.60
	Comparison	7.25*	7.80*	3.27*	3.26*	5.48*	8.24*	5.08*	6.23	5.03*	6.97*
	NONC	7.54*	8.11*	3.24*	2.96*	5.89	8.56*	5.41*	5.91	4.55*	7.27*
-3	National	7.47*	8.12*	3.27*	3.31*	5.65	8.40*	5.19*	6.26*	5.24*	7.13*
	OCM	7.74	8.76	3.44	3.91	5.73	9.04	5.40	6.75	6.55	7.43
	Comparison	7.19*	7.60*	3.19*	3.28*	5.38*	8.06*	4.90*	6.14*	5.05*	6.83*
	NONC	7.41*	7.89*	3.17*	2.99*	5.76	8.04*	5.21	5.78*	4.54*	7.06*
-2	National	7.53*	8.15*	3.27*	3.28*	5.76	8.37*	5.27*	6.39	5.09*	7.17*
	OCM	7.80	8.84	3.45	3.86	5.82	8.82	5.58	6.59	6.24	7.50
	Comparison	7.26*	7.72*	3.19*	3.25*	5.52*	8.17*	4.94*	6.33	4.89*	6.83*
	NONC	7.47*	7.80*	3.17*	2.96*	5.90	8.01*	5.23*	6.19	4.47*	7.11*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A5-2: Part B and D Chemo Services per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Average Number of Part B and D Chemo Services									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	10.08	15.50*	5.06*	2.88*	8.67	9.32*	8.52*	4.94	6.55*	11.19*
	OCM	10.22	16.04	5.19	3.25	8.70	10.09	8.98	5.55	7.41	11.79
	Comparison	9.66*	14.95*	5.05*	2.88*	8.38*	8.65*	8.39*	4.60*	6.41*	10.91*
	NONC	10.25	15.38*	4.95*	2.67*	8.86	9.01*	8.16*	4.55*	6.13*	10.81*
-7	National	10.13	15.55*	5.00*	3.01*	8.55	9.23	8.34*	4.88	6.42*	11.18*
	OCM	10.22	15.91	5.15	3.29	8.33	9.65	8.99	5.25	7.30	11.87
	Comparison	9.84*	15.04*	5.02*	3.01*	8.59	8.95	8.26*	4.48	6.30*	10.83*
	NONC	10.26	15.55	4.86*	2.85*	8.76*	9.00	7.75*	4.83	5.97*	10.77*
-6	National	10.26	15.42*	4.75*	3.09*	8.76	9.12*	8.27	4.71	6.52*	11.27*
	OCM	10.44	16.07	4.82	3.40	8.55	9.88	8.59	4.98	7.46	11.79
	Comparison	10.04*	15.02*	4.84	3.12*	8.87*	8.76*	8.28	4.60	6.54*	10.98*
	NONC	10.26	15.08*	4.63*	2.89*	8.91*	8.51*	7.94*	4.48	5.93*	10.98*
-5	National	10.12	15.17*	4.75*	3.12*	8.80	9.07*	8.07*	4.50	6.59*	11.44*
	OCM	10.17	15.73	4.86	3.49	8.70	9.76	8.70	4.64	7.54	11.97
	Comparison	9.98	14.58*	4.84	3.16*	8.65	8.87*	7.81*	4.47	6.73*	10.99*
	NONC	10.19	15.07*	4.58*	2.88*	9.04*	8.50*	7.63*	4.35	5.93*	11.29*
-4	National	10.09	15.44*	4.75*	3.16*	8.94	9.22	7.86	4.85	6.51*	11.64*
	OCM	10.10	15.85	4.83	3.47	8.77	9.54	8.06	4.72	7.59	11.99
	Comparison	9.90	14.70*	4.85	3.21*	8.87	9.04	7.78	5.12	6.53*	11.37*
	NONC	10.24	15.59	4.60*	2.94*	9.17*	9.01	7.72	4.70	5.83*	11.50*
-3	National	10.07	15.13	4.69*	3.31*	8.82*	9.22	7.68	5.04	6.54*	11.64*
	OCM	10.00	15.31	4.77	3.68	8.55	9.63	7.71	5.09	7.49	11.95
	Comparison	9.90	14.85*	4.78	3.37*	8.78	9.01	7.59	5.16	6.56*	11.38*
	NONC	10.29*	15.19	4.54*	3.05*	9.14*	8.96	7.73	4.84	5.92*	11.54*
-2	National	10.12	15.57	4.71*	3.37*	9.00*	8.78	7.86	5.99	6.50*	11.92*
	OCM	10.09	15.91	4.80	3.75	8.66	8.91	7.88	6.04	7.33	12.20
	Comparison	10.03	15.42*	4.81	3.40*	8.93	8.97	7.97	6.13	6.38*	11.72*
	NONC	10.23	15.34*	4.55*	3.12*	9.49*	8.45	7.74	5.72	6.03*	11.81*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A5-3: ED Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of Emergency Department Visits									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	1.08	0.76	0.40	0.50*	0.66	1.13	0.72	0.82	0.72*	0.89
	OCM	1.06	0.75	0.40	0.54	0.64	1.12	0.74	0.83	0.81	0.88
	Comparison	1.04	0.76	0.40	0.50*	0.65	1.09	0.70	0.86	0.75	0.88
	NONC	1.13*	0.78	0.40	0.49*	0.69*	1.16	0.73	0.77	0.66*	0.91*
-7	National	1.08*	0.80	0.40	0.53*	0.66*	1.14	0.74	0.91	0.75*	0.90
	OCM	1.05	0.77	0.40	0.56	0.63	1.10	0.71	0.92	0.86	0.87
	Comparison	1.03	0.78	0.40	0.50*	0.67	1.19	0.72	0.97	0.73*	0.87
	NONC	1.16*	0.84*	0.41	0.52*	0.70*	1.14	0.77	0.82	0.69*	0.94*
-6	National	1.08	0.80	0.38	0.51*	0.66*	1.12	0.72	0.82	0.72*	0.89
	OCM	1.05	0.79	0.38	0.54	0.62	1.07	0.72	0.82	0.84	0.87
	Comparison	1.06	0.76	0.38	0.49*	0.66	1.14	0.72	0.82	0.73*	0.87
	NONC	1.13*	0.84*	0.39	0.49*	0.69*	1.15	0.72	0.82	0.64*	0.91*
-5	National	1.07	0.80	0.37	0.52*	0.68*	1.14	0.72	0.85	0.74*	0.89
	OCM	1.04	0.77	0.37	0.57	0.65	1.10	0.72	0.86	0.84	0.88
	Comparison	1.02	0.77	0.38	0.51*	0.69	1.17	0.69	0.88	0.76	0.88
	NONC	1.13*	0.85*	0.37	0.50*	0.71*	1.17	0.74	0.83*	0.66*	0.91*
-4	National	1.08*	0.82	0.38	0.52*	0.68	1.16	0.73	1.01	0.76*	0.91
	OCM	1.05	0.80	0.37	0.57	0.65	1.13	0.72	0.97	0.86	0.90
	Comparison	1.05	0.83	0.38	0.49*	0.70	1.15	0.72	1.01	0.71*	0.90
	NONC	1.14*	0.83	0.39*	0.52*	0.70*	1.19	0.75	1.08	0.72*	0.92
-3	National	1.08	0.84	0.39	0.54*	0.70	1.16	0.75	0.93	0.75*	0.92
	OCM	1.05	0.82	0.38	0.59	0.67	1.08	0.71	0.93	0.90	0.91
	Comparison	1.06	0.82	0.39	0.52*	0.69	1.18	0.77*	0.95	0.74*	0.90
	NONC	1.14*	0.87*	0.39*	0.53*	0.74*	1.21*	0.77*	0.92	0.66*	0.94*
-2	National	1.11	0.82	0.39*	0.53*	0.70	1.16	0.74*	0.88	0.75*	0.91*
	OCM	1.09	0.81	0.37	0.56	0.68	1.12	0.68	0.88	0.87	0.89
	Comparison	1.07	0.82	0.39*	0.52*	0.69	1.21	0.80*	0.88	0.70*	0.90
	NONC	1.18*	0.84	0.40*	0.52*	0.74*	1.18	0.76*	0.88	0.71*	0.95*

Source: Episode characteristics file, 2012-2015. Note: * Denotes a significant difference from OCM practices.

Exhibit A5-4: SNF Stays per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Average Number of Skilled Nursing Facility Stays									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	0.10	0.07	0.04	0.05	0.08	0.13	0.07	0.09	0.08	0.09
	OCM	0.09	0.07	0.03	0.05	0.08	0.13	0.06	0.09	0.09	0.09
	Comparison	0.09	0.06	0.03	0.05	0.07	0.11	0.06	0.10	0.08	0.08
	NONC	0.11*	0.08	0.04	0.05	0.08	0.16	0.08*	0.09	0.07	0.10*
-7	National	0.11	0.09	0.04	0.06	0.08	0.15	0.07	0.13	0.09	0.10
	OCM	0.11	0.09	0.04	0.06	0.08	0.15	0.07	0.14	0.10	0.09
	Comparison	0.10	0.08	0.04	0.06	0.09	0.13	0.07	0.11	0.09	0.09
	NONC	0.12*	0.10*	0.04*	0.07	0.09	0.16	0.08	0.12	0.09	0.11*
-6	National	0.10	0.08	0.03	0.05	0.08	0.13	0.07	0.10	0.08*	0.09
	OCM	0.10	0.07	0.03	0.06	0.07	0.13	0.07	0.10	0.10	0.08
	Comparison	0.09	0.07	0.03	0.05	0.07	0.12	0.06	0.10	0.08	0.08
	NONC	0.10	0.08*	0.04	0.05	0.09*	0.15	0.07	0.11	0.06*	0.09*
-5	National	0.11	0.09	0.04	0.07	0.10	0.14	0.07	0.12	0.09	0.10
	OCM	0.11	0.08	0.04	0.07	0.09	0.12	0.07	0.15	0.10	0.10
	Comparison	0.10	0.08	0.04	0.06	0.09	0.13	0.06	0.09*	0.09	0.09
	NONC	0.12	0.10*	0.04	0.07	0.11*	0.16*	0.07	0.11	0.08	0.10
-4	National	0.10	0.07	0.03	0.05	0.08	0.13	0.07	0.12	0.08	0.09
	OCM	0.09	0.07	0.03	0.06	0.07	0.13	0.07	0.14	0.09	0.09
	Comparison	0.09	0.06	0.03	0.05*	0.08	0.11	0.06	0.08*	0.07	0.08*
	NONC	0.11*	0.08	0.04*	0.05	0.08	0.15	0.08	0.13	0.09	0.10
-3	National	0.11	0.08	0.04	0.07	0.09	0.15*	0.08	0.13	0.09*	0.10
	OCM	0.11	0.08	0.04	0.07	0.08	0.12	0.08	0.12	0.12	0.10
	Comparison	0.11	0.07	0.03*	0.06*	0.09	0.17*	0.08	0.14	0.08*	0.09*
	NONC	0.12*	0.09	0.04	0.07	0.10*	0.17*	0.09	0.14	0.07*	0.11*
-2	National	0.10	0.07	0.03	0.05	0.08	0.12	0.06	0.09	0.07	0.09
	OCM	0.10	0.07	0.03	0.06	0.08	0.12	0.06	0.10	0.08	0.09
	Comparison	0.08*	0.07	0.03	0.05	0.07	0.11	0.06	0.08	0.06	0.08*
	NONC	0.11*	0.08*	0.03	0.05	0.08	0.12	0.07	0.11	0.06*	0.10*

Source: Episode characteristics file, 2012-2015. Note: * Denotes a significant difference from OCM practices.

Exhibit A5-5: SNF Days per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Average Skilled Nursing Facility Days (among episodes with 1+ SNF stay)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	25.35	28.29	32.75	33.10	29.92	37.42	32.21	20.63	28.88	28.72
	OCM	25.17	29.52	31.89	30.74	30.13	34.77	32.97	21.71	27.12	29.49
	Comparison	25.44	28.60	33.26	32.18	27.28	39.38	30.45	19.03	28.23	28.89
	NONC	25.43	27.12	33.14	34.96	31.42	38.91	32.50	21.18	30.57	27.98
-7	National	26.58	28.05	36.33	34.55	31.41	40.76	31.50	24.84	26.52	30.14
	OCM	26.12	28.42	34.04	33.27	31.01	41.37	27.24	29.30	29.66	30.02
	Comparison	26.38	28.65	34.25	32.11	31.10	36.93	29.14	18.54*	26.23	30.68
	NONC	27.10	27.43	39.50*	36.67	32.07	42.55	37.10*	24.76	24.62	29.90
-6	National	26.86	26.83	32.46	31.97	29.40	38.23	29.10	27.32	24.08	28.85
	OCM	27.45	28.87	30.55	29.75	30.50	37.38	30.21	31.29	22.87	28.63
	Comparison	26.31	23.58*	32.86	32.71	26.57	38.46	27.66	27.61	26.42	28.64
	NONC	26.70	27.04	33.90*	32.94	30.35	38.94	29.05	23.10	23.49	29.19
-5	National	26.43	28.46	35.46	32.50	32.84	41.77	31.72	24.33	28.10	29.73
	OCM	26.82	28.08	33.98	33.05	32.10	41.33	27.64	24.75	25.65	30.32
	Comparison	26.65	26.70	35.01	31.72	33.53	40.05	35.21	20.09	30.33	28.99
	NONC	25.92	29.90	37.04	32.63	33.07	43.39	33.46	27.64	28.50	29.69
-4	National	26.10	26.67	31.75	31.78	29.04	35.49	30.46	27.93	27.19	29.37
	OCM	26.52	26.20	30.13	31.60	28.86	33.75	30.98	29.15	26.57	29.25
	Comparison	24.56	26.57	30.15	29.52	29.57	32.02	29.25	24.51	26.27	29.57
	NONC	26.74	27.17	34.14*	33.20	28.83	39.53	30.73	29.09	28.17	29.34
-3	National	26.34	28.81	33.84	33.19	32.79	38.26	28.91	28.96	27.27	30.69
	OCM	25.82	28.36	31.97	31.86	31.07	33.25	28.99	30.81	23.65	30.41
	Comparison	25.70	28.30	34.07	34.84	31.60	39.36	28.84	25.40	29.58*	30.10
	NONC	27.29	29.50	35.39*	33.05	35.11*	41.21	28.91	30.78	29.22*	31.40
-2	National	26.14*	27.13	29.36	31.08	29.71	40.07	28.23	26.42	26.20	28.22
	OCM	23.18	26.73	28.17	30.61	28.05	35.53	27.07	26.16	23.55	28.78
	Comparison	26.90*	27.32	29.90	30.09	29.72	41.30	30.77	27.96	25.90	27.80
	NONC	28.45*	27.36	30.08	32.06	31.55	44.11*	27.35	25.38	28.67	27.98

Source: Episode characteristics file, 2012-2015. Note: * Denotes a significant difference from OCM practices.

Exhibit A5-6: Proportion of Episodes Utilizing Radiation Therapy by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/TIN Type	Proportion of Episodes Utilizing Radiation Therapy									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	38.1%	13.4%	13.1%	14.5%	8.5%	62.9%	2.1%	27.3%	14.5%	17.4%
	OCM	38.0%	13.2%	13.3%	13.7%	8.4%	64.3%	2.4%	28.8%	18.6%	17.6%
	Comparison	39.2%	13.7%	13.3%	13.4%	8.5%	62.1%	2.0%	26.5%	15.5%	17.5%
	NONC	37.5%	13.3%	12.8%	15.5%	8.7%	62.0%	1.9%	26.3%	11.5%	16.9%
-7	National	37.1%	13.9%	11.9%	13.2%	8.0%	62.9%	2.1%	27.1%	13.8%	16.9%
	OCM	36.3%	13.5%	12.2%	12.5%	7.3%	61.6%	1.9%	30.4%	17.1%	16.8%
	Comparison	37.7%	13.7%	12.3%	11.8%	8.3%	63.4%	2.3%	25.2%	14.3%	17.0%
	NONC	37.4%	14.6%	11.4%	14.4%	8.4%	64.0%	2.0%	24.6%	11.6%	17.0%
-6	National	37.9%	14.4%	12.2%	14.0%	8.4%	63.7%	1.8%	26.7%	14.0%	16.7%
	OCM	37.7%	14.3%	12.7%	12.7%	8.2%	63.8%	1.9%	28.6%	19.2%	16.6%
	Comparison	38.1%	14.8%	12.2%	13.3%	8.8%	64.9%	1.9%	27.4%	14.4%	16.9%
	NONC	37.9%	14.1%	11.9%	15.1%	8.5%	62.5%	1.7%	23.5%	10.6%	16.7%
-5	National	37.2%	14.2%	11.8%	13.9%	8.4%	64.6%	1.7%	26.2%	13.7%	16.6%
	OCM	37.2%	14.0%	11.9%	13.6%	8.3%	63.2%	1.6%	24.4%	17.7%	16.4%
	Comparison	37.7%	14.0%	11.9%	13.0%	8.7%	66.1%	2.0%	29.1%	14.2%	16.9%
	NONC	36.9%	14.5%	11.7%	14.6%	8.2%	65.0%	1.5%	25.3%	10.8%	16.4%
-4	National	37.9%	14.5%	12.2%	14.2%	8.7%	63.9%	1.9%	27.3%	13.6%	16.4%
	OCM	38.1%	14.7%	12.3%	14.3%	8.8%	63.7%	2.2%	26.8%	19.3%	16.4%
	Comparison	38.6%	14.7%	12.1%	13.2%	9.0%	63.7%	1.6%	28.5%	12.3%	16.5%
	NONC	37.3%	14.3%	12.1%	14.7%	8.4%	64.4%	1.9%	26.4%	11.0%	16.2%
-3	National	38.0%	14.4%	11.9%	14.3%	8.4%	64.2%	1.8%	25.2%	13.7%	16.5%
	OCM	37.7%	14.4%	11.8%	13.6%	7.9%	63.7%	2.0%	24.3%	18.3%	16.3%
	Comparison	38.1%	14.4%	11.9%	13.4%	8.9%	64.0%	2.0%	27.0%	13.4%	16.6%
	NONC	38.3%	14.3%	11.8%	15.3%	8.5%	65.0%	1.5%	24.3%	11.1%	16.7%
-2	National	38.1%	14.4%	12.2%	15.0%	8.3%	64.8%	1.8%	21.3%	14.0%	16.2%
	OCM	36.8%	14.8%	12.2%	13.9%	7.7%	63.9%	1.8%	22.1%	18.1%	15.9%
	Comparison	38.8%	13.6%	12.4%	14.4%	8.4%	64.6%	2.0%	20.9%	12.8%	16.5%
	NONC	38.7%	14.5%	12.0%	16.1%	8.9%	65.9%	1.7%	20.6%	12.0%	16.3%

Source: Episode characteristics file, 2012-2015.

Exhibit A5-7: Radiation Therapy Visits per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/ TIN Type	Average Number of Radiation Therapy Visits (among episodes with 1+ radiation therapy visit)									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	19.35	17.95	19.86	24.76*	16.32	25.51	12.97	10.65	20.39	18.05
	OCM	19.24	17.64	19.79	21.68	15.84	25.33	13.75	10.26	20.64	18.06
	Comparison	19.25	17.92	19.81	23.27*	17.00*	25.64	10.84	11.08	19.85	18.09
	NONC	19.53	18.26	19.96	27.08*	16.32	25.61	13.71	10.71	20.60	17.99
-7	National	19.17	18.42	17.96	24.33*	15.77	26.72	13.20	10.29	20.58	18.35
	OCM	19.24	18.12	17.58	20.94	15.41	26.83	13.96	11.15	20.22	18.32
	Comparison	18.96	18.15	17.89	22.93*	15.43	26.29	13.51	9.74	21.46	18.11
	NONC	19.26	18.88	18.37*	26.77*	16.35	26.94	12.20	9.41	20.24	18.57
-6	National	19.62	18.62	18.02	25.47*	15.55	26.86	14.00	9.86	21.41	18.38
	OCM	19.31	18.49	17.78	21.73	15.91	26.73	13.93	9.27	20.71	18.63
	Comparison	20.03*	18.03	17.85	24.09*	14.97	26.70	14.32	9.74	20.93*	18.07
	NONC	19.60	19.21	18.36*	28.03*	15.63	27.18	13.81	10.91	22.61	18.39
-5	National	19.15	18.45*	17.55	24.00*	15.70	27.20	12.78	9.17	21.03	18.05
	OCM	19.34	17.61	17.37	20.34	15.66	26.70	15.13	8.57	20.48	18.00
	Comparison	18.84	19.16*	17.29	23.12*	15.87	27.34	12.52	9.29	20.03*	17.70
	NONC	19.21	18.73*	17.91	26.48*	15.58	27.61	10.36*	9.79	22.42	18.40
-4	National	19.46	18.66	17.57	25.14*	15.58	26.79	14.89	9.81	20.54	17.77
	OCM	19.54	19.20	17.18	21.96	16.08	26.49	14.52	9.11	20.03	17.94
	Comparison	19.24	18.56	17.84*	24.18*	14.95*	26.85	16.68	10.83	19.87	17.51
	NONC	19.57	18.19*	17.74*	27.50*	15.53	27.05	14.08	9.51	21.59	17.83
-3	National	19.42	18.43	17.09	24.81*	15.33	27.22	12.25	9.29	20.61	18.16
	OCM	19.36	18.57	17.17	20.69	15.45	27.60	12.45	8.53	20.05	17.96
	Comparison	19.41	18.36	17.02	23.80*	14.72	27.60	12.99	8.26	20.48	18.15
	NONC	19.50	18.34	17.08	27.55*	15.72	26.46*	11.14	11.55*	21.31	18.36
-2	National	18.97	18.50	16.75	25.09*	15.09	26.50	12.65	8.61	21.11	17.67
	OCM	18.98	18.75	16.62	21.39	14.86	26.26	11.94	7.91	20.67	17.54
	Comparison	18.83	18.17	16.81	24.63*	15.15	26.46	11.30	9.68	21.02	17.57
	NONC	19.08	18.50	16.83	27.30*	15.28	26.82	14.70	8.30	21.62	17.88

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A5-8: Total Cost of Care per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/ TIN Type	Average Standardized Part A and B, and Part D Costs									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	\$33,330*	\$37,415*	\$12,702*	\$14,554*	\$33,783	\$38,036	\$36,268	\$56,061	\$18,766*	\$33,725*
	OCM	\$34,135	\$38,611	\$13,407	\$16,890	\$34,052	\$39,169	\$37,120	\$56,314	\$22,685	\$34,398
	Comparison	\$32,216*	\$36,417*	\$12,590*	\$14,428*	\$33,530	\$36,454*	\$36,295	\$59,667	\$19,098*	\$33,419*
	NONC	\$33,347*	\$36,991*	\$12,152*	\$13,309*	\$33,687	\$38,035	\$35,392*	\$51,615	\$16,263*	\$33,299*
-7	National	\$34,328*	\$37,639*	\$12,884*	\$15,078*	\$34,093	\$38,223	\$37,038	\$57,609	\$18,584*	\$34,592*
	OCM	\$34,971	\$38,424	\$13,712	\$17,391	\$34,085	\$38,218	\$37,378	\$57,315	\$22,061	\$35,339
	Comparison	\$33,398*	\$37,031*	\$12,817*	\$14,716*	\$34,157	\$38,850	\$37,236	\$63,513	\$18,845*	\$34,369*
	NONC	\$34,376	\$37,310*	\$12,185*	\$13,943*	\$34,055	\$37,756	\$36,552	\$50,896	\$16,347*	\$34,030*
-6	National	\$35,232*	\$35,296*	\$12,679*	\$15,950*	\$35,570	\$38,357	\$39,430	\$57,504	\$18,673*	\$35,819*
	OCM	\$36,216	\$36,381	\$13,301	\$18,319	\$35,381	\$39,011	\$39,862	\$57,671	\$22,880	\$36,676
	Comparison	\$34,601*	\$34,950*	\$12,810*	\$15,991*	\$35,945	\$38,386	\$39,406	\$63,756*	\$19,141*	\$35,753*
	NONC	\$34,729*	\$34,514*	\$12,022*	\$14,570*	\$35,486	\$37,523	\$39,015	\$50,709*	\$15,782*	\$35,016*
-5	National	\$35,194*	\$34,362*	\$12,573*	\$16,534*	\$36,653	\$37,755	\$38,506	\$61,276	\$18,836*	\$35,764*
	OCM	\$35,944	\$35,331	\$13,294	\$19,223	\$36,911	\$38,325	\$39,018	\$64,734	\$22,451	\$36,496
	Comparison	\$34,498*	\$33,665*	\$12,708*	\$16,714*	\$37,142	\$38,054	\$38,193	\$65,290	\$19,469*	\$35,373*
	NONC	\$34,971*	\$33,938*	\$11,817*	\$14,850*	\$35,966	\$36,886	\$38,225	\$51,909*	\$16,212*	\$35,347*
-4	National	\$35,535	\$34,613*	\$12,964*	\$17,119*	\$37,695	\$38,129	\$40,988	\$62,236	\$19,105*	\$36,776*
	OCM	\$36,045	\$35,672	\$13,561	\$19,707	\$37,693	\$38,085	\$40,954	\$62,745	\$23,717	\$37,492
	Comparison	\$34,859*	\$34,294*	\$13,152*	\$17,134*	\$38,347	\$37,997	\$41,736	\$66,882	\$18,906*	\$36,752*
	NONC	\$35,559	\$33,813*	\$12,282*	\$15,593*	\$37,170	\$38,295	\$40,415	\$55,881*	\$16,397*	\$36,060*
-3	National	\$35,932*	\$34,246*	\$13,161*	\$17,586*	\$38,731	\$38,818	\$40,725	\$66,753	\$19,469*	\$36,861*
	OCM	\$36,877	\$35,381	\$13,830	\$19,922	\$38,926	\$39,055	\$40,328	\$67,221	\$24,140	\$37,390
	Comparison	\$35,394*	\$33,341*	\$13,269*	\$17,769*	\$38,771	\$39,502	\$41,964*	\$72,036	\$19,533*	\$36,907
	NONC	\$35,401*	\$33,857*	\$12,468*	\$16,095*	\$38,482	\$37,919	\$40,099	\$60,234*	\$16,477*	\$36,284*
-2	National	\$38,352*	\$34,852*	\$13,764*	\$18,927*	\$40,896	\$38,961	\$44,548	\$66,333	\$19,118*	\$38,975*
	OCM	\$39,108	\$35,978	\$14,303	\$21,406	\$40,690	\$38,263	\$44,439	\$68,457	\$22,942	\$39,636
	Comparison	\$37,924*	\$34,479*	\$13,990*	\$19,039*	\$41,619	\$40,764*	\$45,389	\$66,954	\$18,791*	\$38,845*
	NONC	\$37,924*	\$34,004*	\$13,087*	\$17,354*	\$40,530	\$38,075	\$43,957	\$62,574*	\$16,798*	\$38,401*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A5-9: Cancer-Related E&M Costs per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/ TIN Type	Average Cancer-Related E&M Costs									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	\$566*	\$587*	\$247*	\$230*	\$416*	\$607*	\$402*	\$459*	\$379*	\$540*
	OCM	\$609	\$639	\$274	\$293	\$436	\$690	\$444	\$503	\$495	\$593
	Comparison	\$522*	\$537*	\$227*	\$220*	\$385*	\$553*	\$361*	\$419*	\$356*	\$488*
	NONC	\$555*	\$573*	\$235*	\$202*	\$417*	\$559*	\$390*	\$449*	\$324*	\$529*
-7	National	\$541*	\$573*	\$229*	\$222*	\$382*	\$587*	\$361*	\$433*	\$346*	\$513*
	OCM	\$589	\$639	\$257	\$280	\$401	\$652	\$399	\$475	\$450	\$566
	Comparison	\$499*	\$517*	\$209*	\$209*	\$351*	\$543*	\$318*	\$411*	\$324*	\$468*
	NONC	\$526*	\$549*	\$219*	\$196*	\$384*	\$551*	\$355*	\$397*	\$298*	\$497*
-6	National	\$565*	\$589*	\$237*	\$235*	\$412*	\$613*	\$392*	\$444*	\$377*	\$534*
	OCM	\$622	\$653	\$262	\$293	\$435	\$698	\$437	\$479	\$498	\$586
	Comparison	\$516*	\$536*	\$219*	\$223*	\$381*	\$561*	\$352*	\$418*	\$355*	\$489*
	NONC	\$547*	\$566*	\$227*	\$208*	\$411*	\$558*	\$378*	\$427*	\$317*	\$518*
-5	National	\$536*	\$555*	\$218*	\$218*	\$394*	\$585*	\$353*	\$413*	\$358*	\$506*
	OCM	\$587	\$619	\$243	\$280	\$424	\$651	\$401	\$469	\$476	\$558
	Comparison	\$489*	\$502*	\$202*	\$205*	\$355*	\$547*	\$314*	\$367*	\$338*	\$456*
	NONC	\$519*	\$533*	\$207*	\$190*	\$391*	\$546*	\$335*	\$391*	\$298*	\$493*
-4	National	\$563*	\$594*	\$238*	\$234*	\$421*	\$623*	\$381*	\$450	\$374*	\$536*
	OCM	\$617	\$659	\$263	\$290	\$454	\$693	\$431	\$470	\$506	\$588
	Comparison	\$515*	\$538*	\$221*	\$224*	\$381*	\$560*	\$334*	\$446	\$351*	\$486*
	NONC	\$547*	\$572*	\$228*	\$207*	\$416*	\$600*	\$368*	\$426*	\$307*	\$524*
-3	National	\$535*	\$556*	\$216*	\$222*	\$391*	\$581*	\$342*	\$441*	\$357*	\$500*
	OCM	\$589	\$617	\$239	\$277	\$418	\$664	\$379	\$492	\$487	\$551
	Comparison	\$489*	\$504*	\$199*	\$212*	\$357*	\$532*	\$304*	\$408*	\$328*	\$454*
	NONC	\$516*	\$536*	\$207*	\$196*	\$389*	\$539*	\$336*	\$412*	\$295*	\$486*
-2	National	\$563*	\$584*	\$234*	\$237*	\$422*	\$609*	\$372*	\$470*	\$363*	\$530*
	OCM	\$617	\$652	\$259	\$294	\$447	\$677	\$414	\$499	\$476	\$584
	Comparison	\$522*	\$538*	\$218*	\$226*	\$388*	\$570*	\$333*	\$447*	\$335*	\$483*
	NONC	\$542*	\$552*	\$223*	\$209*	\$421*	\$565*	\$360*	\$456*	\$306*	\$515*

Source: Episode characteristics file, 2012-2015. Note: * Denotes a significant difference from OCM practices.

Exhibit A5-10: Part B and D Chemotherapy Cost per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	Part B and D Chemotherapy Costs									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	\$9,266	\$16,050	\$3,260*	\$3,599*	\$15,763	\$7,705	\$16,800	\$36,637	\$1,763*	\$11,565*
	OCM	\$9,521	\$16,440	\$3,632	\$4,708	\$16,069	\$7,983	\$16,957	\$36,367	\$2,147	\$11,793
	Comparison	\$9,254	\$15,814*	\$3,250*	\$3,768*	\$15,355*	\$7,201	\$16,706	\$39,336	\$1,703*	\$11,580
	NONC	\$9,023*	\$15,850*	\$2,936*	\$2,871*	\$15,742	\$7,793	\$16,714	\$33,897	\$1,572*	\$11,331*
-7	National	\$10,134*	\$15,159	\$3,548*	\$3,996*	\$16,721	\$7,754	\$17,903	\$37,402	\$1,420*	\$12,294*
	OCM	\$10,539	\$15,480	\$3,966	\$5,182	\$16,647	\$8,039	\$18,119	\$36,603	\$1,746	\$12,669
	Comparison	\$10,191	\$15,109	\$3,550*	\$4,187*	\$16,806	\$7,894	\$17,618	\$43,063*	\$1,319*	\$12,244*
	NONC	\$9,690*	\$14,887*	\$3,172*	\$3,183*	\$16,738	\$7,353	\$17,908	\$31,726	\$1,288*	\$11,964*
-6	National	\$10,648*	\$12,592*	\$3,440*	\$4,717*	\$17,749	\$7,269	\$19,379	\$38,372	\$1,398*	\$13,247*
	OCM	\$11,067	\$13,187	\$3,753	\$6,115	\$17,885	\$7,647	\$19,369	\$38,146	\$1,698	\$13,608
	Comparison	\$10,782	\$12,668*	\$3,567*	\$4,984*	\$17,875	\$7,135	\$19,038	\$43,708*	\$1,276*	\$13,477
	NONC	\$10,119*	\$11,969*	\$3,066*	\$3,754*	\$17,505	\$6,925	\$19,664	\$33,029	\$1,287*	\$12,703*
-5	National	\$10,926	\$12,135	\$3,698*	\$4,964*	\$18,192	\$7,405	\$19,439	\$42,324	\$1,425	\$13,716*
	OCM	\$11,082	\$12,423	\$4,093	\$6,401	\$18,421	\$8,098	\$20,002	\$44,632	\$1,675	\$14,171
	Comparison	\$11,136	\$12,218	\$3,857*	\$5,237*	\$18,172	\$7,234	\$18,786*	\$46,349	\$1,407	\$13,564*
	NONC	\$10,600*	\$11,788*	\$3,222*	\$3,956*	\$17,950	\$6,791*	\$19,394	\$34,508*	\$1,281*	\$13,382*
-4	National	\$11,243	\$12,444	\$3,954*	\$5,756*	\$19,631	\$7,577	\$21,724	\$45,371	\$1,584*	\$14,837
	OCM	\$11,460	\$12,567	\$4,351	\$7,212	\$19,809	\$7,843	\$21,521	\$44,751	\$2,357	\$15,107
	Comparison	\$11,346	\$12,487	\$4,068*	\$6,111*	\$19,857	\$7,260	\$22,179	\$50,273*	\$1,360*	\$14,838
	NONC	\$10,937*	\$12,288	\$3,508*	\$4,675*	\$19,247	\$7,561	\$21,565	\$40,342	\$1,258*	\$14,559*
-3	National	\$11,211*	\$12,254	\$4,171*	\$5,943*	\$20,323	\$7,739	\$21,087	\$49,250	\$1,588*	\$14,518
	OCM	\$11,702	\$12,371	\$4,630	\$7,220	\$20,481	\$8,177	\$20,678	\$48,142	\$2,165	\$14,716
	Comparison	\$11,270	\$12,290	\$4,307*	\$6,321*	\$20,456	\$7,764	\$21,640*	\$55,726*	\$1,387*	\$14,636
	NONC	\$10,657*	\$12,111	\$3,649*	\$4,947*	\$20,041	\$7,242	\$21,044	\$43,454	\$1,359*	\$14,217*
-2	National	\$12,985*	\$12,370	\$4,623*	\$7,107*	\$21,846	\$7,570	\$24,056	\$47,987	\$1,604*	\$16,214
	OCM	\$13,472	\$12,455	\$5,044	\$8,609	\$21,675	\$7,515	\$23,963	\$48,902	\$2,095	\$16,473
	Comparison	\$13,443	\$12,536	\$4,836*	\$7,456*	\$22,464*	\$8,146	\$24,154	\$49,039	\$1,413*	\$16,404
	NONC	\$12,078*	\$12,150	\$4,068*	\$5,963*	\$21,528	\$7,086	\$24,068	\$45,382	\$1,408*	\$15,780*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A5-11: Beneficiary Cost Sharing per Episode by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Practice/ TIN Type	Average Standardized Part A and B, and Part D Beneficiary Cost-Sharing									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	\$6,753	\$8,267*	\$2,929*	\$3,028*	\$7,387	\$7,730	\$6,177	\$7,877*	\$3,650*	\$6,231*
	OCM	\$6,851	\$8,481	\$3,087	\$3,457	\$7,349	\$7,885	\$6,340	\$9,024	\$4,287	\$6,364
	Comparison	\$6,619*	\$8,022*	\$2,923*	\$2,927*	\$7,316	\$7,518*	\$6,080*	\$6,742*	\$3,706*	\$6,164*
	NONC	\$6,754	\$8,236*	\$2,794*	\$2,846*	\$7,476	\$7,726	\$6,088*	\$7,705*	\$3,242*	\$6,153*
-7	National	\$7,414*	\$8,624	\$3,137*	\$3,342*	\$8,540	\$8,402	\$6,779	\$8,956*	\$3,984*	\$6,835*
	OCM	\$7,554	\$8,780	\$3,301	\$3,771	\$9,326	\$8,415	\$6,855	\$9,932	\$4,634	\$6,983
	Comparison	\$7,219*	\$8,412*	\$3,123*	\$3,228*	\$7,991	\$8,295	\$6,691	\$8,562*	\$4,008*	\$6,698*
	NONC	\$7,419	\$8,621	\$3,001*	\$3,161*	\$8,102	\$8,469	\$6,771	\$8,000*	\$3,580*	\$6,795*
-6	National	\$7,751*	\$8,241*	\$3,089*	\$3,382*	\$8,603	\$8,803	\$6,674	\$8,778	\$4,062*	\$6,931*
	OCM	\$7,900	\$8,543	\$3,224	\$3,792	\$8,444	\$8,979	\$6,825	\$9,652	\$4,839	\$7,068
	Comparison	\$7,576*	\$8,104*	\$3,147	\$3,364*	\$8,649	\$8,789	\$6,611	\$8,130*	\$4,162*	\$6,822*
	NONC	\$7,738*	\$8,054*	\$2,926*	\$3,158*	\$8,741*	\$8,599	\$6,574	\$8,381*	\$3,520*	\$6,881*
-5	National	\$7,876*	\$8,054*	\$3,160*	\$3,681*	\$8,864	\$8,829	\$6,950*	\$10,165*	\$4,130*	\$7,145*
	OCM	\$8,010	\$8,314	\$3,323	\$4,183	\$8,853	\$8,800	\$7,231	\$11,880	\$4,704	\$7,280
	Comparison	\$7,758*	\$7,864*	\$3,212*	\$3,759*	\$8,774	\$8,922	\$6,832*	\$9,740*	\$4,279*	\$7,005*
	NONC	\$7,831*	\$7,943*	\$2,974*	\$3,340*	\$8,949	\$8,784	\$6,751*	\$8,329*	\$3,683*	\$7,123*
-4	National	\$7,612	\$7,874*	\$3,095*	\$3,435*	\$8,870	\$8,616	\$6,301	\$13,625	\$3,908*	\$6,809*
	OCM	\$7,666	\$8,085	\$3,231	\$3,881	\$8,824	\$8,463	\$6,458	\$13,863	\$4,632	\$6,927
	Comparison	\$7,416*	\$7,759*	\$3,155*	\$3,406*	\$8,928	\$8,604	\$6,198	\$14,592	\$3,905*	\$6,733*
	NONC	\$7,713	\$7,754*	\$2,927*	\$3,193*	\$8,875	\$8,797	\$6,222	\$12,110*	\$3,465*	\$6,752*
-3	National	\$8,054*	\$8,028*	\$3,272*	\$3,809*	\$9,279	\$8,979	\$6,684	\$15,468	\$4,196*	\$7,278
	OCM	\$8,258	\$8,252	\$3,444	\$4,209	\$9,163	\$8,959	\$6,655	\$15,542	\$4,945	\$7,358
	Comparison	\$7,856*	\$7,766*	\$3,312*	\$3,844*	\$9,242	\$8,932	\$6,786	\$16,763	\$4,202*	\$7,205*
	NONC	\$8,008*	\$8,017*	\$3,085*	\$3,551*	\$9,438*	\$9,045	\$6,628	\$13,923*	\$3,719*	\$7,256
-2	National	\$8,269*	\$7,921*	\$3,176*	\$3,595*	\$9,293	\$8,863	\$6,138	\$14,347	\$3,978*	\$7,013*
	OCM	\$8,442	\$8,203	\$3,321	\$3,938	\$9,225	\$8,739	\$6,198	\$14,855	\$4,600	\$7,111
	Comparison	\$8,112*	\$7,755*	\$3,219*	\$3,599*	\$9,237	\$9,043	\$6,122	\$14,327	\$3,883*	\$6,942*
	NONC	\$8,219*	\$7,767*	\$3,008*	\$3,386*	\$9,424	\$8,840	\$6,090	\$13,657	\$3,630*	\$6,972*

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices.

Exhibit A5-12: All-Cause Mortality by Cancer Bundle in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Practice/ TIN Type	All-Cause Mortality Rate									
		Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	National	26.8%	12.3%	3.4%	21.7%	8.5%	20.5%	10.1%	28.1%	10.6%	18.4%
	OCM	27.7%	12.5%	3.6%	6.8%	8.2%	20.1%	11.1%	29.9%	14.0%	18.7%
	Comparison	26.1%	11.9%	3.5%	5.6%	8.1%	19.9%	9.8%	26.5%	11.6%	18.4%
	NONC	26.4%	12.3%	3.1%	20.7%	9.0%	21.2%	9.3%	27.7%	7.9%	18.1%
-7	National	27.8%	13.9%	3.7%	19.8%	8.5%	20.4%	10.4%	27.9%	11.9%	18.5%
	OCM	28.2%	14.4%	4.1%	7.8%	8.5%	20.2%	10.5%	28.8%	15.0%	18.9%
	Comparison	27.3%	13.5%	3.6%	6.0%	8.8%	19.0%	10.2%	26.4%	11.3%	18.3%
	NONC	27.9%	13.6%	3.6%	18.7%	8.2%	21.5%	10.5%	28.4%	10.4%	18.3%
-6	National	26.6%	13.1%	3.2%	20.8%	7.9%	20.0%	10.1%	26.3%	10.5%	17.3%
	OCM	27.0%	12.9%	3.4%	6.8%	7.3%	19.0%	10.7%	28.4%	14.7%	17.6%
	Comparison	25.1%	12.9%	3.2%	5.8%	8.3%	20.7%	10.2%	26.4%	10.7%	17.2%
	NONC	27.3%	13.4%	2.9%	19.4%	8.2%	20.8%	9.5%	23.5%	7.8%	17.3%
-5	National	27.2%	13.5%	3.3%	20.1%	8.5%	18.9%	9.7%	28.4%	11.6%	17.4%
	OCM	28.2%	13.9%	3.5%	7.8%	8.4%	19.5%	9.6%	29.9%	16.0%	17.5%
	Comparison	25.9%	13.6%	3.6%	6.1%	8.1%	18.9%	9.9%	28.9%	11.1%	17.2%
	NONC	27.2%	13.2%	3.0%	18.8%	8.9%	18.2%	9.7%	25.8%	9.2%	17.3%
-4	National	26.4%	12.8%	3.1%	21.1%	8.1%	19.6%	9.4%	26.1%	10.5%	17.0%
	OCM	26.9%	13.1%	3.2%	7.2%	7.7%	20.0%	9.5%	28.7%	14.5%	17.4%
	Comparison	25.6%	13.0%	3.2%	5.7%	8.3%	21.0%	9.0%	23.0%	9.9%	16.9%
	NONC	26.7%	12.3%	2.9%	19.6%	8.2%	17.9%	9.8%	26.2%	8.4%	16.7%
-3	National	26.8%	13.5%	3.3%	19.7%	8.8%	18.4%	9.6%	24.7%	11.1%	17.4%
	OCM	26.8%	14.1%	3.5%	7.0%	8.4%	16.7%	10.4%	24.3%	15.3%	17.6%
	Comparison	26.4%	13.7%	3.3%	6.0%	9.1%	18.6%	9.0%	23.2%	11.0%	17.4%
	NONC	27.1%	12.8%	3.1%	18.5%	9.0%	19.9%	9.3%	27.1%	8.5%	17.2%
-2	National	24.8%	12.4%	3.0%	48.7%	7.9%	19.2%	9.0%	20.5%	11.0%	16.3%
	OCM	25.3%	12.4%	3.0%	6.7%	8.0%	19.6%	8.8%	23.2%	14.0%	16.7%
	Comparison	23.9%	12.2%	2.9%	5.6%	7.7%	18.8%	9.0%	17.7%	11.9%	16.2%
	NONC	25.0%	12.6%	3.0%	20.7%	7.9%	19.1%	9.1%	20.3%	8.3%	15.9%

Source: Episode characteristics file, 2012-2015. Note: * Denotes a significant difference from OCM practices.

Exhibit A5-13: Characteristics of Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/TIN Type	Number of Episodes	Percent of Episodes among Dual Eligibles	Percent of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	Hormonal Therapy Only	OCM	21,436	18.2%	9.9%	28.4%	23.4%	16.9%	12.4%	9.0%
		Comparison	16,571	21.6%*	11.4%*	27.1%*	23.0%	17.4%	12.3%	8.8%
	Other Therapies	OCM	11,084	14.8%†	18.1%†	28.9%	22.4%	14.6%†	9.6%†	6.4%†
		Comparison	7,825	17.7%*†	20.7%*†	28.9%†	21.0%*†	13.9%†	9.1%†	6.4%†
-7	Hormonal Therapy Only	OCM	18,948	18.5%	9.8%	28.2%	23.8%	17.1%	12.0%	9.0%
		Comparison	14,884	22.1%*	11.7%*	27.3%	23.8%	17.0%	11.2%*	9.1%
	Other Therapies	OCM	10,149	14.9%†	17.9%†	28.8%	21.1%†	15.0%†	10.0%†	7.2%†
		Comparison	7,091	18.4%*†	21.8%*†	28.3%	20.5%†	14.2%†	8.8%*†	6.4%†
-6	Hormonal Therapy Only	OCM	22,997	15.4%	9.0%	28.5%	24.0%	17.6%	12.2%	8.8%
		Comparison	18,254	18.9%*	10.6%*	27.4%*	23.9%	17.7%	11.6%	8.8%
	Other Therapies	OCM	10,610	14.3%†	17.7%†	28.4%	22.1%†	14.8%†	9.6%†	7.3%†
		Comparison	7,811	17.8%*†	21.1%*†	28.9%†	20.8%*†	13.8%†	8.8%†	6.4%*†
-5	Hormonal Therapy Only	OCM	22,496	15.2%	8.9%	28.7%	24.2%	17.8%	11.8%	8.6%
		Comparison	17,758	18.4%*	10.6%*	28.0%	23.5%	17.2%	11.7%	8.9%
	Other Therapies	OCM	10,468	14.2%†	17.7%†	28.2%	22.5%†	15.2%†	9.0%†	7.5%†
		Comparison	7,811	18.1%*	20.8%*†	28.1%	21.3%†	14.5%†	8.7%†	6.7%*†
-4	Hormonal Therapy Only	OCM	24,845	14.0%	8.2%	29.2%	25.2%	18.0%	11.2%	8.3%
		Comparison	19,931	16.9%*	10.1%*	28.7%	24.4%*	17.4%	11.1%	8.4%
	Other Therapies	OCM	11,024	13.4%	16.9%†	29.8%	22.4%†	14.8%†	9.0%†	7.2%†
		Comparison	8,289	17.2%*	19.9%*†	29.7%	20.9%*†	14.7%†	8.3%†	6.5%†
-3	Hormonal Therapy Only	OCM	24,280	13.7%	8.2%	29.2%	24.7%	18.2%	11.3%	8.4%
		Comparison	19,627	16.9%*	9.9%*	29.1%	24.1%	17.5%	11.0%	8.5%
	Other Therapies	OCM	10,958	13.4%	16.9%†	29.5%	22.8%†	14.8%†	8.8%†	7.3%†
		Comparison	8,258	17.1%*	20.5%*†	29.2%	22%†	14.2%†	8.3%†	5.7%*†
-2	Hormonal Therapy Only	OCM	26,406	12.7%	7.9%	29.9%	25.0%	17.7%	11.1%	8.4%
		Comparison	21,102	16.0%*	9.8%*	29.2%	24.7%	17.4%	11.0%	7.9%
	Other Therapies	OCM	11,184	12.8%	17.0%†	29.7%	23.0%†	15.1%†	8.5%†	6.8%†
		Comparison	8,468	17.5%*†	20.6%*†	29.4%	22.3%†	13.8%*†	8.2%†	5.6%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-13: Characteristics of Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes by Race				Percent of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	Hormonal Therapy Only	OCM	21,436	83.3%	8.1%	6.1%	2.5%	21.2%
		Comparison	16,571	83.6%	9.7%*	4.1%*	2.6%	22.4%*
	Other Therapies	OCM	11,084	81.3%†	10.6%†	5.4%†	2.7%	55.3%†
		Comparison	7,825	80.7%†	12.0%*†	4.5%*	2.8%	55.8%†
-7	Hormonal Therapy Only	OCM	18,948	83.6%	7.9%	5.9%	2.7%	20.1%
		Comparison	14,884	83.0%	10.0%*	4.2%*	2.8%	20.6%
	Other Therapies	OCM	10,149	81.9%†	10.2%†	4.9%†	2.9%	45.8%†
		Comparison	7,091	80.3%*†	11.7%*†	5.1%†	2.8%	44.7%†
-6	Hormonal Therapy Only	OCM	22,997	83.6%	8.8%	5.3%	2.3%	20.7%
		Comparison	18,254	83.0%	10.3%*	3.9%*	2.8%*	21.9%*
	Other Therapies	OCM	10,610	81.2%†	10.9%†	5.0%	2.9%†	55.4%†
		Comparison	7,811	79.8%*†	12.2%*†	4.7%†	3.3%†	55.7%†
-5	Hormonal Therapy Only	OCM	22,496	83.4%	8.6%	5.2%	2.7%	18.2%
		Comparison	17,758	82.9%	10.1%*	3.9%*	3.1%	19.1%*
	Other Therapies	OCM	10,468	81.5%†	10.3%†	5.1%	3.0%	45.3%†
		Comparison	7,811	79.4%*†	12.3%*†	4.7%†	3.6%*†	45.1%†
-4	Hormonal Therapy Only	OCM	24,845	83.9%	8.3%	5.0%	2.8%	16.6%
		Comparison	19,931	83.2%	10.0%*	3.9%*	2.9%	17.2%
	Other Therapies	OCM	11,024	81.0%†	10.5%†	5.5%	2.9%	51.8%†
		Comparison	8,289	79.9%†	11.7%*†	4.8%*†	3.6%*†	51.8%†
-3	Hormonal Therapy Only	OCM	24,280	83.7%	8.5%	4.8%	3.0%	14.9%
		Comparison	19,627	83.6%	9.6%*	3.7%*	3.1%	15.3%
	Other Therapies	OCM	10,958	81.0%†	10.5%†	5.4%†	3.1%	41.5%†
		Comparison	8,258	80.2%†	11.7%*†	4.6%*†	3.6%*†	42.7%†
-2	Hormonal Therapy Only	OCM	26,406	83.9%	8.3%	4.7%	3.1%	19.9%
		Comparison	21,102	83.7%	9.3%*	3.9%*	3.1%	21.0%*
	Other Therapies	OCM	11,184	80.9%†	10.4%†	5.1%	3.6%†	54.5%†
		Comparison	8,468	79.7%*†	11.8%*†	4.8%†	3.8%†	56.6%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-14: Characteristics of Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes among Dual Eligibles	Percent of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	Hormonal Therapy Only	OCM	9,490	9.0%	3.1%	15.3%	19.4%	21.8%	19.9%	20.6%
		Comparison	10,817	9.3%	2.5%*	13.8%*	18.6%	21.3%	20.0%	23.7%*
	Other Therapies	OCM	2,921	7.9%	5.4%†	19.4%†	23.9%†	23.5%	17.2%†	10.6%†
		Comparison	2,399	11.2%*†	5.6%†	21.1%†	23.8%†	22.6%	16.6%†	10.3%†
-7	Hormonal Therapy Only	OCM	8,212	8.3%	3.2%	14.4%	19.3%	21.8%	19.6%	21.7%
		Comparison	9,156	9.3%*	2.9%	14.7%	18.5%	21.3%	19.5%	23.2%*
	Other Therapies	OCM	2,973	10.2%†	5.3%†	19.3%†	23%†	24.5%†	16.8%†	11.1%†
		Comparison	2,524	12.2%*†	5.9%†	20.1%†	23.3%†	21.6%*	17.2%†	11.9%†
-6	Hormonal Therapy Only	OCM	8,319	8.5%	2.9%	15.0%	19.3%	22.1%	19.7%	21.0%
		Comparison	9,539	8.2%	3.0%	14.8%	19.1%	21.0%	19.1%	23.0%*
	Other Therapies	OCM	3,266	11.0%†	5.3%†	18.7%†	23.3%†	22.5%	18.3%	11.9%†
		Comparison	2,867	11.7%†	6.2%†	19.0%†	23.3%†	20.5%	18.4%	12.6%†
-5	Hormonal Therapy Only	OCM	7,825	8.4%	2.9%	14.8%	20.5%	21.6%	19.2%	20.9%
		Comparison	8,900	8.7%	2.9%	15.0%	19.2%*	20.5%	19.3%	23.1%*
	Other Therapies	OCM	3,412	10.6%†	4.2%†	18.0%†	22.8%†	22.8%	18.4%	13.8%†
		Comparison	2,839	10.5%†	5.5%*†	18.5%†	23.6%†	21.8%	17.6%†	13.0%†
-4	Hormonal Therapy Only	OCM	8,692	7.9%	3.1%	15.6%	19.9%	21.5%	19.3%	20.6%
		Comparison	10,283	7.8%	2.6%*	14.3%*	19.0%	20.9%	19.8%	23.4%*
	Other Therapies	OCM	3,683	9.8%†	4.6%†	17.3%†	23.6%†	22.8%	18.2%	13.4%†
		Comparison	3,322	10.1%†	5.3%†	19.4%*†	23.9%†	22.0%	16.4%*†	13.0%†
-3	Hormonal Therapy Only	OCM	8,053	7.5%	2.7%	15.0%	20.8%	21.0%	19.7%	20.7%
		Comparison	9,600	7.6%	2.5%	14.8%	20.0%	20.7%	19.4%	22.6%*
	Other Therapies	OCM	3,868	10.1%†	4.1%†	18.0%†	24.1%†	22.8%†	17.4%†	13.6%†
		Comparison	3,556	10.6%†	5.5%*†	18.2%†	24.7%†	21.0%	16.5%†	14.0%†
-2	Hormonal Therapy Only	OCM	9,191	7.6%	2.9%	15.7%	20.3%	22.1%	19.1%	19.9%
		Comparison	11,090	7.7%	2.8%	14.9%	20.3%	21.1%	19.3%	21.6%*
	Other Therapies	OCM	3,730	9.7%†	4.4%†	18.2%†	25.2%†	22.2%	17.2%†	12.8%†
		Comparison	3,412	9.9%†	5.2%†	19.0%†	22.9%*†	22.7%†	17.0%†	13.2%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-14: Characteristics of Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes by Race				Percent of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	Hormonal Therapy Only	OCM	9,490	78.1%	13.7%	5.6%	2.6%	39.4%
		Comparison	10,817	80.0%*	13.1%	4.1%*	2.8%	35.3%*
	Other Therapies	OCM	2,921	80.6%†	12.4%	4.5%†	2.5%	72.5%†
		Comparison	2,399	79.3%	12.5%	5.2%†	3.0%	70.4%†
-7	Hormonal Therapy Only	OCM	8,212	79.0%	13.0%	5.4%	2.5%	34.4%
		Comparison	9,156	79.7%	13.2%	4.0%*	3.1%*	31.0%*
	Other Therapies	OCM	2,973	80.0%	12.0%	5.0%	2.9%	59.6%†
		Comparison	2,524	79.5%	12.0%	5.4%†	3.1%	56.9%*†
-6	Hormonal Therapy Only	OCM	8,319	78.4%	13.6%	5.1%	2.9%	39.2%
		Comparison	9,539	79.8%*	13.0%	4.0%*	3.2%	35.1%*
	Other Therapies	OCM	3,266	78.8%	12.6%	5.5%	3.1%	71.7%†
		Comparison	2,867	79.0%	13.4%	4.8%†	2.8%	71.7%†
-5	Hormonal Therapy Only	OCM	7,825	79.0%	13.1%	4.9%	3.0%	33.1%
		Comparison	8,900	79.7%	13.0%	4.0%*	3.3%	30.6%*
	Other Therapies	OCM	3,412	79.5%	12.0%	5.4%	3.0%	60.7%†
		Comparison	2,839	79.7%	13.1%	4.5%	2.7%	60.2%†
-4	Hormonal Therapy Only	OCM	8,692	79.2%	12.8%	5.0%	3.0%	37.0%
		Comparison	10,283	80.2%	12.8%	3.8%*	3.2%	34.0%*
	Other Therapies	OCM	3,683	80.2%	11.3%†	5.5%	3.0%	71.3%†
		Comparison	3,322	79.8%	13.0%*	4.1%*	3.1%	68.4%*†
-3	Hormonal Therapy Only	OCM	8,053	79.4%	12.6%	4.8%	3.2%	31.1%
		Comparison	9,600	80.8%*	12.3%	3.9%*	3.0%	28.0%*
	Other Therapies	OCM	3,868	79.8%	11.8%	5.1%	3.3%	59.6%†
		Comparison	3,556	79.6%	12.9%	4.4%	3.1%	58.5%†
-2	Hormonal Therapy Only	OCM	9,191	79.7%	12.5%	4.8%	3.0%	39.8%
		Comparison	11,090	80.6%	11.9%	4.1%*	3.5%*	37.3%*
	Other Therapies	OCM	3,730	79.4%	11.9%	4.9%	3.8%†	72.8%†
		Comparison	3,412	78.6%†	12.5%	5.1%†	3.9%	73.7%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

**Exhibit A5-15: Utilization within Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period
(Episodes initiating Jan. 2012 – Jun. 2015)**

Performance Period	Group	Practice/TIN Type	Number of Episodes	Number of Cancer Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	Hormonal Therapy Only	OCM	21,436	1.92	1.38	2.49	1.72	0.12	0.41	0.20	0.60
		Comparison	16,571	1.87*	1.30	2.64*	1.74	0.13	0.43	0.21	0.62
	Other Therapies	OCM	11,084	7.37†	4.60	10.41†	7.60	0.39†	0.80	0.33†	0.87
		Comparison	7,825	6.84*†	4.35	10.16*†	7.30	0.39†	0.77	0.37*†	0.98
-7	Hormonal Therapy Only	OCM	18,948	1.92	1.38	2.48	1.71	0.13	0.44	0.20	0.58
		Comparison	14,884	1.87*	1.32	2.67*	1.75	0.13	0.42	0.21*	0.62
	Other Therapies	OCM	10,149	7.01†	4.52	10.13†	7.20	0.38†	0.77	0.33†	0.88
		Comparison	7,091	6.49*†	4.23	9.95†	6.87	0.37†	0.77	0.35†	0.88
-6	Hormonal Therapy Only	OCM	22,997	1.91	1.39	2.38	1.68	0.12	0.43	0.19	0.59
		Comparison	18,254	1.88*	1.33	2.60*	1.76	0.12	0.41	0.21*	0.66
	Other Therapies	OCM	10,610	7.11†	4.49	10.1†	6.97	0.37†	0.76	0.33†	0.80
		Comparison	7,811	6.64*†	4.27	10.07†	6.78	0.37†	0.76	0.36*†	0.81
-5	Hormonal Therapy Only	OCM	22,496	1.89	1.38	2.34	1.68	0.11	0.41	0.19	0.60
		Comparison	17,758	1.84*	1.28	2.50*	1.71	0.11	0.40	0.20	0.61
	Other Therapies	OCM	10,468	7.02†	4.54	10.27†	7.07	0.37†	0.75	0.32†	0.75
		Comparison	7,811	6.49*†	4.25	10.17†	7.06	0.36†	0.74	0.37*†	0.87
-4	Hormonal Therapy Only	OCM	24,845	1.90	1.39	2.32	1.67	0.11	0.40	0.19	0.56
		Comparison	19,931	1.86*	1.30	2.49*	1.72	0.11	0.39	0.21*	0.64
	Other Therapies	OCM	11,024	7.16†	4.56	10.49†	7.01	0.36†	0.75	0.33†	0.76
		Comparison	8,289	6.64*†	4.24	10.54†	7.11	0.37†	0.79	0.38*†	0.88
-3	Hormonal Therapy Only	OCM	24,280	1.87	1.35	2.23	1.65	0.11	0.40	0.19	0.57
		Comparison	19,627	1.83*	1.28	2.40*	1.72	0.12	0.41	0.21*	0.67
	Other Therapies	OCM	10,958	6.92†	4.41	10.40†	7.13	0.35†	0.73	0.34†	0.88
		Comparison	8,258	6.40*†	4.09	10.45†	6.92	0.36†	0.76	0.36†	0.82
-2	Hormonal Therapy Only	OCM	26,406	1.93	1.49	2.30	1.84	0.11	0.40	0.20	0.59
		Comparison	21,102	1.87*	1.41	2.46*	1.92	0.11	0.40	0.21*	0.64
	Other Therapies	OCM	11,184	7.03†	4.34	10.68†	7.04	0.35†	0.74	0.33†	0.77
		Comparison	8,468	6.48*†	4.15	10.66†	6.90	0.33†	0.73	0.40*†	1.00

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-16: Utilization within Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/TIN Type	Number of Episodes	Number of Cancer Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	Hormonal Therapy Only	OCM	9,490	2.95	2.29	2.16	1.94	0.24	0.62	0.27	0.68
		Comparison	10,817	2.51*	2.04	2.03*	1.81	0.23	0.60	0.26	0.67
	Other Therapies	OCM	2,921	7.51†	4.60	6.79†	4.84	0.54†	0.93	0.39†	0.79
		Comparison	2,399	7.01*†	4.38	6.72†	4.95	0.49*†	0.88	0.46*†	0.94
-7	Hormonal Therapy Only	OCM	8,212	2.94	2.28	2.16	1.92	0.24	0.62	0.28	0.70
		Comparison	9,156	2.52*	2.04	2.11	1.84	0.21*	0.57	0.26*	0.68
	Other Therapies	OCM	2,973	6.97†	3.96	6.42†	4.38	0.51†	0.91	0.39†	0.80
		Comparison	2,524	6.29*†	3.92	6.27†	4.24	0.45*†	0.83	0.47*†	0.94
-6	Hormonal Therapy Only	OCM	8,319	2.92	2.29	2.17	1.93	0.23	0.61	0.28	0.74
		Comparison	9,539	2.52*	2.05	2.11*	1.87	0.20*	0.54	0.26*	0.68
	Other Therapies	OCM	3,266	6.54†	3.77	6.53†	4.42	0.45†	0.87	0.39†	0.85
		Comparison	2,867	6.04*†	3.72	6.47†	4.42	0.42†	0.80	0.46*†	1.07
-5	Hormonal Therapy Only	OCM	7,825	2.93	2.30	2.15	1.89	0.24	0.63	0.28	0.75
		Comparison	8,900	2.50*	2.06	2.13	1.89	0.22*	0.57	0.27	0.83
	Other Therapies	OCM	3,412	6.34†	3.84	6.57†	4.55	0.44†	0.85	0.42†	0.93
		Comparison	2,839	5.67*†	3.58	6.38†	4.10	0.39*†	0.80	0.42†	0.91
-4	Hormonal Therapy Only	OCM	8,692	2.89	2.22	2.15	1.90	0.23	0.61	0.28	0.70
		Comparison	10,283	2.48*	1.99	2.09*	1.86	0.20*	0.55	0.27	0.73
	Other Therapies	OCM	3,683	6.13†	3.77	6.57†	4.22	0.45†	0.84	0.43†	0.91
		Comparison	3,322	5.68*†	3.64	6.66†	4.00	0.36*†	0.77	0.42†	0.90
-3	Hormonal Therapy Only	OCM	8,053	2.83	2.15	2.20	1.90	0.23	0.62	0.30	0.77
		Comparison	9,600	2.43*	1.91	2.13*	1.92	0.21*	0.58	0.28	0.72
	Other Therapies	OCM	3,868	6.15†	3.79	6.74†	4.14	0.43†	0.80	0.44†	0.89
		Comparison	3,556	5.59*†	3.52	6.73†	4.05	0.38*†	0.79	0.43†	0.89
-2	Hormonal Therapy Only	OCM	9,191	3.01	2.32	2.41	2.15	0.22	0.60	0.30	0.77
		Comparison	11,090	2.58*	2.09	2.32*	2.19	0.19*	0.54	0.30	0.74
	Other Therapies	OCM	3,730	5.96†	3.68	7.04†	4.30	0.43†	0.84	0.42†	0.88
		Comparison	3,412	5.45*†	3.61	6.90†	3.88	0.38*†	0.80	0.46*†	1.00

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-17: Total Cost of Care and Cost Sharing of Breast Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Standardized Part A and B, and Part D per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	Hormonal Therapy Only	OCM	21,436	\$5,511	\$9,095	\$1,305	\$1,485
		Comparison	16,571	\$5,447	\$9,047	\$1,278	\$1,494
	Other Therapies	OCM	11,084	\$28,676†	\$17,840	\$6,532†	\$3,860
		Comparison	7,825	\$27,717*†	\$17,585	\$6,409*†	\$3,805
-7	Hormonal Therapy Only	OCM	18,948	\$5,627	\$10,035	\$1,458	\$1,738
		Comparison	14,884	\$5,559	\$9,565	\$1,453	\$1,732
	Other Therapies	OCM	10,149	\$28,808†	\$18,465	\$6,742†	\$4,049
		Comparison	7,091	\$28,051*†	\$18,292	\$6,628†	\$3,917
-6	Hormonal Therapy Only	OCM	22,997	\$5,685	\$9,489	\$1,411	\$1,777
		Comparison	18,254	\$5,404*	\$8,923	\$1,363*	\$1,754
	Other Therapies	OCM	10,610	\$29,810†	\$18,971	\$7,152†	\$4,534
		Comparison	7,811	\$30,117†	\$53,204	\$7,316†	\$13,267
-5	Hormonal Therapy Only	OCM	22,496	\$5,345	\$9,301	\$1,424	\$1,692
		Comparison	17,758	\$5,198	\$9,034	\$1,408	\$1,713
	Other Therapies	OCM	10,468	\$30,377†	\$19,955	\$7,404†	\$4,658
		Comparison	7,811	\$29,780*†	\$19,651	\$7,313†	\$4,656
-4	Hormonal Therapy Only	OCM	24,845	\$5,499	\$9,536	\$1,318	\$1,604
		Comparison	19,931	\$5,443	\$9,657	\$1,330	\$1,712
	Other Therapies	OCM	11,024	\$31,729†	\$20,241	\$7,542†	\$4,803
		Comparison	8,289	\$31,686†	\$20,585	\$7,545†	\$4,893
-3	Hormonal Therapy Only	OCM	24,280	\$5,474	\$9,888	\$1,432	\$1,751
		Comparison	19,627	\$5,385	\$9,310	\$1,428	\$1,685
	Other Therapies	OCM	10,958	\$32,343†	\$21,117	\$7,903†	\$4,989
		Comparison	8,258	\$32,009†	\$21,056	\$7,788†	\$4,977
-2	Hormonal Therapy Only	OCM	26,406	\$5,799	\$10,244	\$1,369	\$1,811
		Comparison	21,102	\$5,902	\$10,727	\$1,383	\$1,779
	Other Therapies	OCM	11,184	\$34,382†	\$21,927	\$7,928†	\$5,120
		Comparison	8,468	\$34,144†	\$22,113	\$7,794†	\$5,083

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-18: Total Cost of Care and Cost Sharing of Prostate Cancer Episodes, Hormonal Therapy Only vs. Other Therapies, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Standardized Part A and B, and Part D per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	Hormonal Therapy Only	OCM	9,490	\$10,530	\$13,813	\$2,211	\$2,323
		Comparison	10,817	\$9,681*	\$13,134	\$2,089*	\$2,311
	Other Therapies	OCM	2,921	\$37,550†	\$26,745	\$7,503†	\$5,727
		Comparison	2,399	\$35,829*†	\$27,211	\$6,704*†	\$4,983
-7	Hormonal Therapy Only	OCM	8,212	\$10,383	\$14,609	\$2,422	\$2,533
		Comparison	9,156	\$9,375*	\$13,024	\$2,275*	\$2,489
	Other Therapies	OCM	2,973	\$36,749†	\$26,316	\$7,497†	\$5,858
		Comparison	2,524	\$34,094*†	\$25,192	\$6,683*†	\$5,165
-6	Hormonal Therapy Only	OCM	8,319	\$10,518	\$14,521	\$2,437	\$2,838
		Comparison	9,539	\$9,676*	\$13,003	\$2,335*	\$2,735
	Other Therapies	OCM	3,266	\$38,192†	\$24,770	\$7,243†	\$6,545
		Comparison	2,867	\$37,003†	\$23,557	\$6,785*†	\$6,112
-5	Hormonal Therapy Only	OCM	7,825	\$11,058	\$14,578	\$2,627	\$2,956
		Comparison	8,900	\$10,263*	\$14,797	\$2,523*	\$3,134
	Other Therapies	OCM	3,412	\$37,948†	\$25,549	\$7,752†	\$6,729
		Comparison	2,839	\$36,939†	\$26,714	\$7,635†	\$7,166
-4	Hormonal Therapy Only	OCM	8,692	\$10,870	\$14,339	\$2,500	\$2,995
		Comparison	10,283	\$9,967*	\$13,374	\$2,329*	\$2,791
	Other Therapies	OCM	3,683	\$40,563†	\$25,828	\$7,142†	\$6,774
		Comparison	3,322	\$39,321*†	\$25,111	\$6,740*†	\$6,351
-3	Hormonal Therapy Only	OCM	8,053	\$10,742	\$14,352	\$2,542	\$2,731
		Comparison	9,600	\$10,237*	\$13,852	\$2,508	\$2,804
	Other Therapies	OCM	3,868	\$39,035†	\$24,368	\$7,681†	\$6,139
		Comparison	3,556	\$38,105†	\$24,042	\$7,451†	\$5,967
-2	Hormonal Therapy Only	OCM	9,191	\$12,267	\$18,196	\$2,639	\$3,025
		Comparison	11,090	\$11,264*	\$15,244	\$2,568	\$3,080
	Other Therapies	OCM	3,730	\$43,926†	\$25,581	\$7,140†	\$6,191
		Comparison	3,412	\$44,312†	\$25,372	\$6,948†	\$5,923

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-19: Share of Episodes by Cancer Bundle, Dual vs. Non-Dual Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other
-8	Dual	OCM	11.6%	7.8%	40.6%	8.0%	5.4%	2.3%	4.0%	0.5%	1.2%	18.8%
		Comparison	11.3%	7.4%	39.0%*	10.0%*	5.2%	2.2%	4.3%	0.4%	1.4%	18.8%
	Non-Dual	OCM	11.6%	7.4%	30.8%†	12.9%†	8.6%†	1.6%†	4.0%	0.6%	2.3%†	20.2%†
		Comparison	10.6%*†	6.9%*	28.7%*†	17.7%*†	7.5%*†	1.4%*†	3.8%*†	0.6%*†	3.0%*†	19.6%*†
-7	Dual	OCM	10.8%	7.7%	41.6%	8.2%	5.0%	2.0%	4.0%	0.3%	1.1%	19.3%
		Comparison	10.4%	7.1%	40.3%*	10.1%*	4.2%*	2.1%	4.2%	0.4%	1.4%*	19.7%
	Non-Dual	OCM	10.9%	7.3%	31.5%†	13.3%†	8.3%†	1.6%†	4.0%	0.6%†	2.3%†	20.3%†
		Comparison	10.1%*	6.6%*	29.4%*†	17.8%*†	7.2%*†	1.4%*†	3.8%†	0.6%†	3.0%*†	20.1%
-6	Dual	OCM	11.1%	7.4%	40.4%	8.5%	4.9%	2.3%	4.3%	0.4%	1.1%	19.6%
		Comparison	11.0%	7.6%	39.9%	9.2%*	4.4%*	2.2%	4.3%	0.4%	1.3%	19.7%
	Non-Dual	OCM	10.5%†	6.7%†	33.5%†	12.4%†	7.8%†	1.6%†	4.1%	0.6%†	2.3%†	20.5%†
		Comparison	9.8%*†	6.2%*†	31.4%*†	16.7%*†	6.8%*†	1.4%*†	4.0%	0.6%†	2.9%*†	20.1%
-5	Dual	OCM	10.7%	7.4%	40.3%	8.4%	5.0%	2.1%	4.4%	0.5%	1.4%	19.8%
		Comparison	10.7%	7.4%	39.8%	9.2%*	4.3%*	2.1%	4.4%	0.4%	1.5%	20.1%
	Non-Dual	OCM	10.3%	6.6%†	33.9%†	12.3%†	7.7%†	1.5%†	4.2%	0.6%	2.3%†	20.6%†
		Comparison	9.6%*†	6.2%*†	31.8%*†	16.3%*†	6.8%*†	1.4%*†	4.0%†	0.6%†	2.9%*†	20.3%
-4	Dual	OCM	10.5%	7.6%	39.8%	8.5%	4.7%	2.2%	4.4%	0.5%	1.2%	20.6%
		Comparison	10.6%	7.5%	38.8%	9.2%	4.5%	2.1%	4.7%	0.5%	1.5%*	20.6%
	Non-Dual	OCM	9.9%†	6.5%†	34.1%†	12.5%†	7.5%†	1.4%†	4.3%	0.6%†	2.3%†	20.8%
		Comparison	9.3%*†	6.0%*†	32.0%*†	17.0%*†	6.5%*†	1.3%†	4.0%*†	0.6%†	3.1%*†	20.2%*
-3	Dual	OCM	10.1%	7.3%	40.5%	8.4%	4.8%	2.1%	4.6%	0.5%	1.2%	20.5%
		Comparison	10.6%	7.6%	39.1%*	9.2%*	4.3%	2.3%	4.5%	0.6%	1.2%	20.7%
	Non-Dual	OCM	9.8%	6.3%†	34.7%†	12.5%†	7.2%†	1.4%†	4.3%	0.7%†	2.2%†	20.9%
		Comparison	9.1%*†	6.0%*†	32.3%*†	16.8%*†	6.4%*†	1.4%†	4.2%	0.7%	2.9%*†	20.3%*†
-2	Dual	OCM	10.3%	7.5%	38.8%	8.7%	5.0%	2.3%	4.5%	0.5%	1.2%	21.1%
		Comparison	10.4%	7.5%	38.6%	9.5%*	4.2%*	2.1%	4.6%	0.6%	1.3%	21.1%
	Non-Dual	OCM	9.5%†	6.3%†	34.7%†	12.5%†	7.4%†	1.5%†	4.3%	0.8%†	2.3%†	20.8%
		Comparison	9.1%*†	5.8%*†	31.9%*†	17.2%*†	6.2%*†	1.4%†	4.1%†	0.9%†	2.9%*†	20.6%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-20: Share of Episodes by Cancer Bundle, White vs. Non-White Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/TIN Type	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other
-8	White	OCM	12.0%	7.2%	32.0%	11.6%	8.7%	1.7%	4.1%	0.6%	2.4%	19.7%
		Comparison	11.0%*	6.7%*	30.3%*	15.9%*	7.7%*	1.5%*	4.0%	0.7%	3.0%*	19.1%*
	Non-White	OCM	9.7%†	8.7%†	32.8%†	15.4%†	5.5%†	1.7%	3.3%†	0.2%†	1.1%†	21.6%†
		Comparison	9.6%†	8.2%†	30.5%*	19.2%*†	4.7%*†	1.5%	3.4%†	0.2%†	1.5%*†	21.3%†
-7	White	OCM	11.3%	7.1%	32.9%	12.1%	8.4%	1.6%	4.1%	0.6%	2.3%	19.7%
		Comparison	10.4%*	6.5%*	31.1%*	16.0%*	7.4%*	1.5%*	4.0%	0.7%	3.0%*	19.5%
	Non-White	OCM	9.2%†	8.6%†	33.0%	15.5%†	5.1%†	1.7%	3.4%†	0.2%†	1.2%†	22.2%†
		Comparison	9.0%†	7.8%*†	31.4%*	19.0%*†	4.0%*†	1.6%	3.3%†	0.1%†	1.5%*†	22.4%†
-6	White	OCM	10.9%	6.6%	34.5%	11.3%	8.0%	1.7%	4.2%	0.7%	2.4%	19.9%
		Comparison	10.2%*	6.2%*	32.7%*	15.1%*	6.9%*	1.5%*	4.2%	0.7%	2.9%*	19.6%
	Non-White	OCM	9.2%†	8.0%†	34.1%	14.7%†	4.8%†	1.6%	3.6%†	0.2%†	1.2%†	22.5%†
		Comparison	9.1%†	7.6%†	32.8%*	17.7%*†	4.3%†	1.5%	3.4%†	0.2%†	1.3%†	22.1%†
-5	White	OCM	10.6%	6.5%	34.8%	11.3%	7.8%	1.6%	4.3%	0.7%	2.3%	20.0%
		Comparison	10.0%*	6.2%*	33.0%*	14.8%*	7.0%*	1.5%*	4.2%	0.7%	2.9%*	19.7%
	Non-White	OCM	9.2%†	7.8%†	34.1%	14.1%†	5.0%†	1.5%	3.9%†	0.2%†	1.3%†	22.9%†
		Comparison	8.8%†	7.5%†	33.2%	17.0%*†	4.0%*†	1.5%	3.6%†	0.2%†	1.6%*†	22.6%†
-4	White	OCM	10.3%	6.3%	34.9%	11.5%	7.7%	1.6%	4.4%	0.7%	2.4%	20.2%
		Comparison	9.7%*	6.0%*	33.0%*	15.5%*	6.6%*	1.5%	4.2%*	0.7%	3.1%*	19.7%*
	Non-White	OCM	8.8%†	7.9%†	34.4%	14.3%†	4.9%†	1.4%	3.8%†	0.2%†	1.3%†	23.1%†
		Comparison	8.6%†	7.3%*†	32.5%*	17.6%*†	4.3%*†	1.5%	3.5%†	0.2%†	1.5%†	23.0%†
-3	White	OCM	10.1%	6.1%	35.5%	11.5%	7.4%	1.5%	4.4%	0.7%	2.3%	20.4%
		Comparison	9.4%*	6.0%	33.4%*	15.4%*	6.5%*	1.6%	4.4%	0.8%	2.9%*	19.8%*
	Non-White	OCM	8.4%†	7.8%†	35.0%	14.1%†	4.8%†	1.5%	3.9%†	0.2%†	1.2%†	23.1%†
		Comparison	8.8%†	7.3%†	32.8%*	17.3%*†	4.0%*†	1.5%	3.5%*†	0.2%†	1.5%*†	23.2%†
-2	White	OCM	9.9%	6.2%	35.3%	11.6%	7.6%	1.6%	4.4%	0.9%	2.4%	20.2%
		Comparison	9.5%*	5.8%*	33.0%*	15.7%*	6.4%*	1.5%	4.3%	0.9%	2.9%*	20.1%
	Non-White	OCM	8.0%†	7.8%†	34.5%	14.2%†	5.0%†	1.3%†	3.8%†	0.2%†	1.3%†	23.9%†
		Comparison	8.4%†	7.2%†	32.2%*†	18.0%*†	4.0%*†	1.4%	3.7%†	0.3%*†	1.5%†	23.3%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-21: Share of Episodes by Cancer Bundle, High Risk vs. Low Risk Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other
-8	High Risk	OCM	17.4%	7.3%	22.3%	12.8%	8.3%	1.8%	4.3%	0.6%	3.2%	22.0%
		Comparison	16.1%*	6.8%*	21.0%*	16.9%*	7.4%*	1.9%	4.1%	0.6%	3.8%*	21.3%*
	Low Risk	OCM	6.9%†	7.6%†	40.0%†	11.8%†	8.1%	1.6%†	3.8%†	0.5%	1.3%†	18.4%†
		Comparison	6.6%†	7.1%*	37.6%*†	16.1%*†	6.9%*†	1.3%*†	3.7%†	0.6%	1.9%*†	18.1%†
-7	High Risk	OCM	16.4%	7.2%	23.4%	13.4%	7.8%	1.8%	4.3%	0.5%	3.1%	22.1%
		Comparison	15.2%*	6.5%*	21.7%*	17.1%*	7.1%*	1.7%	4.3%	0.6%	3.8%*	21.9%
	Low risk	OCM	6.5%†	7.5%	40.5%†	12%†	7.8%	1.5%†	3.7%†	0.6%	1.3%†	18.6%†
		Comparison	6.3%†	6.8%*	38.3%*†	16.1%*†	6.5%*†	1.3%*†	3.5%†	0.6%	1.9%*†	18.6%†
-6	High Risk	OCM	16.0%	6.8%	24.2%	12.6%	7.5%	1.9%	4.6%	0.6%	3.2%	22.6%
		Comparison	15.1%*	6.3%*	22.7%*	15.9%*	6.8%*	1.6%*	4.7%	0.6%	3.6%*	22.5%
	Low Risk	OCM	6.4%†	6.8%	42.3%†	11.3%†	7.4%	1.5%†	3.7%†	0.6%	1.4%†	18.6%†
		Comparison	6.1%†	6.5%*	40.2%*†	15.3%*†	6.2%*†	1.4%†	3.5%†	0.6%	1.9%*†	18.2%†
-5	High Risk	OCM	15.9%	6.7%	24.0%	12.6%	7.5%	1.7%	4.6%	0.7%	3.1%	23.2%
		Comparison	14.6%*	6.3%*	23.0%*	15.8%*	7.0%*	1.7%	4.7%	0.6%	3.8%*	22.6%
	Low risk	OCM	6.1%†	6.8%	43.0%†	11.2%†	7.2%	1.5%†	3.9%†	0.5%†	1.4%†	18.4%†
		Comparison	6.1%†	6.5%	40.8%*†	14.7%*†	6.1%*†	1.4%*†	3.7%†	0.6%	1.8%*†	18.5%†
-4	High Risk	OCM	15.2%	6.5%	24.4%	12.8%	7.4%	1.7%	4.8%	0.7%	3.2%	23.4%
		Comparison	14.3%*	6.1%*	22.8%*	16.7%*	6.5%*	1.6%	4.6%	0.6%	4.1%*	22.6%*
	Low Risk	OCM	6.1%†	6.7%	42.7%†	11.4%†	7.0%	1.4%†	3.9%†	0.6%†	1.4%†	18.8%†
		Comparison	5.9%†	6.3%*	40.6%*†	15.3%*†	5.9%*†	1.3%†	3.6%*†	0.6%	1.9%*†	18.5%†
-3	High Risk	OCM	15.1%	6.3%	24.7%	12.5%	7.3%	1.7%	4.8%	0.7%	3.1%	23.7%
		Comparison	14.2%*	5.9%*	23.2%*	16.5%*	6.4%*	1.8%	4.8%	0.7%	3.9%*	22.7%*
	Low risk	OCM	5.8%†	6.5%	43.5%†	11.5%†	6.7%†	1.4%†	3.9%†	0.6%	1.2%†	18.7%†
		Comparison	5.6%†	6.4%†	40.9%*†	15.1%*†	5.8%*†	1.4%†	3.7%†	0.6%	1.7%*†	18.7%†
-2	High Risk	OCM	14.7%	6.3%	24.5%	12.7%	7.5%	1.8%	4.9%	0.8%	3.3%	23.5%
		Comparison	14.3%	5.8%*	22.8%*	16.8%*	6.4%*	1.6%*	4.6%	0.9%*	3.8%*	23.0%
	Low Risk	OCM	5.7%†	6.5%	43.1%†	11.6%†	6.9%†	1.4%†	3.9%†	0.8%	1.4%†	18.9%†
		Comparison	5.6%†	6.2%*†	40.1%*†	15.6%*†	5.7%*†	1.4%†	3.8%†	0.7%†	1.8%*†	19.0%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-22: Episode Services, Dual vs. Non-Dual Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Group	Practice TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	Dual	OCM	13,634	5.44	5.04	7.63	8.35	0.55	1.01	0.54	1.25
		Comparison	12,738	4.95*	4.38	7.25*	7.74	0.50*	0.94	0.57	1.21
	Non-Dual	OCM	87,558	6.05†	5.16	8.33†	9.45	0.31†	0.75	0.446†	0.86
		Comparison	67,607	5.40*†	4.83	7.53*†	8.53	0.33*†	0.78	0.41*†	0.84
-7	Dual	OCM	12,051	5.28	4.93	7.59	8.30	0.51	0.94	0.52	1.21
		Comparison	11,413	4.70*	4.25	7.11*	7.67	0.51	0.95	0.56*	1.19
	Non-Dual	OCM	76,438	5.89†	4.99	8.22†	9.30	0.31†	0.72	0.43†	0.85
		Comparison	59,110	5.23*†	4.66	7.54*†	8.45	0.33*†	0.77	0.40*†	0.81
-6	Dual	OCM	12,514	5.44	5.04	7.72	8.45	0.51	0.96	0.54	1.20
		Comparison	12,117	4.81*	4.34	7.38*	7.90	0.47*	0.94	0.58*	1.25
	Non-Dual	OCM	85,097	5.80†	5.02	8.04†	9.17	0.31†	0.72	0.41†	0.84
		Comparison	67,560	5.24*†	4.74	7.49*	8.51	0.33*†	0.81	0.38*†	0.80
-5	Dual	OCM	12,167	5.23	4.86	7.58	8.35	0.51	0.96	0.52	1.12
		Comparison	11,758	4.74*	4.31	7.32*	7.86	0.47*	0.92	0.58*	1.22
	Non-Dual	OCM	82,860	5.71†	4.95	8.08†	9.18	0.31†	0.78	0.41†	0.82
		Comparison	65,616	5.09*†	4.55	7.45*	8.49	0.33*†	0.81	0.38*†	0.79
-4	Dual	OCM	12,418	5.37	4.91	7.82	8.51	0.51	0.95	0.55	1.16
		Comparison	12,371	4.82*	4.33	7.45*	8.04	0.47*	0.94	0.60*	1.21
	Non-Dual	OCM	90,570	5.69†	4.97	7.98†	9.06	0.32†	0.75	0.40†	0.82
		Comparison	73,272	5.06*†	4.49	7.49*	8.63	0.34*†	0.81	0.37*†	0.79
-3	Dual	OCM	11,820	5.15	4.79	7.63	8.45	0.51	0.96	0.54	1.14
		Comparison	12,103	4.76*	4.19	7.53	8.21	0.47*	0.91	0.58*	1.16
	Non-Dual	OCM	87,780	5.56†	4.84	7.88†	8.98	0.32†	0.75	0.40†	0.82
		Comparison	71,725	4.97*†	4.39	7.48*	8.60	0.34*†	0.81	0.38*†	0.79
-2	Dual	OCM	12,281	5.30	4.72	7.85	8.56	0.50	0.98	0.56	1.12
		Comparison	12,582	4.80*	4.15	7.80	8.48	0.46*	0.92	0.62*	1.32
	Non-Dual	OCM	94,697	5.57†	4.87	7.99†	9.09	0.33†	0.76	0.39†	0.82
		Comparison	77,379	4.99*†	4.42	7.59*†	8.78	0.36*†	0.84	0.36*†	0.78

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-23: Episode Services, White vs. Non-White Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Group	Practice/ TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	White	OCM	83,946	6.00	5.15	8.22	9.25	0.45	0.87	0.33	0.81
		Comparison	66,463	5.34*	4.80	7.47*	8.43	0.42*	0.84	0.35*	0.83
	Non-White	OCM	17,246	5.81†	5.16	8.30	9.58	0.49†	0.94	0.44†	0.96
		Comparison	13,882	5.26*	4.60	7.55*	8.34	0.45*†	0.91	0.46*†	1.03
-7	White	OCM	73,507	5.83	4.98	8.08	9.09	0.44	0.84	0.32	0.78
		Comparison	58,007	5.17*	4.65	7.48*	8.37	0.41*	0.82	0.34*	0.81
	Non-White	OCM	14,982	5.72†	5.03	8.35†	9.56	0.48†	0.93	0.43†	0.94
		Comparison	12,516	5.02*†	4.39	7.41*	8.18	0.44*†	0.91	0.46*†	1.04
-6	White	OCM	80,722	5.76	5.01	7.95	9.01	0.42	0.84	0.33	0.76
		Comparison	65,437	5.21*	4.73	7.43*	8.39	0.39*	0.81	0.35*	0.84
	Non-White	OCM	16,889	5.71	5.06	8.24†	9.37	0.47†	0.92	0.42†	0.97
		Comparison	14,240	5.04*†	4.46	7.68*†	8.54	0.42*†	0.88	0.45*†	1.12
-5	White	OCM	78,395	5.66	4.94	7.96	8.99	0.41	0.83	0.32	0.81
		Comparison	63,369	5.05*	4.55	7.38*	8.36	0.39*	0.80	0.35*	0.85
	Non-White	OCM	16,632	5.61	4.96	8.29†	9.48	0.46†	0.92	0.42†	0.94
		Comparison	14,005	5.00*	4.37	7.69*†	8.56	0.41*†	0.86	0.46*†	1.03
-4	White	OCM	85,243	5.65	4.95	7.88	8.89	0.40	0.82	0.33	0.78
		Comparison	70,245	5.04*	4.50	7.44*	8.49	0.38*	0.80	0.36*	0.84
	Non-White	OCM	17,745	5.63	5.03	8.35†	9.48	0.45†	0.91	0.43†	0.96
		Comparison	15,398	4.97*	4.29	7.69*†	8.78	0.40*†	0.87	0.47*†	1.04
-3	White	OCM	82,362	5.53	4.83	7.78	8.79	0.41	0.82	0.33	0.79
		Comparison	68,993	4.94*	4.39	7.42*	8.49	0.38*	0.80	0.36*	0.84
	Non-White	OCM	17,238	5.42	4.85	8.22†	9.50	0.45†	0.89	0.42†	0.90
		Comparison	14,835	4.95*	4.25	7.77*†	8.78	0.41*†	0.86	0.47*†	1.02
-2	White	OCM	88,472	5.54	4.87	7.91	8.96	0.40	0.83	0.34	0.78
		Comparison	73,938	4.97*	4.43	7.56*	8.68	0.36*	0.78	0.37*	0.87
	Non-White	OCM	18,506	5.49	4.78	8.28†	9.35	0.43†	0.90	0.43†	0.98
		Comparison	16,023	4.90*	4.16	7.92*†	9.00	0.40*†	0.87	0.48*†	1.14

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

**Exhibit A5-24: Episode Cancer E&M Services by Cancer Bundle, High vs. Low Risk Beneficiaries, in the Expanded Baseline Period
(Episodes initiating Jan. 2012 – Jun. 2015)**

Performance Period	Group	Practice/ TIN Type	Average Number of Cancer-Related E&M Services per Episode									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other Cancer
-8	High Risk	OCM	8.06	8.82	3.86	4.19	6.11	9.21	6.57	6.62	7.01	7.73
		Comparison	7.57*	7.77*	3.51*	3.37*	5.86*	7.89*	5.78*	5.78*	5.88*	7.15*
	Low Risk	OCM	8.03	9.32†	3.73†	3.88†	5.73†	9.64	5.89†	6.42	6.05†	8.03†
		Comparison	7.58*	8.24*†	3.44*	3.30*	5.58†	8.74*†	5.48*	6.49†	4.48*†	7.35*†
-7	High Risk	OCM	7.90	8.82	3.78	4.15	5.84	8.67	5.92	6.57	6.69	7.61
		Comparison	7.33*	7.51*	3.44*	3.42*	5.56*	7.97*	5.34*	5.94	5.54*	6.93*
	Low Risk	OCM	7.98	9.51†	3.65†	3.89†	5.44†	9.44†	5.73	6.51	5.73†	7.85†
		Comparison	7.36*	8.08*†	3.32*†	3.27*†	5.36	8.52*	5.07*	6.21	4.15*†	7.18*†
-6	High Risk	OCM	8.05	8.82	3.58	4.02	6.01	8.96	6.17	6.63	6.97	7.58
		Comparison	7.50*	7.71*	3.43*	3.44*	5.81	8.17*	5.67*	5.30*	5.80*	7.09*
	Low Risk	OCM	8.07	9.34†	3.54	3.88†	5.68†	9.82†	5.75†	6.49	6.14†	7.86†
		Comparison	7.38*	8.09*†	3.25*†	3.25*†	5.49†	8.49*	5.22*†	6.60†	4.46*†	7.24*
-5	High Risk	OCM	7.80	8.62	3.68	4.02	6.02	8.78	6.04	6.44	7.06	7.45
		Comparison	7.28*	7.51*	3.37*	3.34*	5.73*	8.14*	5.41*	5.39*	5.78*	6.81*
	Low Risk	OCM	7.88	9.03†	3.45†	3.92	5.74†	9.26	5.49†	6.37	5.77†	7.72†
		Comparison	7.29*	7.83*†	3.21*†	3.21*†	5.25*†	8.57*	4.85*†	5.75	4.32*†	6.98*†
-4	High Risk	OCM	7.91	8.80	3.66	3.97	6.08	8.80	6.13	5.94	7.14	7.48
		Comparison	7.3*	7.62*	3.43*	3.35*	5.71*	8.33	5.11*	5.86	5.54*	6.87*
	Low Risk	OCM	7.78	9.24†	3.45†	3.76†	5.81†	9.36	5.43†	6.28	5.84†	7.72†
		Comparison	7.16*	7.92*†	3.20*†	3.19*†	5.28*†	8.16*	5.05*	6.52	4.22*†	7.06*†
-3	High Risk	OCM	7.72	8.44	3.62	3.98	5.92	8.70	5.68	6.61	6.92	7.35
		Comparison	7.21*	7.40*	3.28*	3.33*	5.56*	8.14*	5.10*	5.78*	5.45*	6.65*
	Low Risk	OCM	7.80	9.00†	3.36†	3.85†	5.58†	9.36†	5.13†	6.86	5.84†	7.51†
		Comparison	7.15*	7.75*†	3.15*†	3.25*	5.23*†	7.99*	4.71*†	6.43	4.36*†	6.99*†
-2	High Risk	OCM	7.81	8.56	3.57	3.92	5.96	8.57	5.94	6.86	6.71	7.35
		Comparison	7.38*	7.54*	3.27*	3.29*	5.78	8.07	5.23*	6.07*	5.25*	6.75*
	Low Risk	OCM	7.78	9.05†	3.39†	3.81†	5.71†	9.05	5.24†	6.38	5.40†	7.64†
		Comparison	7.05*†	7.84*†	3.16*†	3.23*	5.32*†	8.26*	4.69*†	6.57	4.35*†	6.91*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-25: Episode Services, High vs. Low Risk Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 -Jun. 2015)

Performance Period	Group	Practice/ TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	High Risk	OCM	44,977	6.37	5.26	8.44	9.16	0.67	1.03	0.45	0.97
		Comparison	35,056	5.66*	4.88	7.61*	8.37	0.63*	1.01	0.48*	1.03
	Low Risk	OCM	56,215	5.65†	5.04	8.07†	9.42	0.28†	0.69	0.26†	0.70
		Comparison	45,289	5.07*†	4.66	7.38*†	8.45	0.26*†	0.67	0.28*†	0.71
-7	High Risk	OCM	39,503	6.16	5.05	8.28	9.00	0.65	1.00	0.44	0.95
		Comparison	30,511	5.46*	4.69	7.59*	8.25	0.61*	0.99	0.47*	0.96
	Low Risk	OCM	48,986	5.53	4.92	8.01†	9.31	0.27†	0.68	0.26†	0.67
		Comparison	40,012	4.91*†	4.52	7.37*†	8.39	0.26*†	0.66	0.29*†	0.76
-6	High Risk	OCM	42,437	6.14	5.09	8.27	9.11	0.63	1.00	0.44	0.92
		Comparison	34,213	5.58*	4.82	7.79*	8.49	0.59*	0.97	0.5*	1.06
	Low Risk	OCM	55,174	5.46†	4.95	7.8†	9.05	0.27†	0.69	0.26†	0.69
		Comparison	45,464	4.87*†	4.55	7.25*†	8.37	0.25*†	0.66	0.28*†	0.74
-5	High Risk	OCM	41,506	6.08	5.05	8.31	9.07	0.62	0.99	0.44	0.95
		Comparison	33,536	5.42*	4.67	7.70*	8.40	0.57*	0.95	0.48*	0.99
	Low Risk	OCM	53,521	5.32†	4.83	7.79†	9.08	0.26†	0.67	0.26†	0.73
		Comparison	43,838	4.75*†	4.37	7.23*†	8.39	0.25*†	0.65	0.29*†	0.79
-4	High Risk	OCM	44,328	6.08	5.10	8.32	9.07	0.60	0.98	0.46	0.94
		Comparison	36,677	5.41*	4.62	7.72*	8.50	0.57*	0.96	0.49*	0.97
	Low Risk	OCM	58,660	5.32†	4.84	7.69†	8.93	0.27†	0.68	0.27†	0.70
		Comparison	48,966	4.74*†	4.32	7.30*†	8.58	0.24*†	0.65	0.30*†	0.80
-3	High Risk	OCM	43,195	5.95	4.95	8.20	8.98	0.61	0.97	0.46	0.92
		Comparison	36,081	5.27*	4.48	7.65*	8.41	0.58*	0.95	0.5*	1.01
	Low Risk	OCM	56,405	5.17†	4.72	7.58†	8.86	0.27†	0.67	0.27†	0.70
		Comparison	47,747	4.69*†	4.25	7.36*†	8.64	0.25*†	0.65	0.29*†	0.74
-2	High Risk	OCM	45,566	5.96	4.94	8.31	9.06	0.60	0.99	0.46	0.93
		Comparison	37,719	5.34*	4.55	7.91*	8.79	0.55*	0.94	0.52*	1.07
	Low Risk	OCM	61,412	5.22†	4.76	7.72†	9.00	0.26†	0.68	0.27†	0.71
		Comparison	52,242	4.69*†	4.23	7.41*†	8.70	0.24*†	0.65	0.30*†	0.79

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-26: Share of Episodes by Cancer Bundle, High HCC vs. Low HCC Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other
-8	High HCC	OCM	14.8%	9.2%	23.2%	12.7%	7.3%	1.8%	4.4%	0.8%	1.8%	24.1%
		Comparison	13.9%*	9.0%	22.2%*	15.1%*	6.6%*	1.7%	4.4%	0.8%	2.1%*	24.1%*
	Low HCC	OCM	8.9%†	6.0%†	39.7%†	11.9%†	8.9%†	1.6%	3.7%†	0.4%†	2.4%†	16.5%†
		Comparison	8.1%*†	5.4%*†	37.1%*†	17.5%*†	7.7%*†	1.4%*†	3.4%*†	0.4%*†	3.3%*†	15.7%*†
-7	High HCC	OCM	11.6%	8.3%	27.0%	14.7%	6.8%	1.4%	4.7%	0.7%	1.6%	23.3%
		Comparison	11.2%	7.9%	25.6%*	17.5%*	6.2%*	1.3%	4.9%	0.7%	1.7%	22.9%*
	Low HCC	OCM	10.5%†	6.8%†	36.1%†	11.5%†	8.4%†	1.8%†	3.6%†	0.5%†	2.4%†	18.4%†
		Comparison	9.6%*†	6.0%*†	34.1%*†	16.0%*†	7.1%*†	1.6%*†	3.3%*†	0.5%†	3.3%*†	18.5%*†
-6	High HCC	OCM	12.8%	8.6%	25.4%	13.4%	6.2%	1.7%	4.6%	0.8%	1.8%	24.8%
		Comparison	12.0%*	8.3%	24.6%*	15.9%*	5.5%*	1.4%*	4.7%	0.8%	1.7%	25.0%*
	Low HCC	OCM	8.9%†	5.5%†	41.2%†	10.7%†	8.4%†	1.6%	3.8%†	0.5%†	2.5%†	17.0%†
		Comparison	8.5%*†	5.0%*†	38.7%*†	15.3%*†	7.2%*†	1.6%	3.6%*†	0.5%†	3.3%*†	16.4%*†
-5	High HCC	OCM	10.8%	7.7%	27.6%	14.6%	6.4%	1.4%	4.9%	0.7%	1.5%	24.4%
		Comparison	10.2%*	7.5%	26.6%*	17.1%*	5.9%*	1.2%	4.9%	0.8%	1.7%	24.1%*
	Low HCC	OCM	10.1%†	6.3%†	38.3%†	10.4%†	7.8%†	1.7%†	3.8%†	0.5%†	2.5%†	18.6%†
		Comparison	9.6%*†	5.9%*†	36.3%*†	14.2%*†	6.8%*†	1.6%†	3.7%†	0.5%†	3.1%*†	18.3%*†
-4	High HCC	OCM	12.4%	8.6%	23.0%	13.7%	6.5%	1.6%	5.1%	0.8%	1.9%	26.4%
		Comparison	12.1%	8.1%*	21.9%*	16.4%*	5.6%*	1.5%	4.9%	0.8%	2.1%*	26.5%*
	Low HCC	OCM	8.3%†	5.2%†	43.2%†	10.8%†	7.6%†	1.5%	3.7%†	0.5%†	2.4%†	16.7%†
		Comparison	7.6%*†	4.9%*†	40.6%*†	15.5%*†	6.5%*†	1.4%	3.5%*†	0.5%†	3.4%*†	15.9%*†
-3	High HCC	OCM	10.6%	7.5%	25.3%	14.9%	6.5%	1.2%	5.5%	0.7%	1.6%	26.1%
		Comparison	10.5%	7.3%	24.0%*	17.6%*	5.7%*	1.3%	5.5%	0.7%	1.8%*	25.7%*
	Low HCC	OCM	9.5%†	5.9%†	40.2%†	10.6%†	7.2%†	1.6%†	3.8%†	0.6%†	2.3%†	18.4%†
		Comparison	8.8%*†	5.7%†	37.7%*†	14.8%*†	6.3%*†	1.7%†	3.6%†	0.6%	3.0%*†	17.9%*†
-2	High HCC	OCM	11.9%	7.9%	24.3%	13.6%	6.5%	1.6%	5.1%	1.1%	1.8%	26.2%
		Comparison	11.3%*	7.4%*	23.3%*	16.8%*	5.5%*	1.5%	4.9%	1.2%	1.9%	26.2%*
	Low HCC	OCM	7.8%†	5.3%†	43.6%†	10.9%†	7.6%†	1.5%	3.6%†	0.5%†	2.5%†	16.6%†
		Comparison	7.6%†	4.9%*†	40.4%*†	15.6%*†	6.4%*†	1.5%	3.6%†	0.5%†	3.2%*†	16.3%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-27: Episode Services, High vs. Low HCC Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Group	Practice/ TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	High HCC	OCM	46,114	6.75	5.19	9.18	9.70	0.56	0.95	0.40	0.93
		Comparison	36,331	6.05*	4.82	8.39*	8.74	0.53*	0.93	0.43*	0.96
	Low HCC	OCM	55,078	5.31†	5.02	7.44†	8.89	0.37†	0.80	0.30†	0.75
		Comparison	44,014	4.73*†	4.64	6.74*†	8.06	0.34*†	0.78	0.32*†	0.79
-7	High HCC	OCM	31,329	6.18	4.89	8.61	9.43	0.52	0.92	0.40	0.90
		Comparison	24,358	5.50*	4.56	7.89*	8.42	0.49*	0.90	0.43*	0.94
	Low HCC	OCM	57,160	5.6†	5.03	7.87†	9.02	0.40†	0.82	0.31†	0.75
		Comparison	46,165	4.96*†	4.61	7.24*†	8.28	0.37*†	0.80	0.33*†	0.81
-6	High HCC	OCM	41,879	6.46	5.00	8.87	9.40	0.53	0.93	0.40	0.88
		Comparison	33,934	5.84*	4.74	8.33*	8.79	0.49*	0.90	0.44*	1.01
	Low HCC	OCM	55,732	5.23†	4.98	7.35†	8.77	0.35†	0.79	0.29†	0.73
		Comparison	45,743	4.69*†	4.58	6.85*†	8.08	0.33*†	0.76	0.32*†	0.80
-5	High HCC	OCM	31,974	6.04	4.80	8.49	9.15	0.50	0.91	0.40	1.00
		Comparison	25,973	5.37*	4.50	7.91*	8.42	0.46*	0.86	0.43*	0.98
	Low HCC	OCM	63,053	5.45†	5.00	7.78†	9.04	0.38†	0.80	0.31†	0.74
		Comparison	51,401	4.87*†	4.51	7.19*†	8.37	0.36*†	0.78	0.34*†	0.84
-4	High HCC	OCM	42,710	6.44	5.00	9.04	9.43	0.52	0.92	0.42	0.91
		Comparison	35,226	5.74*	4.50	8.51*	8.86	0.48*	0.91	0.46*	0.97
	Low HCC	OCM	60,278	5.08†	4.87	7.20†	8.60	0.34†	0.76	0.30†	0.74
		Comparison	50,417	4.53*†	4.37	6.77*†	8.24	0.31*†	0.73	0.33*†	0.82
-3	High HCC	OCM	32,272	6.00	4.85	8.53	9.16	0.51	0.91	0.41	0.90
		Comparison	27,141	5.35*	4.29	8.17*	8.71	0.48*	0.88	0.44*	0.92
	Low HCC	OCM	67,328	5.27†	4.81	7.53†	8.78	0.37†	0.79	0.32†	0.76
		Comparison	56,687	4.74*†	4.38	7.16*†	8.44	0.35*†	0.77	0.35*†	0.85
-2	High HCC	OCM	46,771	6.23	4.86	8.98	9.43	0.51	0.92	0.42	0.91
		Comparison	39,591	5.55*	4.41	8.58*	9.08	0.45*	0.87	0.47*	1.01
	Low HCC	OCM	60,207	4.99†	4.78	7.19†	8.63	0.33†	0.76	0.29†	0.73
		Comparison	50,370	4.49*†	4.30	6.87*†	8.39	0.31*†	0.73	0.34*†	0.84
		Comparison	46,114	4.60*†	4.35	6.94*†	8.36	0.32*†	0.75	0.34*†	0.84

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-28: Episode Total Cost of Care and Cost Sharing, High vs. Low HCC Beneficiaries, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	High HCC	OCM	46,114	\$30,431	\$24,161	\$6,034	\$4,755
		Comparison	36,331	\$28,380*	\$23,904	\$5,594*	\$4,642
	Low HCC	OCM	55,074	\$21,955†	\$23,642	\$4,583†	\$4,702
		Comparison	44,012	\$20,348*†	\$23,041	\$4,258*†	\$4,558
-7	High HCC	OCM	31,329	\$29,642	\$24,154	\$6,131	\$4,982
		Comparison	24,358	\$28,135*	\$24,307	\$5,747*	\$4,937
	Low HCC	OCM	57,156	\$24,033†	\$24,598	\$5,508†	\$43,660
		Comparison	46,160	\$22,411*†	\$24,820	\$4,950*†	\$4,961
-6	High HCC	OCM	41,879	\$31,409	\$25,420	\$6,492	\$5,519
		Comparison	33,934	\$29,935*	\$25,145	\$6,117*	\$5,424
	Low HCC	OCM	55,719	\$22,424†	\$24,784	\$4,991†	\$5,539
		Comparison	45,734	\$21,233*†	\$31,521	\$4,723*†	\$7,324
-5	High HCC	OCM	31,974	\$31,038	\$25,609	\$6,525	\$5,591
		Comparison	25,973	\$29,427*	\$25,387	\$6,157*	\$5,545
	Low HCC	OCM	63,039	\$23,888†	\$24,926	\$5,424†	\$5,494
		Comparison	51,392	\$22,584*†	\$27,426	\$5,118*†	\$5,514
-4	High HCC	OCM	42,710	\$32,955	\$25,824	\$6,551	\$5,531
		Comparison	35,226	\$31,651*	\$26,308	\$6,234*	\$5,577
	Low HCC	OCM	60,275	\$22,405†	\$24,710	\$4,851†	\$5,326
		Comparison	50,414	\$21,239*†	\$24,781	\$4,585*†	\$5,296
-3	High HCC	OCM	32,272	\$32,763	\$26,428	\$6,724	\$5,640
		Comparison	27,141	\$31,542*	\$26,328	\$6,423*	\$5,571
	Low HCC	OCM	67,322	\$24,180†	\$25,751	\$5,453†	\$5,648
		Comparison	56,684	\$23,075*†	\$25,490	\$5,198*†	\$5,579
-2	High HCC	OCM	46,771	\$34,565	\$27,722	\$6,698	\$5,743
		Comparison	39,591	\$33,312*	\$27,825	\$6,354*	\$5,623
	Low HCC	OCM	60,204	\$23,550†	\$26,378	\$4,989†	\$5,634
		Comparison	50,368	\$22,579*†	\$26,491	\$4,740*†	\$5,663

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-29: Share of Episodes by Cancer Bundle, High vs. Low Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Patient Load Group	Practice/ TIN Type	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other
-8	High	OCM	12.7%	8.1%	31.9%	11.9%	8.4%	1.8%	4.1%	0.5%	2.4%	18.2%
		Comparison	11.2%*	7.1%*	29.8%*	19.8%*	7.5%*	1.4%*	3.5%*	0.4%	3.3%*	15.9%*
	Low	OCM	11.1%†	7.2%†	32.2%	12.4%†	8.1%	1.7%	4.0%	0.6%	2.1%†	20.7%†
		Comparison	10.6%*†	6.9%*	30.6%*†	14.8%*†	7.0%*†	1.6%†	4.0%†	0.7%*†	2.5%*†	21.3%*†
-7	High	OCM	11.7%	7.6%	30.2%	15.1%	7.8%	1.6%	4.0%	0.5%	3.2%	18.2%
		Comparison	10.7%*	6.7%*	30.2%	20.7%*	6.8%*	1.4%*	3.5%	0.4%	3.6%	16.1%*
	Low	OCM	10.8%†	7.3%	33.3%†	12.2%†	7.8%	1.6%	4.0%	0.6%	1.9%†	20.5%†
		Comparison	10.0%*†	6.7%*	31.5%*†	15.0%*†	6.8%*	1.6%†	4.0%†	0.7%†	2.4%*†	21.5%*†
-6	High	OCM	11.6%	7.5%	33.1%	12.8%	7.8%	1.7%	4.2%	0.6%	3.0%	17.7%
		Comparison	10.0%*	6.4%*	31.6%*	20.4%*	6.4%*	1.3%*	3.5%*	0.4%*	3.9%*	16.1%*
	Low	OCM	10.3%†	6.7%†	34.7%†	11.7%†	7.4%†	1.7%	4.1%	0.6%	2.0%†	20.9%†
		Comparison	10.0%*	6.4%	33.1%*†	13.9%*†	6.5%*	1.6%†	4.2%†	0.7%*†	2.2%*†	21.4%*†
-5	High	OCM	11.3%	7.2%	32.4%	13.5%	7.6%	1.6%	4.4%	0.6%	2.9%	18.6%
		Comparison	10.2%*	6.3%*	32.2%	19.3%*	6.4%*	1.3%*	3.9%*	0.4%*	3.8%*	16.3%*
	Low	OCM	10.2%†	6.7%†	35.1%†	11.5%†	7.3%	1.6%	4.2%	0.6%	2.0%†	20.9%†
		Comparison	9.7%*†	6.4%	33.3%*†	13.9%*†	6.5%*	1.6%*†	4.1%	0.7%*†	2.3%*†	21.5%*†
-4	High	OCM	11.2%	7.1%	34.1%	12.4%	7.4%	1.6%	4.3%	0.6%	2.6%	18.9%
		Comparison	9.5%*	5.9%*	31.7%*	20.9%*	6.1%*	1.3%*	3.7%*	0.4%*	4.1%*	16.3%*
	Low	OCM	9.8%†	6.5%†	35.0%†	11.9%	7.1%	1.5%	4.3%	0.6%	2.1%†	21.1%†
		Comparison	9.5%	6.3%†	33.4%*†	14.2%*†	6.2%*	1.5%†	4.2%†	0.7%†	2.4%*†	21.7%*†
-3	High	OCM	11.0%	6.8%	34.1%	13.0%	7.2%	1.7%	4.3%	0.6%	2.4%	18.9%
		Comparison	9.3%*	6.0%*	32.1%*	21.2%*	6.1%*	1.3%*	3.9%*	0.5%	4.0%*	15.7%*
	Low	OCM	9.6%†	6.4%†	35.6%†	11.8%†	6.9%	1.5%†	4.3%	0.7%	2.0%†	21.2%†
		Comparison	9.3%	6.3%	33.6%*†	13.9%*†	6.1%*	1.7%*†	4.3%†	0.7%†	2.2%*†	21.9%*†
-2	High	OCM	10.9%	6.4%	34.1%	13.5%	7.2%	1.6%	4.1%	0.7%	2.8%	18.7%
		Comparison	9.3%*	6.0%	31.5%*	21.7%*	5.9%*	1.3%*	3.7%	0.5%*	4.4%*	15.8%*
	Low	OCM	9.3%†	6.4%	35.4%†	11.8%†	7.1%	1.6%	4.3%	0.8%	2.0%†	21.3%†
		Comparison	9.3%	6.0%*	33.3%*†	14.4%*†	6.0%*	1.5%†	4.3%†	0.9%*†	2.1%†	22.2%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-30: Episode Share by Cancer Bundle, High and Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other
-8	High Cost	OCM	12.2%	8.1%	32.4%	10.5%	8.7%	1.7%	4.1%	0.4%	1.8%	20.2%
		Comparison	12.5%	8.0%	30.8%*	10.5%	8.4%	1.7%	4.5%*	0.8%*	1.9%	20.9%
	Not High Cost	OCM	11.3%†	7.2%†	32.0%	13.0%†	7.9%†	1.7%	3.9%	0.6%†	2.3%†	19.9%
		Comparison	10.1%*†	6.6%*†	30.2%*	18.7%*†	6.7%†	1.5%*†	3.6%*†	0.5%†	3.1%*†	19.0%*†
-7	High Cost	OCM	11.5%	7.6%	32.8%	11.3%	8.3%	1.6%	4.0%	0.4%	1.5%	21.0%
		Comparison	11.6%	7.3%	32.0%	11.4%	7.9%	1.6%	4.4%*	0.7%*	1.7%	21.4%
	Not High Cost	OCM	10.7%†	7.2%†	32.9%	13.1%†	7.6%†	1.6%	3.9%	0.6%†	2.3%†	19.9%†
		Comparison	9.5%*†	6.4%*†	30.8%*†	19.0%*†	6.2%*†	1.5%*	3.6%*†	0.5%	3.2%*†	19.4%*†
-6	High Cost	OCM	10.9%	7.1%	34.2%	10.2%	7.8%	1.7%	4.3%	0.5%	1.7%	22.0%
		Comparison	11.0%	6.5%*	32.2%*	12.6%*	7.1%*	1.6%	4.6%	0.8%*	1.7%	21.9%
	Not High Cost	OCM	10.4%†	6.7%†	34.5%	12.5%†	7.3%†	1.7%	4.0%	0.6%	2.4%†	19.8%†
		Comparison	9.5%*†	6.4%*	33.0%*†	16.9%*†	6.2%*†	1.5%*	3.8%*†	0.5%†	3.0%*†	19.2%*†
-5	High Cost	OCM	11.7%	7.0%	35.0%	9.1%	7.7%	1.5%	4.5%	0.5%	1.5%	21.5%
		Comparison	10.9%*	6.5%	31.5%*	12.7%*	7.3%	1.7%	4.6%	0.9%*	1.9%*	22.1%
	Not High Cost	OCM	10.1%†	6.7%	34.6%	12.3%†	7.3%	1.6%	4.2%	0.6%	2.3%†	20.4%†
		Comparison	9.3%*†	6.4%*	33.7%*†	16.3%*†	6.1%*†	1.4%*†	3.9%*†	0.5%*†	3.0%*†	19.5%*†
-4	High Cost	OCM	11.4%	7.1%	33.4%	9.9%	7.9%	1.5%	4.7%	0.5%	1.8%	22.0%
		Comparison	9.9%*	6.4%*	33.4%	11.9%*	6.9%*	1.5%	4.4%	0.7%*	2.0%	23.0%*
	Not High Cost	OCM	9.7%†	6.5%†	35.1%†	12.5%†	7.0%†	1.5%	4.2%†	0.6%†	2.3%†	20.5%†
		Comparison	9.3%*†	6.2%*	32.7%*	17.8%*†	5.8%*†	1.4%	3.9%*†	0.6%*†	3.3%*†	19.0%*†
-3	High Cost	OCM	11.4%	6.9%	33.9%	9.4%	8.1%	1.5%	4.6%	0.5%	1.6%	22.1%
		Comparison	9.7%*	6.3%*	33.7%	11.8%*	6.6%*	1.7%	4.8%	0.8%*	1.9%*	22.6%
	Not High Cost	OCM	9.5%†	6.3%†	35.7%†	12.5%†	6.7%†	1.5%	4.3%	0.7%†	2.2%†	20.6%†
		Comparison	9.1%*†	6.2%*	33.0%*	17.8%*†	5.8%*†	1.5%†	3.9%*†	0.6%*†	3.0%*†	19.2%*†
-2	High Cost	OCM	10.8%	6.8%	34.3%	10.6%	7.9%	1.6%	4.6%	0.8%	1.7%	21.0%
		Comparison	9.8%*	6.3%*	33.0%*	12.2%*	6.6%*	1.6%	4.5%	0.9%	1.8%	23.3%*
	Not High Cost	OCM	9.3%†	6.4%†	35.3%†	12.4%†	7.0%†	1.6%	4.2%†	0.8%	2.3%†	20.8%
		Comparison	9.0%*†	5.9%*†	32.8%*	18.5%*†	5.6%*†	1.4%*†	4.0%*†	0.8%	3.1%*†	19.1%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-31: Episode Share by Cancer Bundle and Affiliation Type in Performance Period -2 (Episodes initiating Jan. – Jun. 2015)

Affiliation Type	Group	Practice/ TIN Type	Percent of Episodes by Cancer Bundles									
			Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Lymphoma	Head and Neck Cancer	Leukemia	Melanoma	Bladder Cancer	Other
Academic Medical Center Affiliation	Academic	OCM	7.6%	4.8%	31.0%	14.8%	6.5%	1.7%	4.5%	1.4%	2.6%	25.1%
		Comparison	8.4%*	4.8%	28.7%*	15.9%*	5.9%*	2.2%*	4.7%	1.5%	2.5%	25.4%
	Non-Academic	OCM	10.0%†	6.8%†	36.0%†	11.5%†	7.3%†	1.5%	4.2%	0.6%†	2.1%†	19.9%†
		Comparison	9.5%*†	6.3%*†	33.9%*†	16.2%*	6.0%*	1.3%*†	4.0%*†	0.7%†	2.7%*	19.5%†
Health System Affiliation	Health System	OCM	8.0%	5.4%	33.6%	14.3%	6.6%	1.6%	4.2%	1.1%	2.6%	22.7%
		Comparison	9.3%*	5.8%*	33.5%	14.5%	5.9%*	1.6%	4.4%	0.9%*	2.3%	21.7%*
	No Health System	OCM	10.2%†	6.9%†	35.9%†	11.1%†	7.4%†	1.5%	4.3%	0.6%†	2.0%†	20.0%†
		Comparison	9.2%*	6.4%*†	31.9%*†	18.4%*†	6.0%*	1.3%*†	3.8%*†	0.7%†	3.1%*†	19.2%*†
Hospital Ownership	Hospital Ownership	OCM	8.4%	5.4%	33.1%	13.8%	6.9%	1.6%	4.2%	1.2%	2.5%	23.0%
		Comparison	8.9%*	6.0%*	31.9%*	16.0%*	5.4%*	1.7%	4.2%	1.1%	2.2%*	22.6%
	No Hospital Ownership	OCM	9.8%†	6.7%†	35.6%†	11.7%†	7.2%	1.5%	4.3%	0.7%†	2.1%†	20.3%†
		Comparison	9.4%*†	6.0%*	33.3%*†	16.2%*	6.2%*†	1.4%*†	4.2%	0.7%†	2.8%*†	19.7%*†

Source: Episode characteristics file, 2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-32: Episode Characteristics, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes among Dual Eligibles	Percent of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	Large	OCM	79,998	13.0%	10.8%	25.2%	23.0%	18.6%	13.4%	9.0%
		Comparison	40,039	16.6%*	13.4%*	25.5%	22.4%*	17.7%*	12.6%*	8.3%*
	Small	OCM	21,194	15.2%†	11.2%	23.5%†	22.7%	18.5%	13.8%	10.4%†
		Comparison	40,306	15.1%†	10.4%*†	22.3%*†	22.0%	19.3%*†	14.6%*†	11.4%*†
-7	Large	OCM	70,925	13.1%	10.9%	24.9%	22.9%	18.6%	13.4%	9.2%
		Comparison	35,403	16.9%*	13.6%*	25.3%	22.5%	17.7%*	12.2%*	8.7%*
	Small	OCM	17,564	15.7%†	11.3%	22.8%†	22.5%	18.6%	13.9%	10.9%†
		Comparison	35,120	15.5%†	11.0%†	22.5%†	22.1%	19.2%†	13.8%†	11.2%†
-6	Large	OCM	79,183	12.4%	10.8%	24.8%	23.4%	18.6%	13.3%	9.1%
		Comparison	41,134	15.9%*	13.2%*	25.4%*	22.9%*	17.8%*	12.0%*	8.6%*
	Small	OCM	18,428	14.8%†	10.6%	23.4%†	22.5%†	19.2%†	13.9%†	10.5%†
		Comparison	38,543	14.5%†	10.7%†	22.6%*†	22.6%	19.0%†	13.8%†	11.3%*†
-5	Large	OCM	77,515	12.5%	10.7%	24.8%	23.3%	18.9%	13.0%	9.3%
		Comparison	40,897	15.8%*	13.1%*	25.6%*	22.7%*	18.0%*	12.0%*	8.6%*
	Small	OCM	17,512	14.3%†	10.4%	23.0%†	23.1%	19.4%	13.5%	10.6%†
		Comparison	36,477	14.5%†	10.8%†	22.8%†	22.4%*	19.1%†	13.8%†	11.2%*†
-4	Large	OCM	84,031	11.7%	10.2%	25.2%	23.8%	19.1%	12.7%	9.1%
		Comparison	46,457	14.9%*	12.3%*	25.6%	23.0%*	18.3%*	12.0%*	8.8%
	Small	OCM	18,957	13.7%†	10.3%	23.6%†	22.9%†	19.4%	13.4%†	10.4%†
		Comparison	39,186	13.9%†	10.8%†	22.9%†	22.5%	19.2%†	13.4%†	11.2%*†
-3	Large	OCM	80,216	11.4%	10.1%	25.3%	23.9%	19.0%	12.6%	9.1%
		Comparison	46,663	14.9%*	12.5%*	26.0%*	23.2%*	17.8%*	11.8%*	8.6%*
	Small	OCM	19,384	13.7%†	10.3%	23.5%†	23.0%†	19.4%	13.2%†	10.6%†
		Comparison	37,165	13.9%†	10.5%†	23.1%†	22.5%†	19.2%†	13.3%†	11.3%*†
-2	Large	OCM	86,039	11.0%	9.9%	25.8%	23.9%	18.9%	12.4%	9.0%
		Comparison	51,094	14.4%*	12.1%*	26.2%	23.7%	18.0%*	11.7%*	8.3%*
	Small	OCM	20,939	13.4%†	10.3%	23.7%†	23.2%†	19.3%	13.2%†	10.4%†
		Comparison	38,867	13.5%†	10.5%†	23.3%†	22.4%†	19.2%†	13.7%†	10.8%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-32: Episode Characteristics, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015), Continued

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes by Race				Percent of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	Large	OCM	79,998	83.1%	8.8%	5.5%	2.6%	45.6%
		Comparison	40,039	82.2%*	10.0%*	4.2%*	3.5%*	46.7%*
	Small	OCM	21,194	82.5%†	9.9%†	4.4%†	3.2%†	45.6%
		Comparison	40,306	83.2%*†	10.3%	4.3%	2.2%*†	43.7%*†
-7	Large	OCM	70,925	83.1%	9.0%	5.2%	2.7%	35.5%
		Comparison	35,403	81.1%*	10.3%*	4.8%*	3.8%*	36.0%
	Small	OCM	17,564	82.9%	9.0%	4.7%†	3.4%†	35.1%
		Comparison	35,120	83.4%†	10.3%*	4.0%*†	2.3%*†	33.0%*†
-6	Large	OCM	79,183	82.8%	9.4%	5.0%	2.8%	43.1%
		Comparison	41,134	80.7%*	10.8%*	4.6%*	4.0%*	44.4%*
	Small	OCM	18,428	82.3%	9.7%	4.7%	3.4%†	41.9%†
		Comparison	38,543	83.7%*†	10.3%*†	3.8%*†	2.3%*†	40.7%*†
-5	Large	OCM	77,515	82.5%	9.3%	5.2%	3.0%	33.9%
		Comparison	40,897	80.6%*	10.6%*	4.5%*	4.3%*	34.9%*
	Small	OCM	17,512	82.3%	9.6%	4.5%†	3.6%†	32.5%†
		Comparison	36,477	83.4%*†	10.1%†	4.0%*†	2.5%*†	32.1%†
-4	Large	OCM	84,031	82.8%	9.0%	5.2%	3.1%	41.7%
		Comparison	46,457	81.1%*	10.2%*	4.4%*	4.3%*	43.0%*
	Small	OCM	18,957	82.7%	9.2%	4.4%†	3.6%†	40.4%†
		Comparison	39,186	83.2%†	10.6%*	3.8%*†	2.5%*†	39.0%*†
-3	Large	OCM	80,216	82.7%	9.0%	5.1%	3.2%	32.6%
		Comparison	46,663	81.2%*	10.0%*	4.4%*	4.3%*	33.8%*
	Small	OCM	19,384	82.8%	9.4%	4.2%†	3.6%†	31.6%†
		Comparison	37,165	83.7%*†	10.0%*	3.7%*†	2.5%*†	30.6%*†
-2	Large	OCM	86,039	82.7%	9.0%	4.9%	3.3%	44.1%
		Comparison	51,094	81.3%*	9.4%*	4.7%*	4.6%*	45.6%*
	Small	OCM	20,939	82.7%	9.3%	4.1%†	4.0%†	42.1%†
		Comparison	38,867	83.3%*†	10.4%*†	3.7%*†	2.6%*†	41.1%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-33: Episode Characteristics, Low vs. High Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes among Dual Eligibles	Percent of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	High	OCM	27,737	12.5%	10.0%	23.5%	23.1%	19.3%	14.0%	10.0%
		Comparison	26,325	12.9%	9.6%	21.8%*	21.4%*	19.7%	15.0%*	12.3%*
	Low	OCM	73,455	13.8%†	11.2%†	25.4%†	22.8%	18.2%†	13.3%†	9.0%†
		Comparison	54,020	17.3%*†	13.0%*†	24.9%†	22.6%†	17.9%†	12.9%*†	8.7%*†
-7	High	OCM	12,347	10.7%	8.6%	21.8%	22.9%	19.8%	15.2%	11.7%
		Comparison	19,560	13.3%*	10.1%*	21.9%	21.5%*	19.6%	14.6%	12.4%
	Low	OCM	76,142	14.1%†	11.4%†	24.9%†	22.8%	18.4%†	13.2%†	9.2%†
		Comparison	50,963	17.3%*†	13.2%*†	24.7%†	22.6%†	18.0%*†	12.4%*†	9.1%†
-6	High	OCM	18,127	11.3%	9.9%	22.2%	23.2%	19.5%	14.6%	10.5%
		Comparison	20,817	12.6%*	10.0%	22.4%	22.1%*	19.4%	14.3%	11.8%*
	Low	OCM	79,484	13.2%†	10.9%†	25.0%†	23.3%	18.5%†	13.2%†	9.1%†
		Comparison	58,860	16.1%*†	12.7%*†	24.6%†	23.0%†	18.1%*†	12.5%*†	9.2%†
-5	High	OCM	15,616	10.0%	8.8%	21.9%	23.0%	20.5%	14.7%	11.1%
		Comparison	18,450	11.7%*	10.0%*	22.8%	22.2%	19.3%*	13.9%*	11.8%*
	Low	OCM	79,411	13.3%†	11.0%†	25.0%†	23.4%	18.6%†	12.8%†	9.2%†
		Comparison	58,924	16.3%*†	12.7%*†	24.7%†	22.7%*	18.2%*†	12.5%†	9.2%†
-4	High	OCM	17,497	9.6%	9.0%	22.6%	24.0%	20.4%	13.7%	10.3%
		Comparison	22,034	10.7%*	9.1%	22.1%	22.1%*	19.8%	14.5%*	12.4%*
	Low	OCM	85,491	12.6%†	10.5%†	25.4%†	23.5%	18.9%†	12.7%†	9.1%†
		Comparison	63,609	15.7%*†	12.5%*†	25.2%†	23.0%*†	18.3%*†	12.0%*†	9.0%†
-3	High	OCM	15,741	9.2%	8.7%	22.4%	23.9%	20.5%	14.0%	10.4%
		Comparison	20,975	10.6%*	9.0%	22.3%	22.2%*	19.7%*	14.3%	12.5%*
	Low	OCM	83,859	12.3%†	10.4%†	25.4%†	23.7%	18.9%†	12.5%†	9.2%†
		Comparison	62,853	15.7%*†	12.5%*†	25.5%†	23.1%*†	18.0%*†	11.9%*†	8.9%*†
-2	High	OCM	19,730	9.5%	8.9%	23.2%	23.5%	20.0%	13.7%	10.6%
		Comparison	21,304	10.6%*	9.3%	22.6%	22.4%*	19.4%	14.4%*	11.8%*
	Low	OCM	87,248	11.9%†	10.2%†	25.9%†	23.8%	18.7%†	12.3%†	9.0%†
		Comparison	68,657	15.0%*†	12.1%*†	25.7%†	23.4%†	18.2%*†	12.0%†	8.6%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-33: Episode Characteristics, Low vs. High Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes by Race				Percent of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	High	OCM	27,737	86.7%	8.9%	2.6%	1.8%	47.0%
		Comparison	26,325	85.8%*	9.8%*	2.7%	1.7%	42.3%*
	Low	OCM	73,455	81.5%†	9.1%	6.3%†	3.0%†	45.0%†
		Comparison	54,020	81.2%†	10.3%*†	5.0%*†	3.4%*†	46.7%*†
-7	High	OCM	12,347	88.9%	6.1%	3.2%	1.7%	37.5%
		Comparison	19,560	85.4%*	10.7%*	2.4%*	1.4%*	32.2%*
	Low	OCM	76,142	82.1%†	9.5%†	5.4%†	3.0%†	35.1%†
		Comparison	50,963	81.0%*†	10.2%*	5.1%*†	3.6%*†	35.4%†
-6	High	OCM	18,127	87.9%	7.3%	2.9%	1.8%	43.4%
		Comparison	20,817	85.3%*	11.0%*	2.1%*	1.6%	39.0%*
	Low	OCM	79,484	81.5%†	10.0%†	5.4%†	3.1%†	42.8%
		Comparison	58,860	81.0%*†	10.3%*†	4.9%*†	3.7%*†	43.9%*†
-5	High	OCM	15,616	87.8%	7.3%	3.1%	1.7%	34.9%
		Comparison	18,450	84.3%*	11.7%*	2.3%*	1.7%	31.4%*
	Low	OCM	79,411	81.5%†	9.7%†	5.4%†	3.4%†	33.4%†
		Comparison	58,924	81.2%†	10.0%†	4.9%*†	4.0%*†	34.3%*†
-4	High	OCM	17,497	88.1%	6.6%	3.4%	1.9%	41.9%
		Comparison	22,034	84.9%*	11.1%*	2.2%*	1.8%	38.0%*
	Low	OCM	85,491	81.7%†	9.6%†	5.3%†	3.4%†	41.4%
		Comparison	63,609	81.0%*†	10.1%*†	4.8%*†	4.1%*†	42.2%*†
-3	High	OCM	15,741	87.9%	7.1%	3.2%	1.9%	33.7%
		Comparison	20,975	85.0%*	11.0%*	2.2%*	1.8%	29.9%*
	Low	OCM	83,859	81.7%†	9.5%†	5.2%†	3.6%†	32.2%†
		Comparison	62,853	81.4%†	9.7%†	4.7%*†	4.1%*†	33.2%*†
-2	High	OCM	19,730	87.0%	7.4%	3.3%	2.3%	44.3%
		Comparison	21,304	85.1%*	10.9%*	2.2%*	1.8%*	40.0%*
	Low	OCM	87,248	81.7%†	9.5%†	5.1%†	3.72%†	43.6%
		Comparison	68,657	81.3%*†	9.5%†	4.9%†	4.3%*†	45.3%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-34: Episode Characteristics, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes among Dual Eligibles	Percent of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	Onc Only	OCM	19,362	12.7%	11.2%	25.1%	23.0%	18.8%	13.1%	8.8%
		Comparison	23,884	15.5%*	11.0%	24.2%*	22.6%	19.0%	13.9%*	9.3%
	Multi	OCM	81,830	13.7%†	10.8%	24.8%	22.9%	18.5%	13.6%	9.4%†
		Comparison	56,461	16.0%*	12.3%*†	23.8%*	22.0%*	18.3%†	13.5%	10.1%*†
-7	Onc Only	OCM	17,249	13.5%	11.1%	24.8%	22.9%	18.7%	13.2%	9.2%
		Comparison	20,960	14.9%*	11.3%	23.7%*	23.2%	19.3%	13.1%	9.4%
	Multi	OCM	71,240	13.7%	11.0%	24.4%	22.8%	18.6%	13.6%	9.6%
		Comparison	49,563	16.7%*†	12.7%*†	24.0%	21.9%*†	18.0%*†	13.0%*	10.2%*†
-6	Onc Only	OCM	22,337	12.7%	11.0%	24.9%	22.9%	19.1%	13.2%	8.9%
		Comparison	25,101	14.2%*	11.1%	24.1%*	23.6%	18.7%	13.0%	9.5%*
	Multi	OCM	75,274	12.9%	10.7%	24.4%	23.3%	18.6%	13.5%	9.5%†
		Comparison	54,576	15.7%*†	12.4%*†	24.0%	22.3%*†	18.3%	12.9%*	10.1%*†
-5	Onc Only	OCM	20,645	12.6%	10.9%	24.6%	23.2%	19.2%	13.0%	9.0%
		Comparison	20,320	13.9%*	11.1%	24.1%	23.1%	19.2%	12.6%	9.9%*
	Multi	OCM	74,382	12.9%	10.5%	24.4%	23.3%	18.9%	13.1%	9.66%†
		Comparison	57,054	15.7%*†	12.3%*†	24.3%	22.4%*†	18.2%*†	12.9%	9.8%
-4	Onc Only	OCM	21,598	11.3%	10.9%	24.8%	23.5%	19.3%	12.8%	8.7%
		Comparison	23,067	13.0%*	10.8%	24.6%	23.2%	19.1%	12.8%	9.5%*
	Multi	OCM	81,390	12.3%†	10.1%†	24.9%	23.6%	19.1%	12.8%	9.5%†
		Comparison	62,576	15.0%*†	11.9%*†	24.3%*	22.6%*	18.5%*†	12.6%	10.1%*†
-3	Onc Only	OCM	20,560	11.6%	10.5%	25.0%	23.7%	18.9%	12.7%	9.3%
		Comparison	21,256	13.3%*	11.4%*	25.2%	22.8%*	18.8%	12.5%	9.2%
	Multi	OCM	79,040	11.9%	10.0%	24.9%	23.7%	19.2%	12.7%	9.4%
		Comparison	62,572	14.8%*†	11.7%*	24.5%†	23.0%*	18.3%*	12.5%	10.0%*†
-2	Onc Only	OCM	19,147	11.5%	10.5%	25.4%	23.4%	18.9%	12.7%	9.1%
		Comparison	22,241	12.6%*	11.2%*	25.5%	23.3%	18.7%	12.8%	8.5%*
	Multi	OCM	87,831	11.5%	9.9%†	25.4%	23.8%	19.0%	12.5%	9.3%
		Comparison	67,720	14.5%*†	11.5%*	24.7%*†	23.2%*	18.4%*	12.5%	9.7%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-34: Episode Characteristics, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes by Race				Percent of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	Onc Only	OCM	19,362	83.8%	10.4%	3.8%	2.1%	47.2%
		Comparison	23,884	81.8%*	10.9%	4.6%*	2.6%*	47.9%
	Multi	OCM	81,830	82.8%†	8.8%†	5.6%†	2.8%†	45.2%†
		Comparison	56,461	83.1%†	9.8%*†	4.1%*†	3.0%†	44.1%*†
-7	Onc Only	OCM	17,249	82.3%	11.0%	4.3%	2.4%	36.3%
		Comparison	20,960	82.4%	11.1%	4.0%	2.6%	35.8%
	Multi	OCM	71,240	83.2%†	8.5%†	5.3%†	2.9%†	35.2%†
		Comparison	49,563	82.2%*	10.0%*†	4.5%*†	3.2%*†	34.0%*†
-6	Onc Only	OCM	22,337	82.7%	10.8%	4.0%	2.6%	44.3%
		Comparison	25,101	82.1%	11.2%	4.0%	2.7%	44.1%
	Multi	OCM	75,274	82.7%	9.1%†	5.2%†	3.0%†	42.5%†
		Comparison	54,576	82.2%*	10.2%*†	4.3%*	3.4%*†	41.9%*†
-5	Onc Only	OCM	20,645	82.6%	10.7%	4.0%	2.7%	34.4%
		Comparison	20,320	82.3%	11.0%	4.1%	2.5%	33.3%*
	Multi	OCM	74,382	82.5%	9.0%†	5.3%†	3.2%†	33.4%†
		Comparison	57,054	81.7%*	10.1%*†	4.3%*	3.8%*†	33.7%
-4	Onc Only	OCM	21,598	84.0%	9.9%	3.6%	2.5%	42.7%
		Comparison	23,067	81.8%*	12.5%*	3.2%*	2.4%	41.2%*
	Multi	OCM	81,390	82.5%†	8.8%†	5.4%†	3.3%†	41.2%†
		Comparison	62,576	82.1%	9.6%*†	4.4%*†	3.9%*†	41.1%
-3	Onc Only	OCM	20,560	83.4%	10.2%	3.6%	2.7%	33.3%
		Comparison	21,256	81.8%*	12.4%*	3.2%*	2.6%	32.1%*
	Multi	OCM	79,040	82.5%†	8.8%†	5.2%†	3.4%†	32.2%†
		Comparison	62,572	82.5%†	9.3%*†	4.4%*†	3.9%*†	32.5%
-2	Onc Only	OCM	19,147	84.9%	8.3%	4.0%	2.8%	44.2%
		Comparison	22,241	82.3%*	12.4%*	2.7%*	2.6%	44.0%
	Multi	OCM	87,831	82.2%†	9.3%†	4.9%†	3.6%†	43.6%
		Comparison	67,720	82.2%	9.0%*†	4.8%†	4.1%*†	44.0%

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-35: Episode Characteristics, High vs. Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes among Dual Eligibles	Percent of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	High Cost	OCM	29,672	13.2%	10.2%	25.0%	22.8%	18.5%	13.8%	9.6%
		Comparison	21,887	15.0%*	12.4%*	24.5%	22.8%	18.4%	13.2%	8.6%*
	Not High Cost	OCM	71,520	13.6%	11.2%†	24.8%	23.0%	18.5%	13.3%†	9.2%†
		Comparison	58,458	16.1%*†	11.7%*†	23.7%*†	22.0%*†	18.6%	13.7%*	10.4%*†
-7	High Cost	OCM	23,625	13.1%	10.6%	24.3%	23.0%	18.9%	13.7%	9.5%
		Comparison	22,274	14.7%*	12.5%*	24.5%	22.8%	18.6%	12.7%*	8.8%*
	Not High Cost	OCM	64,864	13.8%†	11.2%†	24.5%	22.8%	18.5%	13.4%	9.5%
		Comparison	48,249	16.8%*†	12.2%*	23.7%*†	22.1%*†	18.4%	13.2%	10.5%*†
-6	High Cost	OCM	27,940	12.4%	9.9%	24.3%	23.4%	19.1%	13.7%	9.5%
		Comparison	24,890	16.3%*	13.2%*	25.0%	22.9%	18.1%*	12.3%*	8.6%*
	Not High Cost	OCM	69,671	13.0%†	11.1%†	24.6%	23.2%	18.6%†	13.3%	9.3%
		Comparison	54,787	14.8%*†	11.4%†	23.6%*†	22.7%†*	18.6%	13.2%†	10.5%*†
-5	High Cost	OCM	14,213	11.8%	10.1%	24.2%	23.0%	19.1%	13.6%	10.0%
		Comparison	23,596	17.1%*	13.7%*	25.1%*	22.9%	18.0%*	11.9%*	8.4%*
	Not High Cost	OCM	80,814	13.0†	10.7%†	24.5%	23.4%	18.9%	13.0%	9.4%†
		Comparison	53,778	14.4%*†	11.3%*†	23.9%*†	22.4%†*	18.7%†	13.2%†	10.5%*†
-4	High Cost	OCM	18,359	11.3%	10.0%	24.7%	23.7%	19.4%	12.8%	9.3%
		Comparison	27,815	15.7%*	12.7%*	25.3%	23.3%	18.4%*	11.9%*	8.4%*
	Not High Cost	OCM	84,629	12.2%†	10.3%	24.9%	23.6%	19.1%	12.8%	9.3%
		Comparison	57,828	13.9%*†	11.1%*†	23.9%*†	22.5%*†	18.8%	13.0%†	10.6%*†
-3	High Cost	OCM	16,264	11.5%	10.6%	24.6%	24.1%	18.9%	12.3%	9.5%
		Comparison	29,519	15.6%*	12.8%*	25.9%*	23.6%	18.0%*	11.5%*	8.2%*
	Not High Cost	OCM	83,336	11.9%	10.0%†	25.0%	23.6%	19.2%	12.8%	9.4%
		Comparison	54,309	13.8%*†	11.0%*†	24.1%*†	22.5%*†	18.7%*†	13.0%†	10.7%*†
-2	High Cost	OCM	17,103	10.6%	9.3%	25.4%	24.1%	19.0%	12.6%	9.7%
		Comparison	33,943	15.4%*	12.6%*	25.8%	23.1%*	18.1%*	12.1%	8.3%*
	Not High Cost	OCM	89,875	11.6%†	10.1%†	25.4%	23.7%	19.0%	12.5%	9.2%
		Comparison	56,018	13.1%*†	10.7%*†	24.4%*†	23.3%	18.7%†	12.9%†	10.0%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-35: Episode Characteristics, High vs. Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued

Performance Period	Group	Practice/ TIN Type	Number of Episodes	Percent of Episodes by Race				Percent of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	High Cost	OCM	29,672	81.8%	7.7%	7.9%	2.6%	46.3%
		Comparison	21,887	82.4%	9.8%*	5.4%*	2.4%	47.8%*
	Not High Cost	OCM	71,520	83.5%†	9.6%†	4.2%†	2.7%	45.3%†
		Comparison	58,458	82.8%*	10.3%*	3.8%*†	3.1%*†	44.2%*†
-7	High Cost	OCM	23,625	81.3%	8.7%	7.7%	2.3%	36.4%
		Comparison	22,274	83.6%*	9.4%*	4.4%*	2.6%	36.1%
	Not High Cost	OCM	64,864	83.7%†	9.1%	4.2%†	3.0%†	35.1%†
		Comparison	48,249	81.6%*†	10.8%*†	4.4%	3.2%*†	33.8%*†
-6	High Cost	OCM	27,940	80.3%	9.2%	7.7%	2.9%	44.2%
		Comparison	24,890	80.9%*	10.0%*	5.6%*	3.5%*	45.7%*
	Not High Cost	OCM	69,671	83.7%†	9.6%	3.9%†	2.9%	42.4%†
		Comparison	54,787	82.7%*†	10.8%*†	3.5%*†	3.0%†	41.2%*†
-5	High Cost	OCM	14,213	83.4%	8.5%	4.7%	3.5%	35.6%
		Comparison	23,596	80.4%*	10.8%*	5.3%*	3.6%	35.9%
	Not High Cost	OCM	80,814	82.3%†	9.5%†	5.1%†	3.0%†	33.3%†
		Comparison	53,778	82.6%†	10.2%*†	3.8%*†	3.4%*	32.5%*†
-4	High Cost	OCM	18,359	81.6%	10.0%	4.6%	3.8%	45.0%
		Comparison	27,815	79.4%*	11.0%*	5.3%*	4.3%*	43.9%*
	Not High Cost	OCM	84,629	83.0%†	8.8%†	5.1%†	3.0%†	40.7%†
		Comparison	57,828	83.3%†	10.1%*†	3.5%*†	3.1%†	39.8%*†
-3	High Cost	OCM	16,264	83.0%	9.8%	3.9%	3.3%	35.0%
		Comparison	29,519	78.1%*	11.6%*	6.0%*	4.2%*	33.6%*
	Not High Cost	OCM	83,336	82.6%	9.0%†	5.1%†	3.3%	31.9%†
		Comparison	54,309	84.6%*†	9.2%†	3.1%*†	3.2%†	31.7%†
-2	High Cost	OCM	17,103	82.7%	8.7%	4.8%	3.8%	45.8%
		Comparison	33,943	79.6%*	10.0%*	5.8%*	4.5%*	46.4%
	Not High Cost	OCM	89,875	82.7%	9.2%†	4.7%†	3.4%†	43.3%†
		Comparison	56,018	83.7%*†	9.7%*	3.3%*†	3.2%†	42.6%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-36: Episode Characteristics by Affiliation Type in Performance Period -2 (Episodes initiating Jan. – Jun. 2015)

Affiliation Type	Group	Practice/TIN Type	Number of Episodes	Percent of Episodes among Dual Eligibles	Percent of Episodes by Age Bracket						Percent of Episodes by Race				Percent of Episodes with HCC Score >= 2
					< 65	65-69	70-74	75-79	80-84	85+	Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
Academic Medical Center Affiliation	Academic	OCM	19,527	14.5%	12.4%	27.8%	23.7%	17.8%	10.6%	7.8%	77.3%	13.4%	4.8%	4.5%	45.5%
		Comparison	17,372	17.1%*	14.8%*	28.1%	24.3%	16.4%*	10.1%	6.4%*	75.9%*	13.1%	5.5%*	5.5%*	46.5%
Center Affiliation	Non-Academic	OCM	87,451	10.8%†	9.4%†	24.9%†	23.8%	19.3%†	13.0%†	9.6%†	83.9%†	8.1%†	4.7%	3.2%†	43.3%†
		Comparison	72,589	13.2%*†	10.6%*†	24.2%*†	22.9%*†	19.0%†	13.2%†	10.1%*†	83.7%†	9.1%*†	3.9%*†	3.3%†	43.4%†
Health System Affiliation	Health System	OCM	33,749	13.6%	11.8%	26.6%	23.4%	18.0%	11.5%	8.7%	79.0%	13.3%	4.0%	3.7%	43.6%
		Comparison	52,541	14.2%*	12.3%*	26.0%*	23.4%	17.9%	11.9%	8.5%	82.7%*	9.7%*	3.8%	3.8%	43.8%
	No Health System	OCM	73,229	10.5%†	9.1%†	24.9%†	23.9%	19.5%†	13.1%†	9.5%†	84.4%†	7.2%†	5.1%†	3.3%†	43.8%
		Comparison	37,420	13.7%*	10.2%*†	23.5%*†	22.8%*†	19.3%†	13.6%*†	10.5%*†	81.4%*†	10.0%*	4.9%†	3.7%*	44.3%
Hospital Ownership	Hospital Ownership	OCM	20,319	14.5%	12.4%	26.4%	23.3%	18.3%	11.2%	8.4%	78.4%	13.0%	4.9%	3.7%	43.9%
		Comparison	29,340	15.9%*	12.8%	25.5%*	23.4%	18.0%	11.8%*	8.5%	80.2%*	9.5%*	5.7%*	4.6%*	46.8%*
	No Hospital Ownership	OCM	86,659	10.7%†	9.4%†	25.2%†	23.9%	19.1%†	12.9%†	9.5%†	83.7%†	8.2%†	4.7%	3.4%†	43.7%
		Comparison	60,621	13.0%*†	10.8%*†	24.6%*†	23.1%*	18.7%*†	13.0%†	9.8%*†	83.2%*†	10.0%*†	3.6%*†	3.3%†	42.7%*†

Source: Episode characteristics file, 2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-37: Episode Services, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	Large	OCM	79,998	6.00	5.15	8.27	9.42	0.45	0.88	0.34	0.84
		Comparison	40,039	4.88*	4.07	7.19*	7.91	0.42*	0.86	0.38*	0.89
	Small	OCM	21,194	5.83†	5.14	8.10†	8.88	0.45	0.88	0.35	0.82
		Comparison	40,306	5.77†	5.33	7.77*†	8.88	0.43*	0.85	0.35†	0.85
-7	Large	OCM	70,925	5.86	5.00	8.20	9.27	0.44	0.86	0.34	0.81
		Comparison	35,403	4.77*	3.96	7.25*	7.91	0.42*	0.84	0.38*	0.88
	Small	OCM	17,564	5.60†	4.97	7.85†	8.77	0.44	0.87	0.34	0.82
		Comparison	35,120	5.53†	5.14	7.69*†	8.73	0.42*	0.83	0.35†	0.83
-6	Large	OCM	79,183	5.81	5.03	8.05	9.14	0.43	0.86	0.34	0.80
		Comparison	41,134	4.86*	4.11	7.35*	8.11	0.40*	0.84	0.38*	0.93
	Small	OCM	18,428	5.52†	5.00	7.78†	8.80	0.40†	0.82	0.35	0.80
		Comparison	38,543	5.52†	5.21	7.61*†	8.74	0.39	0.81	0.36†	0.86
-5	Large	OCM	77,515	5.70	4.95	8.08	9.18	0.42	0.85	0.34	0.85
		Comparison	40,897	4.76*	3.99	7.30*	8.05	0.40*	0.83	0.39*	0.90
	Small	OCM	17,512	5.42†	4.92	7.77†	8.62	0.41	0.84	0.34	0.78
		Comparison	36,477	5.35†	5.02	7.59*†	8.76	0.38*†	0.79	0.35*†	0.87
-4	Large	OCM	84,031	5.71	4.99	8.02	9.08	0.42	0.84	0.35	0.80
		Comparison	46,457	4.76*	3.98	7.37*	8.33	0.39*	0.83	0.39*	0.89
	Small	OCM	18,957	5.38†	4.83	7.73†	8.64	0.39†	0.81	0.35	0.87
		Comparison	39,186	5.35†	4.96	7.61†	8.79	0.37*†	0.79	0.38*	0.88
-3	Large	OCM	80,216	5.55	4.85	7.87	8.93	0.42	0.84	0.35	0.81
		Comparison	46,663	4.74*	3.95	7.43*	8.34	0.40*	0.83	0.38*	0.86
	Small	OCM	19,384	5.35†	4.77	7.76	8.85	0.39†	0.80	0.36†	0.84
		Comparison	37,165	5.20*†	4.82	7.55*	8.78	0.38†	0.79	0.37	0.89
-2	Large	OCM	86,039	5.57	4.88	7.99	9.02	0.41	0.85	0.35	0.81
		Comparison	51,094	4.79*	4.02	7.64*	8.62	0.38*	0.82	0.40*	0.94
	Small	OCM	20,939	5.37†	4.74	7.90	9.08	0.38†	0.81	0.35	0.84
		Comparison	38,867	5.18*†	4.81	7.60*	8.90	0.36*†	0.77	0.38*†	0.91

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-38: Episode Services, Low vs. High Patient Load Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Group	Practice/TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	High	OCM	27,737	6.28	5.23	8.55	9.23	0.44	0.85	0.33	0.80
		Comparison	26,325	5.54*	5.11	7.61*	8.77	0.42*	0.84	0.36*	0.91
	Low	OCM	73,455	5.85†	5.12	8.12†	9.34	0.46	0.89	0.35†	0.85
		Comparison	54,020	5.22*†	4.59	7.42*†	8.23	0.43*	0.86	0.37*†	0.85
-7	High	OCM	12,347	6.36	5.34	8.59	9.37	0.42	0.83	0.30	0.71
		Comparison	19,560	5.30*	5.00	7.40*	8.52	0.40	0.82	0.35*	0.83
	Low	OCM	76,142	5.72†	4.93	8.06†	9.14	0.45†	0.86	0.35†	0.83
		Comparison	50,963	5.09*†	4.44	7.49*	8.26	0.42*†	0.84	0.37*†	0.87
-6	High	OCM	18,127	6.08	5.25	8.50	9.33	0.39	0.81	0.33	0.75
		Comparison	20,817	5.21*	5.02	7.39*	8.69	0.37*	0.78	0.35*	0.87
	Low	OCM	79,484	5.68†	4.97	7.89†	9.02	0.43†	0.86	0.34	0.81
		Comparison	58,860	5.16*	4.56	7.51*	8.32	0.41*†	0.84	0.38*†	0.91
-5	High	OCM	15,616	6.39	5.37	8.54	9.34	0.41	0.83	0.30	0.74
		Comparison	18,450	5.22*	4.85	7.40*	8.57	0.36*	0.76	0.33*	0.83
	Low	OCM	79,411	5.50†	4.84	7.92†	9.03	0.42	0.85	0.35†	0.86
		Comparison	58,924	4.98*†	4.40	7.44*	8.34	0.40*†	0.82	0.38*†	0.90
-4	High	OCM	17,497	5.96	4.96	8.32	9.16	0.40	0.81	0.31	0.75
		Comparison	22,034	5.03*	4.70	7.31*	8.51	0.36*	0.77	0.36*	0.86
	Low	OCM	85,491	5.6†	4.96	7.89†	8.96	0.42†	0.84	0.36†	0.83
		Comparison	63,609	5.03*	4.38	7.54*†	8.56	0.39*†	0.83	0.39*†	0.89
-3	High	OCM	15,741	5.83	4.90	8.34	9.17	0.39	0.79	0.32	0.75
		Comparison	20,975	4.85*	4.53	7.18*	8.39	0.36*	0.77	0.35*	0.85
	Low	OCM	83,859	5.45†	4.82	7.76†	8.87	0.42†	0.84	0.35†	0.82
		Comparison	62,853	4.97*†	4.30	7.59*†	8.59	0.40*†	0.82	0.39*†	0.88
-2	High	OCM	19,730	5.87	4.99	8.14	9.18	0.39	0.81	0.32	0.79
		Comparison	21,304	4.96*	4.71	7.35*	8.70	0.34*	0.74	0.36*	0.85
	Low	OCM	87,248	5.46†	4.82	7.93†	9.00	0.41†	0.85	0.36†	0.82
		Comparison	68,657	4.96*	4.27	7.71*†	8.75	0.38*†	0.81	0.40*†	0.95

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-39: Episode Services, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	Onc Only	OCM	19,362	6.26	4.97	8.80	9.81	0.47	0.88	0.38	0.90
		Comparison	23,884	6.38*	5.52	8.29*	8.78	0.42*	0.83	0.37	0.90
	Multi	OCM	81,830	5.90†	5.19	8.10†	9.18	0.45†	0.88	0.34†	0.82
		Comparison	56,461	4.88*†	4.33	7.14*†	8.23	0.43*	0.86	0.37*	0.86
-7	Onc Only	OCM	17,249	6.17	5.00	8.78	9.79	0.45	0.86	0.35	0.81
		Comparison	20,960	6.09	5.40	8.13*	8.61	0.41*	0.84	0.37	0.83
	Multi	OCM	71,240	5.72†	4.98	7.97†	9.01	0.44	0.86	0.34†	0.81
		Comparison	49,563	4.75*†	4.16	7.19*†	8.20	0.41*	0.84	0.37*	0.87
-6	Onc Only	OCM	22,337	6.13	5.01	8.51	9.42	0.43	0.85	0.36	0.80
		Comparison	25,101	6.07	5.43	8.19*	8.78	0.39*	0.80	0.37	0.86
	Multi	OCM	75,274	5.64†	5.02	7.85†	8.97	0.43	0.86	0.33†	0.80
		Comparison	54,576	4.77*†	4.24	7.15*†	8.23	0.40*†	0.84	0.37*	0.92
-5	Onc Only	OCM	20,645	5.88	4.86	8.50	9.38	0.42	0.84	0.36	0.84
		Comparison	20,320	5.94	5.33	8.12*	8.78	0.39*	0.80	0.36	0.90
	Multi	OCM	74,382	5.59†	4.96	7.89†	8.99	0.42	0.85	0.33†	0.84
		Comparison	57,054	4.72*†	4.14	7.19*†	8.24	0.39*	0.81	0.37*†	0.88
-4	Onc Only	OCM	21,598	5.89	4.87	8.27	9.07	0.42	0.83	0.37	0.87
		Comparison	23,067	5.78*	5.08	8.19	8.85	0.38*	0.80	0.36	0.87
	Multi	OCM	81,390	5.58†	4.99	7.88†	8.98	0.41	0.84	0.35†	0.80
		Comparison	62,576	4.75*†	4.18	7.22*†	8.42	0.38*	0.82	0.39*†	0.89
-3	Onc Only	OCM	20,560	5.77	4.77	8.09	8.72	0.41	0.82	0.36	0.84
		Comparison	21,256	5.65*	5.02	8.16	8.81	0.39*	0.80	0.37	0.90
	Multi	OCM	79,040	5.44†	4.85	7.79†	8.97	0.41	0.84	0.34†	0.81
		Comparison	62,572	4.70*†	4.09	7.25*†	8.43	0.39*	0.81	0.38*	0.87
-2	Onc Only	OCM	19,147	5.74	4.73	8.30	9.12	0.40	0.82	0.36	0.84
		Comparison	22,241	5.79	5.18	8.22	8.85	0.38*	0.79	0.39*	0.93
	Multi	OCM	87,831	5.49†	4.88	7.90†	9.01	0.41	0.85	0.35	0.81
		Comparison	67,720	4.69*†	4.05	7.43*†	8.70	0.37*†	0.80	0.39*	0.93

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-40: Episode Services, High vs. Non-High Cost Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Group	Practice/TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	High Cost	OCM	29,672	6.13	5.23	9.02	10.28	0.48	0.91	0.34	0.85
		Comparison	21,887	5.95*	5.29	8.57*	9.24	0.47	0.91	0.37*	0.90
	Not High Cost	OCM	71,520	5.90†	5.11	7.91†	8.86	0.44†	0.87	0.34	0.83
		Comparison	58,458	5.10*†	4.53	7.08*†	8.04	0.41*†	0.83	0.37*	0.86
-7	High Cost	OCM	23,625	5.82	4.91	8.82	10.06	0.48	0.90	0.35	0.79
		Comparison	22,274	5.56*	4.92	8.28*	8.93	0.47	0.89	0.38*	0.88
	Not High Cost	OCM	64,864	5.80	5.02	7.88†	8.82	0.43†	0.85	0.34	0.82
		Comparison	48,249	4.95*†	4.44	7.09*†	8.02	0.39*†	0.81	0.36*	0.84
-6	High Cost	OCM	27,940	6.16	5.29	8.58	9.82	0.46	0.89	0.33	0.76
		Comparison	24,890	5.38*	4.88	8.10*	8.79	0.44*	0.87	0.38*	0.87
	Not High Cost	OCM	69,671	5.59†	4.90	7.77†	8.75	0.41†	0.84	0.34†	0.82
		Comparison	54,787	5.09*†	4.59	7.19*†	8.23	0.38*†	0.80	0.37*	0.91
-5	High Cost	OCM	14,213	6.19	5.46	8.16	8.57	0.48	0.91	0.34	0.79
		Comparison	23,596	5.45*	4.80	8.21	8.94	0.43*	0.86	0.38*	0.87
	Not High Cost	OCM	80,814	5.55†	4.84	7.99†	9.17	0.41†	0.83	0.34	0.85
		Comparison	53,778	4.86*†	4.37	7.09*†	8.12	0.37*†	0.79	0.36*†	0.89
-4	High Cost	OCM	18,359	6.04	5.36	8.22	8.82	0.47	0.91	0.33	0.76
		Comparison	27,815	5.53*	4.85	8.03*	8.83	0.40*	0.84	0.38*	0.89
	Not High Cost	OCM	84,629	5.56†	4.87	7.91†	9.04	0.40†	0.82	0.35†	0.83
		Comparison	57,828	4.79*†	4.25	7.22*†	8.39	0.37*†	0.80	0.38*	0.88
-3	High Cost	OCM	16,264	5.85	5.07	8.18	8.58	0.50	0.93	0.36	0.79
		Comparison	29,519	5.26*	4.49	7.91*	8.74	0.40*	0.83	0.38*	0.90
	Not High Cost	OCM	83,336	5.44†	4.78	7.79†	8.98	0.40†	0.82	0.35†	0.82
		Comparison	54,309	4.77*†	4.28	7.25*†	8.42	0.38*†	0.80	0.38*	0.86
-2	High Cost	OCM	17,103	5.96	5.20	8.24	8.94	0.46	0.91	0.34	0.77
		Comparison	33,943	5.24*	4.47	8.18	9.03	0.39*	0.83	0.39*	0.90
	Not High Cost	OCM	89,875	5.45†	4.78	7.92†	9.05	0.40†	0.83	0.35	0.83
		Comparison	56,018	4.79*†	4.32	7.28*†	8.55	0.36*†	0.78	0.39*	0.94

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-41: Episode Services by Affiliation Type in Performance Period -2 (Episodes initiating Jan. – Jun. 2015)

Affiliation Type	Group	Practice/ TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
Academic Medical Center Affiliation	Academic	OCM	19,527	4.97	4.41	7.12	7.91	0.45	0.93	0.36	0.81
		Comparison	17,372	4.71*	3.88	7.72*	8.98	0.42*	0.90	0.44*	1.00
	Non-Academic	OCM	87,451	5.66†	4.94	8.16†	9.25	0.40†	0.82	0.35	0.82
		Comparison	72,589	5.02*†	4.49	7.60*	8.68	0.36*†	0.77	0.38*†	0.91
Health System Affiliation	Health System	OCM	33,749	4.88	4.24	7.30	8.38	0.42	0.89	0.36	0.83
		Comparison	52,541	4.69*	3.98	7.53*	8.76	0.39*	0.83	0.41*	0.95
	No Health System	OCM	73,229	5.84†	5.08	8.28†	9.30	0.40†	0.82	0.35†	0.81
		Comparison	37,420	5.33*†	4.87	7.75*†	8.72	0.34*†	0.75	0.37*†	0.90
Hospital Ownership	Hospital Ownership	OCM	20,319	4.81	4.14	7.27	8.19	0.42	0.89	0.37	0.85
		Comparison	29,340	4.78	4.01	7.61*	8.66	0.36*	0.80	0.41*	0.92
	No Hospital Ownership	OCM	86,659	5.70†	4.99	8.13†	9.21	0.40†	0.83	0.35†	0.81
		Comparison	60,621	5.05*†	4.55	7.63*	8.78	0.37*	0.79	0.39*†	0.93

Source: Episode characteristics file, 2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-42: Episode Total Cost of Care and Cost Sharing, Large vs. Small Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	Large	OCM	79,998	\$25,910	\$24,328	\$5,254	\$4,765
		Comparison	40,039	\$24,514*	\$24,565	\$4,897*	\$4,669
	Small	OCM	21,194	\$25,468†	\$23,947	\$5,205	\$4,841
		Comparison	40,306	\$23,449*†	\$22,948	\$4,827*†	\$4,620
-7	Large	OCM	70,925	\$26,264	\$24,649	\$5,806	\$39,252
		Comparison	35,403	\$25,241*	\$25,982	\$5,321*	\$5,005
	Small	OCM	17,564	\$25,029†	\$24,316	\$5,414†	\$5,099
		Comparison	35,120	\$23,530*†	\$23,505	\$5,130*†	\$4,928
-6	Large	OCM	79,183	\$26,602	\$25,688	\$5,694	\$5,618
		Comparison	41,134	\$26,222*	\$33,721	\$5,514*	\$7,715
	Small	OCM	18,428	\$24,887†	\$24,353	\$5,382†	\$5,407
		Comparison	38,543	\$23,569*†	\$23,596	\$5,106*†	\$5,189
-5	Large	OCM	77,515	\$26,561	\$25,505	\$5,842	\$5,557
		Comparison	40,897	\$25,977*	\$29,145	\$5,620*	\$5,680
	Small	OCM	17,512	\$25,120†	\$24,806	\$5,589†	\$5,523
		Comparison	36,477	\$23,657*†	\$24,204	\$5,297*†	\$5,388
-4	Large	OCM	84,031	\$27,109	\$25,890	\$5,613	\$5,490
		Comparison	46,457	\$26,629*	\$27,083	\$5,393*	\$5,580
	Small	OCM	18,957	\$25,323†	\$24,836	\$5,304†	\$5,411
		Comparison	39,186	\$24,208*†	\$24,430	\$5,109*†	\$5,342
-3	Large	OCM	80,216	\$27,282	\$26,536	\$5,912	\$5,683
		Comparison	46,663	\$26,966*	\$27,191	\$5,758*	\$5,718
	Small	OCM	19,384	\$25,627†	\$25,156	\$5,668†	\$5,644
		Comparison	37,165	\$24,371*†	\$24,507	\$5,388*†	\$5,454
-2	Large	OCM	86,039	\$28,735	\$27,793	\$5,799	\$5,767
		Comparison	51,094	\$28,586	\$28,831	\$5,626*	\$5,730
	Small	OCM	20,939	\$26,848†	\$26,329	\$5,478†	\$5,644
		Comparison	38,867	\$25,615*†	\$25,808	\$5,219*†	\$5,658

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

**Exhibit A5-43: Episode Total Cost of Care and Cost Sharing, Low vs. High Patient Load Practices, in the Expanded Baseline Period
(Episodes initiating Jan. 2012 – Jun. 2015)**

Performance Period	Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	High	OCM	27,737	\$27,146	\$24,253	\$5,688	\$5,055
		Comparison	26,325	\$23,096*	\$22,926	\$4,815*	\$4,675
	Low	OCM	73,359	\$25,339†	\$24,234	\$5,080†	\$4,664
		Comparison	53,624	\$24,508*†	\$24,172	\$4,904*†	\$4,634
-7	High	OCM	12,347	\$27,738	\$25,057	\$6,171	\$5,555
		Comparison	19,560	\$22,948*	\$23,233	\$5,028*	\$4,904
	Low	OCM	76,056	\$25,760†	\$24,503	\$5,661†	\$37,918
		Comparison	50,702	\$25,017*†	\$25,368	\$5,316*†	\$4,993
-6	High	OCM	18,127	\$27,607	\$25,498	\$6,079	\$5,862
		Comparison	20,817	\$22,643*	\$23,374	\$4,944*	\$5,133
	Low	OCM	79,394	\$25,996†	\$25,435	\$5,537†	\$5,510
		Comparison	58,859	\$25,749†	\$31,078	\$5,448*†	\$7,064
-5	High	OCM	15,616	\$28,127	\$25,828	\$6,456	\$6,059
		Comparison	18,450	\$23,164*	\$23,804	\$5,289*	\$5,463
	Low	OCM	79,323	\$25,956†	\$25,284	\$5,670†	\$5,438
		Comparison	58,924	\$25,421*†	\$27,845	\$5,524*†	\$5,571
-4	High	OCM	17,497	\$27,776	\$25,212	\$5,968	\$5,637
		Comparison	22,034	\$23,339*	\$24,205	\$5,018*	\$5,383
	Low	OCM	85,484	\$26,577†	\$25,805	\$5,472†	\$5,439
		Comparison	63,609	\$26,277*†	\$26,461	\$5,348*†	\$5,503
-3	High	OCM	15,741	\$27,720	\$25,812	\$6,284	\$5,913
		Comparison	20,975	\$23,677*	\$24,497	\$5,322*	\$5,541
	Low	OCM	83,858	\$26,818†	\$26,366	\$5,786†	\$5,627
		Comparison	62,853	\$26,529*†	\$26,532	\$5,685*†	\$5,624
-2	High	OCM	19,730	\$28,805	\$26,899	\$6,084	\$5,936
		Comparison	21,304	\$24,981*	\$25,928	\$5,211*	\$5,985
	Low	OCM	87,248	\$28,266†	\$27,661	\$5,657†	\$5,698
		Comparison	68,656	\$28,022†	\$28,066	\$5,524*†	\$5,610

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-44: Episode Total Cost of Care and Cost Sharing, Oncology Only vs. Multi-Specialty Practices, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	Onc Only	OCM	19,362	\$26,880	\$24,125	\$5,573	\$4,970
		Comparison	23,884	\$24,866*	\$23,107	\$5,092*	\$4,626
	Multi	OCM	81,830	\$25,566†	\$24,272	\$5,166†	\$4,732
		Comparison	56,461	\$23,605*†	\$24,040	\$4,765*†	\$4,649
-7	Onc Only	OCM	17,249	\$27,154	\$24,756	\$5,959	\$5,393
		Comparison	20,960	\$25,359*	\$24,117	\$5,462*	\$5,047
	Multi	OCM	71,240	\$25,744†	\$24,540	\$5,673	\$39,157
		Comparison	49,563	\$23,979*†	\$25,064	\$5,126*†	\$4,930
-6	Onc Only	OCM	22,337	\$27,215	\$24,620	\$5,926	\$5,586
		Comparison	25,101	\$25,664*	\$24,283	\$5,503*	\$5,350
	Multi	OCM	75,274	\$26,001†	\$25,685	\$5,549†	\$5,575
		Comparison	54,576	\$24,605*†	\$31,325	\$5,231*†	\$7,124
-5	Onc Only	OCM	20,645	\$27,147	\$24,960	\$6,075	\$5,733
		Comparison	20,320	\$25,269*	\$24,452	\$5,667*	\$5,561
	Multi	OCM	74,382	\$26,059†	\$25,495	\$5,718†	\$5,498
		Comparison	57,054	\$24,746*†	\$27,789	\$5,397*†	\$5,540
-4	Onc Only	OCM	21,598	\$27,531	\$25,566	\$5,818	\$5,677
		Comparison	23,067	\$26,311*	\$25,319	\$5,544*	\$5,656
	Multi	OCM	81,390	\$26,581†	\$25,743	\$5,487†	\$5,420
		Comparison	62,576	\$25,230*†	\$26,147	\$5,159*†	\$5,402
-3	Onc Only	OCM	20,560	\$27,481	\$25,409	\$6,073	\$5,740
		Comparison	21,256	\$26,498*	\$25,509	\$5,872*	\$5,856
	Multi	OCM	79,040	\$26,825†	\$26,501	\$5,810†	\$5,658
		Comparison	62,572	\$25,584*†	\$26,250	\$5,500*†	\$5,514
-2	Onc Only	OCM	19,147	\$29,232	\$27,067	\$6,017	\$5,898
		Comparison	22,241	\$27,855*	\$26,802	\$5,652*	\$5,681
	Multi	OCM	87,831	\$28,177†	\$27,617	\$5,675†	\$5,709
		Comparison	67,720	\$27,121*†	\$27,861	\$5,384*†	\$5,708

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

**Exhibit A5-45: Episode Total Cost of Care and Cost Sharing, High vs. Non-High Cost Practices, in the Expanded Baseline Period
(Episodes initiating Jan. 2012 – Jun. 2015)**

Performance Period	Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	High Cost	OCM	29,672	\$26,850	\$24,752	\$5,381	\$4,817
		Comparison	21,887	\$27,797*	\$25,815	\$5,586*	\$5,039
	Not High Cost	OCM	71,520	\$25,389†	\$24,025	\$5,187†	\$4,765
		Comparison	58,458	\$22,550*†	\$22,799	\$4,591*†	\$4,458
-7	High Cost	OCM	23,625	\$27,196	\$25,351	\$5,787	\$5,163
		Comparison	22,274	\$27,868*	\$27,692	\$5,969*	\$5,422
	Not High Cost	OCM	64,864	\$25,590†	\$24,291	\$5,707	\$41,013
		Comparison	48,249	\$22,783*†	\$23,160	\$4,882*†	\$4,703
-6	High Cost	OCM	27,940	\$27,294	\$26,970	\$5,766	\$5,909
		Comparison	24,890	\$28,449*	\$38,939	\$5,923*	\$9,042
	Not High Cost	OCM	69,671	\$25,871†	\$24,803	\$5,583†	\$5,441
		Comparison	54,787	\$23,344*†	\$23,473	\$5,041*†	\$5,130
-5	High Cost	OCM	14,213	\$29,328	\$26,973	\$6,481	\$5,944
		Comparison	23,596	\$28,360*	\$32,588	\$6,123*	\$6,144
	Not High Cost	OCM	80,814	\$25,762†	\$25,056	\$5,675†	\$5,471
		Comparison	53,778	\$23,358*†	\$23,910	\$5,180*†	\$5,237
-4	High Cost	OCM	18,359	\$29,646	\$28,025	\$6,092	\$5,813
		Comparison	27,815	\$28,635*	\$28,169	\$5,854*	\$5,879
	Not High Cost	OCM	84,629	\$26,158†	\$25,135	\$5,440†	\$5,394
		Comparison	57,828	\$24,024*†	\$24,643	\$4,979*†	\$5,244
-3	High Cost	OCM	16,264	\$30,308	\$28,129	\$6,493	\$6,087
		Comparison	29,519	\$28,483*	\$28,090	\$6,071*	\$5,906
	Not High Cost	OCM	83,336	\$26,307†	\$25,854	\$5,742†	\$5,584
		Comparison	54,309	\$24,366*†	\$24,779	\$5,335*†	\$5,417
-2	High Cost	OCM	17,103	\$31,218	\$29,129	\$6,360	\$6,178
		Comparison	33,943	\$30,454*	\$29,516	\$5,944*	\$5,811
	Not High Cost	OCM	89,875	\$27,823†	\$27,172	\$5,618†	\$5,651
		Comparison	56,018	\$25,393*†	\$26,196	\$5,151*†	\$5,614

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-46: Episode Total Cost of Care and Cost Sharing by Affiliation Type in Performance Period -2 (Episodes initiating Jan. - Jun. 2015)

Affiliation Type	Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
Academic Medical Center Affiliation	Academic	OCM	19,527	\$29,038	\$29,344	\$5,459	\$5,582
		Comparison	17,372	\$30,618*	\$30,255	\$5,717*	\$5,844
	Non-Academic	OCM	87,451	\$28,215†	\$27,097	\$5,798†	\$5,779
		Comparison	72,589	\$26,509*†	\$26,872	\$5,387*†	\$5,666
Health System Affiliation	Health System	OCM	33,749	\$28,085	\$28,704	\$5,397	\$5,555
		Comparison	52,541	\$27,625*	\$27,583	\$5,469	\$5,782
	No Health System	OCM	73,229	\$28,495†	\$26,960	\$5,892†	\$5,823
		Comparison	37,420	\$26,850*†	\$27,630	\$5,423*	\$5,588
Hospital Ownership	Hospital Ownership	OCM	20,319	\$28,427	\$28,893	\$5,420	\$5,610
		Comparison	29,340	\$28,249	\$28,966	\$5,456	\$5,514
	No Hospital Ownership	OCM	86,659	\$28,351	\$27,191	\$5,810†	\$5,774
		Comparison	60,621	\$26,844*†	\$26,910	\$5,447*	\$5,791

Source: Episode characteristics file, 2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-47: Episode Characteristics, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Income Group	Practice/ TIN Type	Number of Episodes	Percentage of Episodes among Dual Eligibles	Percentage of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	High	OCM	30,455	13.3%	10.3%	25.1%	22.6%	18.8%	13.6%	9.6%
		Comparison	24,206	14.1%*	9.5%*	22.8%*	21.6%*	19.2%	14.8%*	12.0%*
	Low	OCM	70,737	13.5%	11.1%†	24.8%	23.0%	18.4%	13.4%	9.2%
		Comparison	56,139	16.6%*†	12.9%*†	24.3%†	22.4%*†	18.2%†	13.1%†	9.0%†
-7	High	OCM	27,189	13.6%	10.3%	24.7%	22.6%	18.7%	13.9%	9.8%
		Comparison	19,721	14.7%*	9.8%*	23.0%*	21.9%	18.9%	14.1%	12.2%*
	Low	OCM	61,300	13.6%	11.3%†	24.4%	23.0%	18.6%	13.3%†	9.4%†
		Comparison	50,802	16.8%*†	13.3%*†	24.23%†	22.5%*	18.3%	12.61%*†	9.1%†
-6	High	OCM	38,178	13.3%	10.2%	24.5%	22.9%	18.7%	14.0%	9.7%
		Comparison	30,027	15.9%*	10.2%	23.5%*	22.5%	18.5%	13.9%	11.3%*
	Low	OCM	59,433	12.5%†	11.1%†	24.5%	23.4%	18.8%	13.1%†	9.1%†
		Comparison	49,650	14.7%*†	13.0%*†	24.3%†	22.9%*	18.3%	12.4%*†	9.1%†
-5	High	OCM	37,012	13.4%	10.3%	24.5%	23.2%	18.9%	13.3%	9.8%
		Comparison	29,533	15.7%*	10.1%	23.5%*	22.2%*	18.8%	13.8%	11.7%*
	Low	OCM	58,015	12.4%†	10.8%†	24.5%	23.4%	19.0%	13.0%	9.3%†
		Comparison	47,841	14.9%*†	13.2%*†	24.7%†	22.8%*†	18.3%*	12.2%*†	8.7%*†
-4	High	OCM	54,908	12.0%	9.4%	25.2%	23.8%	19.2%	13.0%	9.3%
		Comparison	35,160	15.0%*	10.2%*	23.8%*	22.7%*	19.1%	13.1%	11.1%*
	Low	OCM	48,080	12.2%	11.2%†	24.5%†	23.4%	19.0%	12.6%	9.3%
		Comparison	50,483	14.1%*†	12.6%*†	24.8%†	22.8%*	18.4%*†	12.3%†	9.1%†
-3	High	OCM	51,755	12.1%	9.3%	24.9%	24.0%	19.1%	13.1%	9.6%
		Comparison	34,510	15.3%*	10.2%*	24.4%	22.9%*	18.5%*	13.3%	10.7%*
	Low	OCM	47,845	11.6%†	11.0%†	24.9%	23.4%†	19.1%	12.3%†	9.2%
		Comparison	49,318	13.9%*†	12.6%*†	24.9%	22.9%*	18.4%*	12.0%†	9.2%†
-2	High	OCM	56,575	11.7%	9.1%	25.4%	23.9%	19.1%	12.9%	9.6%
		Comparison	37,428	14.6%*	10.2%*	24.7%*	23.5%	18.5%*	12.9%	10.3%*
	Low	OCM	50,403	11.3%	10.9%†	25.4%	23.6%	18.9%	12.2%†	9.0%†
		Comparison	52,533	13.5%*†	12.3%*†	25.1%	23.0%*	18.4%	12.4%†	8.7%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-47: Episode Characteristics, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015), Continued

Performance Period	Income Group	Practice/ TIN Type	Number of Episodes	Percentage of Episodes by Race				Percentage of Episodes with HCC Score >= 2.0
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	High	OCM	30,455	82.8%	9.7%	4.2%	3.3%	47.4%
		Comparison	24,206	83.4%*	7.0%*	5.2%*	4.3%*	44.0%*
	Low	OCM	70,737	83.0%	8.8%†	5.7%†	2.4%†	44.8%†
		Comparison	56,139	82.4%*†	11.5%*†	3.8%*†	2.3%†	45.8%*†
-7	High	OCM	27,189	82.7%	9.6%	4.3%	3.4%	36.9%
		Comparison	19,721	83.8%*	6.8%*	5.0%*	4.4%*	34.4%*
	Low	OCM	61,300	83.2%†	8.7%†	5.5%†	2.5%†	34.7%†
		Comparison	50,802	81.7%*†	11.7%*†	4.1%*†	2.5%†	34.6%
-6	High	OCM	38,178	81.8%	9.9%	4.6%	3.7%	44.2%
		Comparison	30,027	81.9%	6.8%*	5.9%*	5.5%*	42.6%*
	Low	OCM	59,433	83.3%†	9.2%†	5.1%†	2.4%†	42.1%†
		Comparison	49,650	82.3%*	12.8%*†	3.2%*†	1.8%*†	42.6%
-5	High	OCM	37,012	81.4%	9.7%	4.8%	4.1%	34.4%
		Comparison	29,533	81.6%	6.6%*	5.9%*	5.9%*	33.9%
	Low	OCM	58,015	83.2%†	9.1%†	5.2%†	2.5%†	33.2%†
		Comparison	47,841	82.1%*	12.7%*†	3.3%*†	1.9%*†	33.4%
-4	High	OCM	54,908	81.2%	8.7%	6.4%	3.7%	41.8%
		Comparison	35,160	82.1%*	6.6%*	5.5%*	5.8%*	41.5%
	Low	OCM	48,080	84.6%†	9.4%†	3.5%†	2.5%†	41.1%†
		Comparison	50,483	81.9%*	13.0%*†	3.2%*†	1.9%*†	40.9%
-3	High	OCM	51,755	80.8%	9.0%	6.3%	3.8%	32.9%
		Comparison	34,510	81.4%*	7.3%*	5.5%*	5.9%*	32.9%
	Low	OCM	47,845	84.7%†	9.3%	3.3%†	2.7%†	31.9%†
		Comparison	49,318	82.9%*	12.0%*†	3.2%†	1.9%*†	32.1%†
-2	High	OCM	56,575	80.9%	8.8%	6.2%	4.1%	44.2%
		Comparison	37,428	81.4%*	7.0%*	5.6%*	6.0%*	44.5%
	Low	OCM	50,403	84.7%†	9.4%†	3.2%†	2.7%†	43.2%†
		Comparison	52,533	82.8%*	11.9%*†	3.3%†	2.1%*†	43.7%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-48: Episode Characteristics, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Supply Group	Practice/ TIN Type	Number of Episodes	Percentage of Episodes among Dual Eligibles	Percentage of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	High	OCM	42,229	13.6%	11.3%	24.8%	22.6%	18.1%	13.5%	9.5%
		Comparison	40,539	14.9%*	12.1%*	24.3%	21.7%*	18.3%	13.5%	10.1%*
	Low	OCM	58,963	13.4%	10.6%†	24.9%	23.1%	18.8%†	13.4%	9.2%
		Comparison	39,806	16.9%*†	11.7%*	23.5%*†	22.7%*†	18.8%	13.7%	9.7%*
-7	High	OCM	36,567	13.9%	11.4%	24.2%	22.4%	18.3%	13.8%	9.9%
		Comparison	35,072	15.3%*	12.6%*	24.2%	22.1%	18.0%	13.0%*	10.2%
	Low	OCM	51,922	13.5%	10.7%†	24.6%	23.2%†	18.9%†	13.3%	9.2%†
		Comparison	35,451	17.1%*†	12.1%*†	23.7%*	22.6%*	18.9%†	13.1%	9.8%*
-6	High	OCM	39,463	13.3%	11.2%	24.4%	22.8%	18.2%	13.7%	9.7%
		Comparison	39,495	14.3%*	12.5%*	24.5%	22.6%	18.0%	12.6%*	9.9%
	Low	OCM	58,148	12.5%†	10.4%†	24.6%	23.5%†	19.1%†	13.2%†	9.1%†
		Comparison	40,182	16.1%*†	11.5%*†	23.6%*†	22.9%*	18.8%†	13.3%†	9.9%*
-5	High	OCM	38,509	13.4%	11.2%	24.6%	23.0%	18.4%	13.0%	9.8%
		Comparison	38,574	14.4%*	12.5%*	24.7%	22.2%*	18.3%	12.5%*	9.9%
	Low	OCM	56,518	12.4%†	10.2%†	24.4%	23.5%	19.4%†	13.2%	9.3%†
		Comparison	38,800	15.9%*†	11.5%*†	23.8%*†	22.9%*†	18.7%*	13.2%†	9.8%*
-4	High	OCM	51,128	12.5%	10.8%	25.1%	23.2%	18.6%	12.7%	9.5%
		Comparison	47,737	13.9%*	12.0%*	24.7%	22.5%*	18.3%	12.6%	9.9%*
	Low	OCM	51,860	11.6%†	9.7%†	24.7%	24.0%†	19.6%†	12.9%	9.1%†
		Comparison	37,906	15.2%*†	11.1%*†	24.0%*†	23.0%*	19.2%†	12.8%	10.0%*
-3	High	OCM	49,317	12.4%	10.6%	25.5%	23.2%	18.7%	12.4%	9.5%
		Comparison	46,320	13.9%*	12.1%*	25.0%	23.0%	18.0%*	12.3%	9.6%
	Low	OCM	50,283	11.3%†	9.6%†	24.4%†	24.2%†	19.5%†	13.1%†	9.4%
		Comparison	37,508	15.1%*†	11.1%*†	24.3%†	22.8%*	19.0%*†	12.7%	10.1%*†
-2	High	OCM	54,946	11.9%	10.4%	26.0%	23.5%	18.6%	12.2%	9.3%
		Comparison	49,044	13.6%*	11.9%*	25.2%*	23.3%	17.9%*	12.3%	9.2%
	Low	OCM	52,032	11.0%†	9.5%†	24.9%†	24.1%†	19.4%†	12.9%†	9.2%
		Comparison	40,917	14.5%*†	10.9%*†	24.6%†	23.0%*	19.1%†	12.9%†	9.5%

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-48: Episode Characteristics, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued

Performance Period	Supply Group	Practice/ TIN Type	Number of Episodes	Percentage of Episodes by Race				Percentage of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	High	OCM	42,229	83.9%	9.7%	3.4%	2.9%	45.7%
		Comparison	40,539	81.8%*	12.2%*	3.3%	2.6%*	44.7%*
	Low	OCM	58,963	82.3%†	8.6%†	6.6%†	2.5%†	45.5%
		Comparison	39,806	83.6%*†	8.0%*†	5.2%*†	3.1%*†	45.7%†
-7	High	OCM	36,567	83.7%	10.0%	3.3%	3.0%	35.7%
		Comparison	35,072	81.3%*	12.6%*	3.4%	2.7%	34.6%*
	Low	OCM	51,922	82.6%†	8.3%†	6.4%†	2.7%†	35.2%
		Comparison	35,451	83.2%*†	8.1%†	5.4%*†	3.3%*†	34.5%*
-6	High	OCM	39,463	83.1%	10.4%	3.3%	3.2%	43.5%
		Comparison	39,495	81.4%*	12.5%*	3.2%	2.9%*	41.9%*
	Low	OCM	58,148	82.5%†	8.8%†	6.0%†	2.7%†	42.5%†
		Comparison	40,182	82.8%†	8.6%†	5.1%*†	3.4%*†	43.3%*†
-5	High	OCM	38,509	82.6%	10.5%	3.5%	3.4%	33.7%
		Comparison	38,574	81.0%*	12.5%*	3.3%	3.2%*	33.4%
	Low	OCM	56,518	82.4%	8.6%†	6.1%†	2.9%†	33.6%
		Comparison	38,800	82.8%†	8.2%*†	5.3%*†	3.7%*†	33.8%
-4	High	OCM	51,128	82.1%	11.1%	3.4%	3.4%	41.7%
		Comparison	47,737	81.0%*	12.3%*	3.5%	3.2%	41.3%
	Low	OCM	51,860	83.4%†	7.0%†	6.6%†	2.9%†	41.2%
		Comparison	37,906	83.3%†	8.0%*†	4.9%*†	3.8%*†	40.9%
-3	High	OCM	49,317	81.6%	11.2%	3.6%	3.6%	32.1%
		Comparison	46,320	81.3%	11.8%*	3.4%	3.4%	32.4%
	Low	OCM	50,283	83.7%†	7.1%†	6.2%†	3.0%†	32.7%†
		Comparison	37,508	83.5%†	7.8%*†	4.9%*†	3.8%*†	32.3%
-2	High	OCM	54,946	81.8%	10.7%	3.6%	3.8%	43.7%
		Comparison	49,044	81.8%	11.4%*	3.2%*	3.6%	44.3%*
	Low	OCM	52,032	83.6%†	7.4%†	5.9%†	3.1%†	43.8%
		Comparison	40,917	82.7%*†	7.9%*†	5.5%*†	3.9%*	43.6%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-49: Episode Characteristics, Large vs. Small Population Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Population Group	Practice/ TIN Type	Number of Episodes	Percentage of Episodes among Dual Eligibles	Percentage of Episodes by Age Bracket					
					< 65	65-69	70-74	75-79	80-84	85+
-8	High	OCM	85,750	13.5%	10.7%	24.9%	22.9%	18.4%	13.6%	9.5%
		Comparison	56,433	16.0%*	11.6%*	24.3%*	21.9%*	18.3%	13.7%	10.2%*
	Low	OCM	15,442	13.5%	12.0%†	24.7%	23.1%	19.1%	12.7%†	8.4%†
		Comparison	23,912	15.5%*	12.6%†	23.0%*†	22.0%†	19.0%†	13.3%	9.2%*†
-7	High	OCM	75,851	13.6%	10.7%	24.5%	22.9%	18.6%	13.6%	9.7%
		Comparison	49,292	16.4%*	11.9%*	24.1%	22.2%*	18.2%	13.2%	10.3%*
	Low	OCM	12,638	13.6%	12.6%†	24.4%	22.7%	18.8%	13.0%	8.5%†
		Comparison	21,231	15.7%*†	13.2%†	23.5%*†	22.6%	19.0%†	12.6%†	9.1%*†
-6	High	OCM	82,732	12.8%	10.5%	24.5%	23.3%	18.6%	13.5%	9.6%
		Comparison	56,846	15.2%*	11.6%*	24.4%	22.7%*	18.2%*	13.0%*	10.2%*
	Low	OCM	14,879	13.1%	12.1%†	24.7%	23.1%	19.3%	12.7%†	8.1%†
		Comparison	22,831	15.2%*	13.0%*†	23.2%*†	22.9%	19.0%†	12.9%	9.1%*†
-5	High	OCM	80,656	12.8%	10.4%	24.5%	23.3%	19.0%	13.2%	9.7%
		Comparison	55,082	15.1%*	11.6%*	24.5%	22.5%*	18.3%*	12.8%*	10.2%*
	Low	OCM	14,371	13.0%	12.1%†	24.4%	23.5%	18.6%	12.6%	8.7%†
		Comparison	22,292	15.3%*	13.0%*†	23.7%†	22.6%	19.0%†	12.8%	8.9%†
-4	High	OCM	87,715	12.0%	9.9%	25.0%	23.7%	19.1%	12.9%	9.4%
		Comparison	60,586	14.4%*	11.2%*	24.7%	22.6%*	18.5%*	12.6%	10.2%*
	Low	OCM	15,273	12.5%	11.9%†	24.6%	23.3%	19.2%	12.4%	8.6%†
		Comparison	25,057	14.5%*	12.6%*†	23.5%*†	22.9%	19.1%	12.7%	9.1%*†
-3	High	OCM	84,567	11.8%	9.8%	25.0%	23.7%	19.1%	12.8%	9.6%
		Comparison	59,232	14.4%*	11.3%*	25.1%	22.9%*	18.3%*	12.5%	9.9%*
	Low	OCM	15,033	12.4%†	11.8%†	24.6%	23.7%	19.2%	12.4%	8.4%†
		Comparison	24,596	14.6%*	12.4%*†	23.7%*†	23.1%	18.9%†	12.5%	9.4%*†
-2	High	OCM	91,267	11.4%	9.7%	25.5%	23.8%	19.0%	12.6%	9.4%
		Comparison	64,822	14.0%*	11.2%*	25.3%	23.4%	18.2%*	12.5%	9.5%
	Low	OCM	15,711	11.9%	11.6%†	25.1%	23.5%	18.8%	12.5%	8.5%†
		Comparison	25,139	14.0%*	12.1%†	24.2%*†	22.7%†	19.1%†	12.8%	9.2%*†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-49: Episode Characteristics, Large vs. Small Population Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015), Continued

Performance Period	Population Group	Practice/ TIN Type	Number of Episodes	Percentage of Episodes by Race				Percentage of Episodes with HCC Score >= 2
				Non-Hispanic White	Non-Hispanic Black	Hispanic	Other	
-8	High	OCM	85,750	82.2%	8.9%	6.0%	3.0%	45.7%
		Comparison	56,433	80.5%*	10.3%*	5.5%*	3.7%*	45.9%*
	Low	OCM	15,442	87.4%†	9.8%†	1.5%†	1.2%†	45.0%
		Comparison	23,912	87.9%†	9.7%†	1.3%†	1.1%†	43.6%†
-7	High	OCM	75,851	82.0%	9.2%	5.7%	3.0%	35.6%
		Comparison	49,292	80.1%*	10.5%*	5.7%	3.8%*	35.1%
	Low	OCM	12,638	89.3%†	7.8%†	1.5%†	1.4%†	34.0%†
		Comparison	21,231	87.3%*†	10.0%*†	1.4%†	1.3%†	33.2%†
-6	High	OCM	82,732	81.8%	9.5%	5.5%	3.2%	43.0%
		Comparison	56,846	80.0%*	10.8%*	5.3%	4.0%*	43.2%
	Low	OCM	14,879	87.8%†	9.3%	1.6%†	1.4%†	42.3%†
		Comparison	22,831	87.5%†	9.9%*†	1.4%†	1.2%†	41.0%†
-5	High	OCM	80,656	81.6%	9.4%	5.7%	3.4%	33.9%
		Comparison	55,082	79.7%*	10.6%*	5.4%*	4.3%*	34.3%
	Low	OCM	14,371	87.5%†	9.4%	1.6%†	1.5%†	32.4%†
		Comparison	22,292	87.4%†	9.7%†	1.5%†	1.4%†	31.8%†
-4	High	OCM	87,715	81.9%	9.1%	5.6%	3.4%	41.6%
		Comparison	60,586	79.9%*	10.6%*	5.2%*	4.3%*	42.0%
	Low	OCM	15,273	87.8%†	9.0%	1.5%†	1.6%†	40.4%†
		Comparison	25,057	87.2%*†	9.9%*†	1.5%†	1.4%†	39.0%*†
-3	High	OCM	84,567	81.8%	9.1%	5.5%	3.6%	32.7%
		Comparison	59,232	80.3%*	10.1%*	5.2%*	4.4%*	33.4%*
	Low	OCM	15,033	87.6%†	9.2%	1.5%†	1.8%†	30.7%†
		Comparison	24,596	87.0%†	9.9%*	1.5%†	1.5%†	30.0%†
-2	High	OCM	91,267	81.3%	9.1%	5.3%	3.8%	44.0%
		Comparison	64,822	80.3%*	9.8%*	5.3%	4.5%*	44.6%*
	Low	OCM	15,711	87.7%†	9.2%	1.4%†	1.6%†	42.1%†
		Comparison	25,139	86.9%*†	9.9%*	1.6%†	1.6%†	42.4%†

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-50: Episode Services, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Income Group	Practice/ TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	High	OCM	30,455	6.32	5.37	8.16	9.15	0.46	0.89	0.35	0.85
		Comparison	24,206	5.18*	4.75	6.79*	7.78	0.38*	0.81	0.34	0.84
	Low	OCM	70,737	5.81†	5.04	8.27	9.38	0.44†	0.87	0.34	0.83
		Comparison	56,139	5.39*†	4.77	7.77*†	8.66	0.44†	0.87	0.37*†	0.88
-7	High	OCM	27,189	6.11	5.27	8.18	9.24	0.45	0.88	0.33	0.83
		Comparison	19,721	4.96*	4.57	6.78*	7.69	0.37*	0.81	0.34	0.82
	Low	OCM	61,300	5.67†	4.85	8.11	9.15	0.44	0.85	0.34	0.80
		Comparison	50,802	5.21*†	4.61	7.73*†	8.56	0.42*†	0.85	0.37*†	0.87
-6	High	OCM	38,178	5.98	5.20	7.84	8.90	0.43	0.87	0.32	0.78
		Comparison	30,027	4.96*	4.63	6.91*	7.89	0.36*	0.79	0.35*	0.87
	Low	OCM	59,433	5.60†	4.90	8.10†	9.19	0.42†	0.85	0.35†	0.82
		Comparison	49,650	5.30*†	4.71	7.81*†	8.71	0.43†	0.85	0.38*†	0.91
-5	High	OCM	37,012	5.84	5.16	7.85	8.87	0.43	0.86	0.33	0.83
		Comparison	29,533	4.84*	4.54	6.90*	7.99	0.35*	0.78	0.34	0.88
	Low	OCM	58,015	5.52†	4.79	8.12†	9.21	0.42	0.84	0.34	0.85
		Comparison	47,841	5.15*†	4.50	7.76*†	8.62	0.41†	0.83	0.39*†	0.89
-4	High	OCM	54,908	5.84	5.17	8.06	9.30	0.42	0.84	0.34	0.82
		Comparison	35,160	4.88*	4.51	7.05*	8.27	0.35*	0.79	0.35	0.84
	Low	OCM	48,080	5.42†	4.71	7.84†	8.64	0.41	0.83	0.36†	0.82
		Comparison	50,483	5.13*†	4.43	7.78†	8.72	0.40†	0.83	0.40*†	0.91
-3	High	OCM	51,755	5.72	5.07	7.95	9.24	0.42	0.84	0.33	0.79
		Comparison	34,510	4.81*	4.37	7.12*	8.38	0.36*	0.79	0.35*	0.80
	Low	OCM	47,845	5.27†	4.56	7.74†	8.55	0.41	0.83	0.36†	0.84
		Comparison	49,318	5.03*†	4.35	7.73†	8.64	0.41†	0.83	0.40*†	0.92
-2	High	OCM	56,575	5.80	5.13	8.09	9.33	0.41	0.85	0.34	0.81
		Comparison	37,428	4.8*	4.38	7.33*	8.58	0.35*	0.79	0.37*	0.86
	Low	OCM	50,403	5.2†	4.51	7.83†	8.67	0.40	0.83	0.36†	0.82
		Comparison	52,533	5.0*†	4.38	7.83†	8.85	0.38*†	0.80	0.41*†	0.97

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-51: Episode Services, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Supply Group	Practice/TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	High	OCM	42,229	5.66	4.89	7.64	8.61	0.47	0.91	0.34	0.81
		Comparison	40,539	4.93*	4.46	7.12*	8.10	0.42*	0.85	0.37*	0.83
	Low	OCM	58,963	6.18†	5.32	8.66†	9.76	0.44†	0.86	0.35†	0.85
		Comparison	39,806	5.74*†	5.02	7.85*†	8.70	0.43*	0.86	0.37*	0.91
-7	High	OCM	36,567	5.53	4.79	7.48	8.26	0.46	0.89	0.33	0.79
		Comparison	35,072	4.79*	4.31	7.11*	7.91	0.41*	0.85	0.37*	0.85
	Low	OCM	51,922	6.01†	5.12	8.59†	9.75	0.43†	0.83	0.35†	0.83
		Comparison	35,451	5.50*†	4.85	7.82*†	8.72	0.41*	0.82	0.36*	0.86
-6	High	OCM	39,463	5.54	4.85	7.42	8.20	0.46	0.90	0.33	0.80
		Comparison	39,495	4.88*	4.43	7.24*	8.27	0.40*	0.84	0.37*	0.90
	Low	OCM	58,148	5.90†	5.13	8.40†	9.61	0.41†	0.82	0.34†	0.80
		Comparison	40,182	5.46*†	4.91	7.72*†	8.56	0.40	0.82	0.37*	0.89
-5	High	OCM	38,509	5.42	4.78	7.47	8.32	0.44	0.89	0.34	0.82
		Comparison	38,574	4.73*	4.21	7.21*	8.17	0.39*	0.83	0.37*	0.86
	Low	OCM	56,518	5.80†	5.04	8.40†	9.55	0.40†	0.81	0.34	0.85
		Comparison	38,800	5.34*†	4.78	7.66*†	8.61	0.39*	0.79	0.37*	0.91
-4	High	OCM	51,128	5.46	4.88	7.50	8.30	0.43	0.87	0.35	0.80
		Comparison	47,737	4.78*	4.19	7.26*	8.33	0.39*	0.83	0.38*	0.87
	Low	OCM	51,860	5.83†	5.04	8.42†	9.62	0.40†	0.81	0.36	0.84
		Comparison	37,906	5.34*†	4.77	7.77*†	8.80	0.37*†	0.79	0.38*	0.90
-3	High	OCM	49,317	5.31	4.77	7.36	8.24	0.43	0.87	0.34	0.81
		Comparison	46,320	4.72*	4.10	7.29	8.27	0.40*	0.83	0.37*	0.84
	Low	OCM	50,283	5.70†	4.89	8.33†	9.51	0.40†	0.80	0.36†	0.81
		Comparison	37,508	5.21*†	4.65	7.71*†	8.86	0.38*†	0.79	0.39*	0.91
-2	High	OCM	54,946	5.37	4.83	7.48	8.26	0.42	0.87	0.34	0.79
		Comparison	49,044	4.76*	4.15	7.41	8.52	0.37*	0.81	0.39*	0.91
	Low	OCM	52,032	5.71†	4.87	8.50†	9.75	0.39†	0.81	0.36†	0.84
		Comparison	40,917	5.20*†	4.64	7.87*†	8.99	0.37*	0.78	0.39*	0.94

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-52: Episode Services, Large vs. Small Population Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 - Jun. 2015)

Performance Period	Population Group	Practice/TIN Type	N	Number of Cancer-Related E&M Services per Episode		Number of Part B and Part D Chemo Visits Services per Episode		Number of Inpatient Admissions per Episode		Number of ED Visits Not Resulting in IP Stay per Episode	
				Mean	Std Dev	Mean	Std Dev	Mean	Std Dev	Mean	Std Dev
-8	Large	OCM	85,750	6.00	5.21	8.24	9.34	0.46	0.89	0.33	0.82
		Comparison	56,433	5.38*	4.87	7.37*	8.31	0.42*	0.86	0.35*	0.85
	Small	OCM	15,442	5.76†	4.79	8.21	9.16	0.43†	0.83	0.39†	0.92
		Comparison	23,912	5.21*†	4.51	7.74*†	8.64	0.43	0.85	0.41*†	0.92
-7	Large	OCM	75,851	5.85	5.04	8.15	9.21	0.45	0.87	0.33	0.80
		Comparison	49,292	5.14*	4.65	7.36*	8.26	0.41*	0.84	0.35*	0.84
	Small	OCM	12,638	5.55†	4.69	8.04	8.98	0.42†	0.82	0.40†	0.89
		Comparison	21,231	5.16*	4.48	7.71*†	8.50	0.41	0.83	0.41†	0.90
-6	Large	OCM	82,732	5.81	5.08	7.96	9.08	0.43	0.86	0.33	0.78
		Comparison	56,846	5.17*	4.72	7.42*	8.37	0.40*	0.83	0.35*	0.85
	Small	OCM	14,879	5.43†	4.71	8.25†	9.06	0.40†	0.81	0.40†	0.89
		Comparison	22,831	5.18*	4.59	7.63*†	8.55	0.40	0.82	0.42†	1.00
-5	Large	OCM	80,656	5.70	5.01	7.99	9.08	0.42	0.85	0.33	0.83
		Comparison	55,082	5.04*	4.53	7.35*	8.36	0.40*	0.82	0.35*	0.86
	Small	OCM	14,371	5.35†	4.54	8.17†	9.11	0.40†	0.82	0.39†	0.90
		Comparison	22,292	5.05*	4.47	7.64*†	8.46	0.39	0.79	0.41*†	0.94
-4	Large	OCM	87,715	5.71	5.05	7.93	9.02	0.42	0.85	0.34	0.80
		Comparison	60,586	5.04*	4.49	7.42*	8.59	0.38*	0.82	0.36*	0.84
	Small	OCM	15,273	5.30†	4.44	8.11†	8.90	0.39†	0.79	0.41†	0.92
		Comparison	25,057	5.01*	4.41	7.63*†	8.45	0.38	0.79	0.43*†	0.97
-3	Large	OCM	84,567	5.55	4.90	7.81	8.88	0.42	0.84	0.34	0.79
		Comparison	59,232	4.97*	4.40	7.47*	8.57	0.39*	0.82	0.36*	0.82
	Small	OCM	15,033	5.26†	4.47	8.09†	9.11	0.39†	0.81	0.40†	0.92
		Comparison	24,596	4.86*†	4.28	7.51*	8.48	0.39	0.79	0.43*†	0.98
-2	Large	OCM	91,267	5.59	4.92	7.91	8.96	0.41	0.85	0.34	0.79
		Comparison	64,822	4.97*	4.39	7.59*	8.72	0.37*	0.81	0.37*	0.87
	Small	OCM	15,711	5.25†	4.42	8.34†	9.40	0.39†	0.79	0.41†	0.95
		Comparison	25,139	4.93*	4.37	7.72*†	8.79	0.36*	0.76	0.45*†	1.05

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-53: Episode Total Cost of Care and Cost Sharing, High vs. Low Income Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Income Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	High	OCM	30,455	\$26,358	\$24,551	\$5,335	\$4,796
		Comparison	24,206	\$21,886*	\$22,642	\$4,563*	\$4,589
	Low	OCM	70,737	\$25,584†	\$24,115	\$5,204†	\$4,775
		Comparison	56,139	\$24,882*†	\$24,189	\$4,991*†	\$4,662
-7	High	OCM	27,189	\$26,549	\$24,753	\$6,080	\$63,063
		Comparison	19,721	\$22,481*	\$23,634	\$4,899*	\$4,950
	Low	OCM	61,300	\$25,783†	\$24,511	\$5,572	\$5,113
		Comparison	50,802	\$25,130*†	\$25,191	\$5,353*†	\$4,968
-6	High	OCM	38,178	\$26,672	\$25,722	\$5,711	\$5,601
		Comparison	30,027	\$24,001*	\$35,710	\$5,090*	\$8,257
	Low	OCM	59,433	\$26,026†	\$25,271	\$5,586†	\$5,566
		Comparison	49,650	\$25,506*†	\$24,598	\$5,454*†	\$5,385
-5	High	OCM	37,012	\$26,603	\$26,102	\$5,820	\$5,569
		Comparison	29,533	\$23,751*	\$25,226	\$5,203*	\$5,440
	Low	OCM	58,015	\$26,099†	\$24,913	\$5,780	\$5,541
		Comparison	47,841	\$25,582*†	\$27,944	\$5,631*†	\$5,605
-4	High	OCM	54,908	\$26,735	\$25,921	\$5,508	\$5,465
		Comparison	35,160	\$24,784*	\$26,592	\$5,060*	\$5,414
	Low	OCM	48,080	\$26,831	\$25,464	\$5,611†	\$5,489
		Comparison	50,483	\$26,035*†	\$25,448	\$5,405*†	\$5,511
-3	High	OCM	51,755	\$27,015	\$26,480	\$5,824	\$5,683
		Comparison	34,510	\$25,042*	\$26,668	\$5,398*	\$5,550
	Low	OCM	47,845	\$26,900	\$26,064	\$5,908†	\$5,668
		Comparison	49,318	\$26,357*†	\$25,625	\$5,731*†	\$5,640
-2	High	OCM	56,575	\$28,436	\$27,939	\$5,690	\$5,742
		Comparison	37,428	\$26,888*	\$28,561	\$5,287*	\$5,600
	Low	OCM	50,403	\$28,286	\$27,047	\$5,788†	\$5,747
		Comparison	52,533	\$27,598*†	\$26,899	\$5,566*†	\$5,771

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

Exhibit A5-54: Episode Total Cost of Care and Cost Sharing, High vs. Low Specialty Supply Markets, in the Expanded Baseline Period (Episodes initiating Jan. 2012 – Jun. 2015)

Performance Period	Supply Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	High	OCM	42,229	\$25,192	\$24,625	\$5,054	\$4,692
		Comparison	40,539	\$23,569*	\$23,978	\$4,741*	\$4,600
	Low	OCM	58,963	\$26,265†	\$23,967	\$5,380†	\$4,840
		Comparison	39,806	\$24,398*†	\$23,556	\$4,985*†	\$4,686
-7	High	OCM	36,567	\$25,543	\$24,842	\$5,747	\$54,429
		Comparison	35,072	\$24,021*	\$25,446	\$5,089*	\$4,908
	Low	OCM	51,922	\$26,354†	\$24,402	\$5,715	\$5,201
		Comparison	35,451	\$24,753*†	\$24,127	\$5,361*†	\$5,022
-6	High	OCM	39,463	\$26,298	\$25,951	\$5,558	\$5,451
		Comparison	39,495	\$24,739*	\$33,311	\$5,227*	\$7,696
	Low	OCM	58,148	\$26,265	\$25,105	\$5,687†	\$5,665
		Comparison	40,182	\$25,135*	\$24,715	\$5,405*†	\$5,350
-5	High	OCM	38,509	\$26,125	\$25,893	\$5,660	\$5,472
		Comparison	38,574	\$24,743*	\$25,231	\$5,390*	\$5,441
	Low	OCM	56,518	\$26,411	\$25,030	\$5,888†	\$5,603
		Comparison	38,800	\$25,023*	\$28,563	\$5,545*†	\$5,648
-4	High	OCM	51,128	\$26,715	\$26,270	\$5,474	\$5,456
		Comparison	47,737	\$25,458*	\$25,818	\$5,193*	\$5,406
	Low	OCM	51,860	\$26,843	\$25,143	\$5,637†	\$5,496
		Comparison	37,906	\$25,601*	\$26,072	\$5,351*†	\$5,557
-3	High	OCM	49,317	\$26,922	\$26,947	\$5,768	\$5,703
		Comparison	46,320	\$25,816*	\$26,018	\$5,502*	\$5,532
	Low	OCM	50,283	\$26,997	\$25,611	\$5,960†	\$5,649
		Comparison	37,508	\$25,814*	\$26,128	\$5,707*†	\$5,692
-2	High	OCM	54,946	\$28,269	\$28,155	\$5,619	\$5,698
		Comparison	49,044	\$27,072*	\$27,310	\$5,367*	\$5,560
	Low	OCM	52,032	\$28,468	\$26,838	\$5,859†	\$5,792
		Comparison	40,917	\$27,578*†	\$27,952	\$5,550*†	\$5,867

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).

**Exhibit A5-55: Episode Total Cost of Care and Cost Sharing, Large vs. Small Population Markets, in the Expanded Baseline Period
(Episodes initiating Jan. 2012 – Jun. 2015)**

Performance Period	Population Group	Practice/ TIN Type	N	Standardized Part A and B, and Part D Costs per Episode		Standardized Part A and B, and Part D Beneficiary Cost-Sharing per Episode	
				Mean	Std Dev	Mean	Std Dev
-8	High	OCM	85,750	\$25,939	\$24,446	\$5,238	\$4,774
		Comparison	56,433	\$24,270*	\$24,102	\$4,875*	\$4,659
	Low	OCM	15,442	\$25,139†	\$23,114	\$5,277	\$4,821
		Comparison	23,912	\$23,294*†	\$22,965	\$4,831*	\$4,611
-7	High	OCM	75,851	\$26,250	\$24,824	\$5,766	\$37,978
		Comparison	49,292	\$24,741*	\$25,493	\$5,247*	\$5,004
	Low	OCM	12,638	\$24,629†	\$23,074	\$5,506	\$5,149
		Comparison	21,231	\$23,570*†	\$23,069	\$5,177*	\$4,880
-6	High	OCM	82,732	\$26,373	\$25,728	\$5,626	\$5,609
		Comparison	56,846	\$25,347*	\$31,328	\$5,358*	\$7,110
	Low	OCM	14,879	\$25,753†	\$23,842	\$5,686	\$5,415
		Comparison	22,831	\$23,921*†	\$23,445	\$5,213*†	\$5,194
-5	High	OCM	80,656	\$26,415	\$25,626	\$5,787	\$5,548
		Comparison	55,082	\$25,246*	\$28,106	\$5,463*	\$5,588
	Low	OCM	14,371	\$25,620†	\$23,968	\$5,841	\$5,572
		Comparison	22,292	\$23,987*†	\$23,845	\$5,478*	\$5,443
-4	High	OCM	87,715	\$26,925	\$25,950	\$5,554	\$5,469
		Comparison	60,586	\$25,984*	\$26,614	\$5,291*	\$5,516
	Low	OCM	15,273	\$25,947†	\$24,259	\$5,568	\$5,518
		Comparison	25,057	\$24,402*†	\$24,165	\$5,196*†	\$5,370
-3	High	OCM	84,567	\$27,148	\$26,575	\$5,868	\$5,670
		Comparison	59,232	\$26,242*	\$26,594	\$5,628*	\$5,612
	Low	OCM	15,033	\$25,901†	\$24,534	\$5,844	\$5,710
		Comparison	24,596	\$24,787*†	\$24,723	\$5,512*†	\$5,588
-2	High	OCM	91,267	\$28,452	\$27,769	\$5,716	\$5,728
		Comparison	64,822	\$27,791*	\$28,319	\$5,461*	\$5,591
	Low	OCM	15,711	\$27,862†	\$26,040	\$5,853†	\$5,841
		Comparison	25,139	\$26,043*†	\$25,631	\$5,422*	\$5,980

Source: Episode characteristics file, 2012-2015. **Note:** * Denotes a significant difference from OCM practices. † Denotes a significant difference between subgroups (within OCM practices and comparison TINs).